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Summary
Attention deficit-/hyperactivity disorder (ADHD) is a psychiatric condition that can 
affect both children and adults. It is characterised by behavioural and attention 
difficulties. Sleep deficits are a prominent characteristic of the disorder and some of 
the core symptoms of ADHD are known characteristics of sleep deprivation. The 
circadian clock is integral to determining the rhythm of the sleep/wake cycle. 
Furthermore the two main forms of pharmacological treatment for ADHD, namely 
the psychostimulant methylphenidate, and the non-stimulant atomoxetine, along with 
the targets of these drugs noradrenaline and dopamine, appear to both interact and be 
under the regulation of the circadian clock.
This thesis aimed firstly to develop a non-invasive technique for the real time RT- 
PCR quantification of circadian clock gene expression in the human oral mucosa. 
Secondly to address how circadian clock functioning may be disturbed in adult 
ADHD via measurement of a number of molecular, endocrine and behavioural 
markers, for which real-time RT-PCR, ELISA and actigraphy techniques were 
employed. Thirdly to examine the effects of ADHD medication upon circadian clock 
protein expression in the rodent brain using immunohistochemistry methods.
Here it is demonstrated that disturbances in the rhythmic secretion of endocrine 
factors that are key outputs and regulators of the master circadian pacemaker, the 
circadian clock gene expression of a peripheral oscillator and the actigraphic 
measures of circadian organization of gross behaviour are associated with adult 
ADHD. Furthermore, both atomoxetine and methylphenidate are shown to effect 
circadian clock protein expression. Collectively this data suggests a key role for the 
circadian clock not only in the pathophysiology of adult ADHD but also indicates a 
role for pharmacological treatments in the modulation of the circadian clock.
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Chapter 1: Introduction
Chapter 1: Introduction
1.1 Introduction to the Circadian Clock
Circadian rhythms are recurring patterns in behaviour and physiology that repeat 
approximately every twenty-four hours (Hastings and Maywood, 2000, Reppert and 
Weaver, 2001). This time-keeping system enables an organism to predict cyclical 
changes in its environment and to synchronize and temporally coordinate numerous 
behavioural and physiological processes accordingly, thus enabling the organism to 
function in the most efficient manner in response to its environmental conditions 
(Hastings and Maywood, 2000, Guilding and Piggins, 2007, Emerson et al., 2008). 
Circadian rhythms are observed throughout biology, in as varied processes as 
sleeping, eating, mental alertness, seasonal migration and cell proliferation (Gillette 
and Sejnowski, 2005, Guilding and Piggins, 2007).
In mammals the master circadian pacemaker resides in the suprachiasmatic nuclei 
(SCN) of the anterior hypothalamus (Guilding and Piggins, 2007) and it is 
responsible for the generation of circadian rhythms. The SCN is entrained to the 24 
hour day by receiving light pulses via a specialised neural tract, termed the 
retinohypothalamic tract (RHT) (Piggins and Loudon, 2005), although the presence 
of an extra SCN food entrainable oscillator has also been demonstrated (Herzog and 
Muglia, 2006). The role of the SCN as the master pacemaker is confirmed by 
evidence that SCN lesions abolish most physiological, endocrine and behavioural 
rhythms (Moore and Eichler, 1972, Stephan and Zucker, 1972, Guilding and Piggins, 
2007), and SCN transplants can restore rhythmicity in previously arrhythmic, SCN- 
lesioned rodents (Ralph et al., 1990, King et al., 2003, Sujino et al., 2003, Guilding 
and Piggins, 2007). Furthermore, the tau mutant hamster, which possesses a gain-of- 
fimction mutation in the casein kinase Is (CKls) gene, the protein of which is key 
for post-translational modifications of the molecular circadian clock, exhibits a 
shortened, 20-h clock period (Ralph and Menaker, 1988, Reppert and Weaver, 2001, 
Meng et al., 2008). However, transplantation of the SCN of wild-type hamsters into 
the tau mutant hamster, has been shown to lengthen the circadian period, producing a 
free-running rhythm set by the transplanted SCN (Ralph et al., 1990). The SCN 
consists of two paired nuclei, each nucleus containing -10000 neurons (Reppert and
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Weaver, 2001, Guilding and Piggins, 2007), and it is situated bilateral to the third 
ventricle and immediately dorsal to the optic chiasm (Abrahamson and Moore, 2001, 
Guilding and Piggins, 2007). The positioning o f the SCN is therefore optimal for 
receiving visual input for entrainment to the light-dark cycle (Reppert and Weaver, 
2001 ).
Daily rhythms in 
physiology and behavior
Brainstem
Orexin
PBN
DMH
CNOC VMH
ARC
Pituitary
Food-entrainable
oscillator
Light-entrainable
oscillator
Figure 1.1 Saggital view o f the anatomical position o f the suprachiasmatic nucleus 
o f the hypothalamus (SCN) within the rat brain. The SCN is the site o f the master 
pacemaker, for which the light-dark cycle is the predominant entrainment factor, and 
is located above the optic chiasm (OC). A food-entrainable oscillator also exists, 
although its brain site has not been confirmed. DMH = dorsomedial hypothalamic 
nucleus, PVN = paraventricular hypothalamic nucleus, VMH = ventromedial 
hypothalamic nucleus, ARH = arcuate nucleus, LH = lateral hypothalamus, PBN = 
parabrachial nucleus (Herzog and Muglia, 2006).
The SCN can be separated into a ventrolateral ‘core’ region and a dorsomedial ‘shell’ 
region (Guilding and Piggins, 2007), which are functionally distinct with the core 
region receiving direct retinal innervations from the RHT and hence providing a 
daily entrainment signal through the activation o f core clock genes and intracellular 
signalling pathways, to synchronize the rhythmic output from the SCN shell 
(Guilding and Piggins, 2007). Furthermore the molecular clockwork o f the two
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regions differs as a greater number of cells exhibit rhythmic clock gene expression in 
the shell than the core SCN, the acrophase of expression occurs earlier in the day in 
the shell than the core (Hamada et al., 2001, Guilding and Piggins, 2007), whilst light 
induced phase shifts in clock gene expression are delayed in the shell region 
compared to the core SCN (Hamada et a l, 2001, Guilding and Piggins, 2007). 
Moreover, the two regions can also be distinguished on their cell type, with arginine 
vasopressin (AVP) synthesizing neurons being characteristic of the shell region 
(Vandesande et al., 1975, van den Pol and Tsujimoto, 1985), whilst vasoactive 
intestinal polypeptide (VIP) and gastrin-releasing peptide expressing neurons are 
associated with the core region of the SCN (Card et al., 1981, Card and Moore, 1984, 
Card et al., 1988).
Electrical output o f the SCN
Neuronal firing is a key output signal of the SCN (Hirota and Fukada, 2004), which 
has been demonstrated in rats, where when SCN neuronal firing is blocked, their 
behaviour becomes arrhythmic, and rhythmicity is only restored when SCN neuronal 
firing is restored (Schwartz et al., 1987, Schwartz, 1991). This demonstrates that not 
only is rhythmic electrically activity an output of the SCN rather than a critical 
component of the clock, but also that the clock continues to keep time when 
electrical output is silenced (Reppert and Weaver, 2001). Electrical firing rate 
exhibits a rhythm with a period of ~ 24 hours in the SCN, with a higher frequency 
during the day and lower frequency during the night (Inouye and Kawamura, 1979, 
Green and Gillette, 1982, Groos and Hendriks, 1982, Shibata et al., 1982, Meijer et 
al., 1998, Guilding and Piggins, 2007).
There are core and shell differences in electrical activity however, with generally a 
greater number of cells possessing circadian rhythmicity in electrical activity in the 
shell than in the core, and peak firing rate occurs earlier in the day in the SCN shell 
than the core (Hamada et al., 2001, Schaap et al., 2003, Yamaguchi et al., 2003 
Hamada et al., 2004, Maywood et al., 2006). The synchronization of electrical 
activity of the individual neurons to a single period in the SCN is thought to be due 
to sodium-dependant action potentials (Yamaguchi et al., 2003), with rhythmic 
alterations in membrane potential and/or channel activity being thought to be
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responsible for the rhythmic electrical activity of SCN neurons (de Jeu et al., 1998, 
Schaap et al., 1999, Reppert and Weaver, 2001). Additionally, the neuropeptide VIP 
has been implicated in the maintenance and synchronisation of the molecular 
clockwork and electrical firing of SCN neurons (Cutler et al., 2003, Aton et al., 2005, 
Brown et al., 2005, Maywood et al., 2006, Brown et al., 2007, Guilding and Piggins, 
2007).
Efficient coupling of the SCN is essential for entrainment of the circadian clock, 
since this will enable the whole network to resynchronize when a subset of cells 
receive phase shifting stimuli (Reppert and Weaver, 2001). Gap junctions have been 
proposed to contribute to the synchronisation of subsets of SCN neurons and the 
amplification of their collective output (Reppert and Weaver, 2001), and the 
neurotransmitter GABA. Nearly all the neurons of the SCN express the 
neurotransmitter GABA (Moore and Speh, 1993, Reppert and Weaver, 2001, 
Guilding and Piggins, 2007), which is responsible for exciting SCN neurons in the 
daytime and inhibiting electrical activity during the night (Wagner et al., 1997), and 
has been implicated in the synchronizing of SCN neurons in vitro (Liu and Reppert,
2000). The neuronal cell adhesion molecule PSA-NCAM has also been proposed as a 
possible synchronizing factor of the SCN (Reppert and Weaver, 2001), since it is 
known to play a role in the regulation of neuronal plasticity in other systems 
(Theodosis et al., 1999). Furthermore, PSA-NCAM deficient mice exhibit shortened 
circadian periods of behaviour eventually becoming arrhythmic in constant 
conditions, thus suggesting that PSA-NCAM could be involved in SCN coupling 
(Shen et al., 1997, Reppert and Weaver, 2001).
The molecular basis o f the circadian clock
The molecular basis of circadian rhythm generation consists of both positive and 
negative transcriptional/translational feed forward and feedback loops of clock genes 
and their protein products (figure 1.2). The positive loop consists of the basic helix- 
loop-helix transcription factors BMAL1 and CLOCK, which form a heterodimer in 
the cytoplasm via PAS (Period-Amt-Single-minded) domains (Guilding and Piggins,
2007), the BMAL1-CLOCK complex then translocates to the nucleus where it 
activates the transcription of PER, CRY, REV-ERB a, ROR a and various clock
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controlled genes by binding to E-box enhancer sequences (Gekakis et al., 1998, van 
der Horst et al., 1999, Guilding and Piggins, 2007, Zanquetta et al., 2010). 
Accumulation of the PER and CRY proteins then occurs in the cytoplasm, where the 
proteins dimerize and are translocated to the nucleus, thus inhibiting CLOCK- 
BMAL1-dependent transcriptional activation, which in turn inhibits their own 
transcription (Reppert and Weaver, 2002, Hastings and Herzog, 2004, Hirota and 
Fukada, 2004, Guilding and Piggins, 2007, Zanquetta et al., 2010) The PER2 and 
ROR a proteins also support the rhythmic transcription o f BMAL1, thus forming a 
positive feedback loop (Reppert and Weaver, 2001, Zanquetta et al., 2010). REV­
ERB a  has an inhibitory effect upon the transcription o f BMAL1, whereas PER-CRY 
inhibits REV-ERB a  transcription, therefore forming a positive loop, that prohibits 
REV-ERB a  inhibition o f BMAL1 transcription, and so activates the system (Preitner 
et al., 2002, Guilding and Piggins, 2007). Since presumably the BMAL1 rhythm 
drives the BMAL1 protein rhythm with a 4-6hr delay, the renewal o f BMAL1 
protein levels at the appropriate circadian time will result in a restart o f the cycle and 
it would therefore seem that BMAL1 protein levels are a rate-limiting factor for 
heterodimer formation (Reppert and Weaver, 2001).
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Figure 1.2. Illustration o f the molecular mechanism o f the circadian clock. CCGs = 
clock controlled genes. Solid line = positive feedback, dashed line = negative 
feedback. (Zanquetta et al., 2010).
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The majority of the core molecular clockwork components of the SCN exhibit a 
circadian rhythm in their expression under both a light-dark (LD) cycle and constant 
conditions, including PERI, PER2, CRY1, REV-ERB a and BMAL1 (Guilding and 
Piggins, 2007). CRY2 is expressed in the SCN, but without a clearly defined rhythm, 
and CLOCK is constitutively expressed across the circadian cycle (Gekakis et al., 
1998, Oster et al., 2003, Guilding and Piggins, 2007). In addition to the core clock 
genes, there are also a number of clock controlled genes that are rhythmically 
expressed in the SCN, including arginine vasopressin (AVP) and albumin D- 
element-binding-protein (DBP) (Reppert and Weaver, 2001). AVP is thought to play 
a role in augmenting SCN excitability (Mihai et al., 1994, Ingram et al., 1996) via 
both autocrine and paracrine mechanisms (Reppert and Weaver, 2001), whereas DBP 
acts as a transcription factor that may regulate the availability of a channel involved 
in the regulation of membrane potential (Reppert and Weaver, 2001), although, it has 
been speculated that DBP may actually play a role in the circadian clock, since DBP- 
deficient mice exhibit shortened circadian periods of locomotor activity (Lopez- 
Molina et al., 1997, Reppert and Weaver, 2001).
Analysis of rodent models that are deficient in various core clock components 
provides further information on their roles in the molecular circadian clock as well as 
possible non-clock functions. Some of the core clock components of the circadian 
system appear to be functionally redundant in the SCN (Lakin-Thomas, 2006), as 
demonstrated by the maintenance of circadian rhythms of locomotor activity and 
clock gene expression in the SCN in CLOCK knockout mice (Debruyne et al., 2006, 
Guilding and Piggins, 2007). In this situation it has been proposed that Neuronal 
PAS domain protein 2 (NPAS2), a functional analogue of CLOCK (Reick et al.,
2001) may be able to function in the place of CLOCK under these conditions in the 
mouse SCN (Asher and Schibler, 2006). However, although NPAS2 is thought to be 
a functional analogue of CLOCK, it does not function as efficiently as its 
counterpart. This is demonstrated by the shortened circadian periods in constant 
darkness of mice that are deficient in CLOCK but possess one functional NPAS2 
allele, in comparison to NPAS2 deficient mice that possess one functional CLOCK 
allele and display behavioural rhythmicity in constant darkness that is similar to the 
wild-type control (DeBruyne et al., 2007a). However, it is not yet clear whether 
NPAS2 only plays a functionally relevant role in the absence of CLOCK or whether
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both proteins actually function co-ordinately within the SCN (DeBruyne et al., 
2007a). However a number of alterations in the dopaminergic reward system of 
CLOCK mutant mice suggest that this protein may also have a non-clock function in 
the system. These alterations include elevated locomotion levels and increased 
sensitivity to cocaine reward, increased expression of tyrosine hydroxylase mRNA 
and protein, (the rate limiting en2yme for dopamine biosynthesis), increased levels of 
the phosphorylated form of the protein in die ventral tegmental area (VTA) and 
elevated impulse activity of the VTA dopaminergic neurons (McClung et al., 2005). 
Furthermore, CLOCK mutant mice have been shown to exhibit an increase in 
exploratory activity in novel environments (Easton et al., 2003, McClung et al., 
2005, Roybal et al., 2007, Rosenwasser, 2010) and decreased depression and 
anxiety-like behaviours (Roybal et al., 2007, Rosenwasser, 2010), and therefore 
CLOCK mutant mice have been proposed as a rodent model for mania (Roybal et al., 
2007, Lamont et al., 2010). NPAS2 has been shown to be implicated in the 
regulation of behaviour, as demonstrated by an association of a mutation in NPAS2 
with increased spontaneous wheel running behaviour (Dudley et al., 2003, 
Rosenwasser, 2010). It has been postulated that one mechanism by which clock 
genes could interact with the dopaminergic system is via E-box element sequences 
found on the tyrosine hydroxylase gene (Yoon and Chikaraishi, 1994, McClung et 
al., 2005).
A recent study has suggested that BMAL1 may not be essential for circadian clock 
functioning, since BMAL1 knockout mice exhibit circadian rhythmicity in numerous 
physiological activities including metabolism and locomotor activity, when BMAL2 
is expressed from a constitutively expressed promoter (Shi et al., 2010) It is therefore 
thought that BMAL1 and BMAL2 form a functionally redundant paralogue pair (Shi 
et al., 2010). Furthermore, in BMAL1 knockout mice BMAL2 expression is 
downregulated, and therefore it would seem that the BMAL2 promoter may be under 
a form of regulation by BMAL1/CLOCK and BMAL1/NPAS2 transactivation in the 
mouse (Shi et al., 2010). However, BMAL1 does appear to be important in sleep 
regulation as homozygous BMAL1 knockout mice exhibit dampened sleep/wake 
rhythms and sleep abnormalities such as increased sleep duration and fragmentation, 
and insufficiencies in the response to sleep deprivation (Laposky et al., 2005).
22
In mice deletion of CRY2 lengthens the circadian period, whereas CRY1 deletion 
shortens the circadian period: it has been postulated that this difference may arise 
from differing affinities of the proteins for other clock components, or differing 
expression levels of the proteins, which may affect the kinetics of the molecular 
feedback loops (Reppert and Weaver, 2001). However when both genes are deleted 
there is a complete loss of circadian rhythmicity in locomotor activity immediately 
upon placement in constant darkness (DD), thus indicating that the proteins are 
mutually redundant (van der Horst et a l, 1999, Vitatema et al., 1999, Reppert and 
Weaver, 2001). Additionally, when both CRY2 and CRY1 are deleted there is a loss 
of circadian rhythmicity and maintenance of expression at mid-high levels across the 
circadian cycle of PERI and PER2 in the SCN (Vitatema et al., 1999, Reppert and 
Weaver, 2001).
Homozygous mPER2 Brdml mutant mice, have a deletion that encodes an 87 residue 
carboxyl section of the PAS dimerization domain (Zheng et al., 1999, Reppert and 
Weaver, 2001), and exhibit shorter circadian periods followed by a loss of circadian 
rhythmicity in DD (Reppert and Weaver, 2001). The RNA levels of PERI, PER2 and 
CRY1 are still rhythmic in the SCN of these mice, however they are reduced in 
amplitude (Zheng et al., 1999, Shearman et al., 2000b, Reppert and Weaver, 2001). 
Furthermore, homozygous mPER2Brdrnl mutant mice exhibit blunted BMAL1 rhythms, 
thus supporting the role of PER2 in the positive regulation of BMAL1 transcription 
(Zheng et al., 1999, Reppert and Weaver, 2001). Moreover, the altered response to 
drugs of abuse and the dampened expression of monoamine oxidase a {MAOA) and 
monoamine oxidase b (MAOB) in these animals implicates PER2 in the mesolimbic 
dopaminergic system (Abarca et al., 2002, Spanagel et al., 2005, Hampp et al.,
2008). The rhythmic expression of mMAOA is dampened in the VTA and expression 
of both mMAOA and mMAOB is dampened in the ventral striatum (nucleus 
accumbens) of mPER2 Brdml mutant mice, thus lowering the activity of MAO and 
causing an elevation of dopamine levels in the striatum (Hampp et al., 2008).
In PERI deficient mice PER2 rhythms are unaltered and circadian rhythms in 
behaviour are maintained, hence it is thought that PERI is not as essential to core 
molecular clockwork as PER2 (Zheng et al., 1999, Reppert and Weaver, 2001). 
PERI is thought to instead have influences at a post-transcriptional level by
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regulating the stability of other circadian regulatory proteins (Bae et al., 2001). PER3 
is also not thought to be involved in the core circadian clockwork, since PER3 
mutant mice display a shortened circadian period, but maintain rhythmicity in DD 
(Shearman et al., 2000a, Reppert and Weaver, 2001), and although expression of 
mutant PER3 transcripts is reduced in the SCN, its disruption does not have any 
considerable effect upon expression of other core clock components (Reppert and 
Weaver, 2001). It is however postulated that PER3 may play a role in clock output 
(Reppert and Weaver, 2001), and in the human system PER3 has been implicated in 
various aspects of sleep homeostasis and circadian timing. This is demonstrated by a 
variable-number (4 or 5) tandem-repeat polymorphism in the coding region of the 
clock gene PER3, which has been implicated in sleep homeostasis (Viola et al., 
2007) and in executive performance under conditions of increasing sleep pressure 
due to sleep deprivation (Groeger et al., 2008, Vandewalle et al., 2009). This 
polymorphism has also been implicated in circadian timing, with an association of 
the 5-repeat polymorphism with morning preference and the 4-repeat polymorphism 
with evening preference (Dijk and Archer, 2010). Two single nucleotide 
polymorphisms (SNPs) within a polymorphic cluster of the gene have also been 
associated with delayed sleep phase syndrome (DSPS) (Archer et al., 2010).
The clock proteins are subject to post-translational modifications, thereby 
contributing to their stability and function and this process is thought to contribute to 
the imposing of a 24-hour time constant to the circadian clockwork (Reppert and 
Weaver, 2001), with in particular, the phosphorylation of PER2 being shown to be 
significantly involved in setting the period of the clock (Wilkins et al., 2007). 
Phosphorylation of these proteins regulates the formation of protein complexes, their 
nuclear entry and their degradation via ubiquination pathways (Meng et al., 2008). 
This post-translational modification is mainly carried out by two core clock 
components casein kinase Is (CKls) and casein kinase 18 (CK18), which are highly 
homologous (Reppert and Weaver, 2001, Guilding and Piggins, 2007). As previously 
described the tau mutation is a gain-of-function mutation in the CKls gene, resulting 
in a shortened circadian period by ~ 4 hours in comparison to the wild type animals 
(Ralph and Menaker, 1988, Reppert and Weaver, 2001, Meng et al., 2008). The 
mutation causes a substitution of a cysteine for a conserved arginine at residue 178, 
and functional analyses reveal that the mutant enzyme has reduced maximal velocity
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and reduced autophosphorylation, therefore resulting in an enzyme with increased 
affinity to bind to PERI and PER2, but decreased ability to phosphorylate them 
(Reppert and Weaver, 2001, Wilkins et al., 2007). In this situation binding of the 
mutant enzyme to PER, prevents PER from being able to bind to a functional enzyme 
(Reppert and Weaver, 2001). This is likely to impact upon PER by increasing its 
degradation, altering its stability and accelerating its turnover (Meng et al., 2008). 
Furthermore, in humans, a mutation in PER2 at the site of phosphorylation (Ser 659) 
by CKle is associated with a type of familial advanced sleep phase syndrome 
(FASPS) (Toh et al., 2001). The mutation causes hypophosphorylation, resulting in a 
phase advance, which is typically associated with a shorter free running period (Toh 
et al., 2001, Wilkins et al., 2007). Alterations in CK18 have also been associated with 
a form of familial advanced sleep phase syndrome (FASPS) (Xu et al., 2005, Wilkins 
et al., 2007). As previously mentioned, transplantation of the SCN of a wild-type 
hamster into the tau mutant hamster lengthens the circadian period, hence suggesting 
that the SCN is the site of the mutant CKIs/tau gene that is responsible for the tau 
phenotype (Ralph et al., 1990). Furthermore, transfer of the wild-type CKIe gene via 
electroporation into the SCN of tau mutant hamsters has been shown to lengthen the 
circadian period by up to 42 minutes (Wang et al., 2007). Although a lengthening of 
the circadian period was observed, the shortening by 4 hours observed in tau mutants 
was not restored, and this was thought to be due to the maintenance of the other 
casein kinases still present, which would compete with the transplanted CKIe protein 
(Ishida et al., 2001, Wang et al., 2007).
The functional hierarchy o f the circadian clock
The circadian system can be explained as a hierarchy, consisting of a master 
circadian pacemaker, and peripheral clocks, which are either semi-autonomous 
oscillators or slave oscillators (Guilding and Piggins, 2007) and which oscillate via a 
similar molecular mechanism to the master pacemaker (Balsalobre, 2002). A master 
circadian pacemaker can be defined as an oscillator that exhibits an endogenous, self- 
sustaining, approximate 24-hr rhythm that persists in isolation from all other tissues 
and external time-keeping cues, that maintains its period of free-running rhythms 
regardless of physiological temperature, that has the capacity to be reset (entrained) 
to environmental stimuli, and can communicate entrainment signals to other tissues
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(Guilding and Piggins, 2007). Semi-autonomous oscillators are populations of cells 
that can oscillate autonomously, but only with input from the master circadian 
pacemaker to synchronize these rhythms to a single rhythmic output within the tissue 
(Guilding and Piggins, 2007), whereas slave oscillators are independently arrhythmic 
tissues, but possess the capability to produce a rhythmic output entirely dependant on 
input from a master circadian pacemaker (Balsalobre, 2002, Reppert and Weaver, 
2002, Guilding and Piggins, 2007).
Clock gene expression has been widely documented in a number of regions of the 
mammalian brain outside of the SCN, for example the hypothalamic nuclei (Wyse 
and Coogan, 2010), the VTA (McClung et al., 2005, Hampp et al., 2008, Wang et al.,
2009), the hippocampus (Wakamatsu et al., 2001, Lamont et al., 2005, Chaudhury et 
al., 2008) and the amygdala (Lamont et al., 2005, Wang et al., 2009), and in the 
peripheral tissues; the liver, heart and skeletal muscle (Zylka et al., 1998, Reppert 
and Weaver, 2001, Storch et al., 2002). The peripheral tissues have been shown to 
contain circadian clocks, and clock gene expression has been shown to be 3-9 hours 
delayed in the peripheral clocks in comparison to the SCN (Balsalobre et al., 1998, 
Reppert and Weaver, 2001, Balsalobre, 2002). The peripheral oscillators are thought 
to be entrained to the light-dark cycle through a combination of neural and humoral 
output signals from the SCN (Oishi et al., 1998, Ueyama et al., 1999, Balsalobre et 
al., 2000, Reppert and Weaver, 2001, Keller et al., 2006), including the hormones 
melatonin and cortisol, which have been implicated in the entrainment of the 
peripheral oscillators (Keller et al., 2006, Wiechmann and Summers, 2008). The role 
of the peripheral oscillators in the regulation of biological processes is thought to be 
in receiving signals from the SCN, which then coordinate the expression of clock 
controlled genes, which in turn are thought to regulate more local rhythms in 
physiology and behaviour (Reppert and Weaver, 2001, Balsalobre, 2002, Reppert 
and Weaver, 2002).
Evidence suggests that there may be slight differences in the molecular clockwork at 
the peripheral level in comparison to the master pacemaker. For example, whilst 
NPAS2 is able to compensate for the loss of functional CLOCK protein in the SCN, 
such that SCN rhythmicity is maintained, NPAS2 alone is not capable of maintaining 
circadian rhythmicity in the absence of CLOCK in the peripheral oscillators of the
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liver and lung (DeBruyne et al., 2007a, DeBruyne et al., 2007b). Conversely, in the 
forebrain, NPAS2 is believed to function in the place of CLOCK (Reick et al., 2001). 
Additionally, in homozygous clock mutant mice, BMAL1 expression is elevated in 
the peripheral tissues, whilst its expression is dampened in the SCN (Oishi et al., 
2000, Reppert and Weaver, 2001).
More recently, the rhythmic expression of clock genes in the peripheral oscillators of 
human tissues, including peripheral blood mononuclear cells, fibroblasts, oral 
mucosa and hair follicle cells, have been utilised as a method of assessing human 
circadian clock functioning. Circadian oscillations of clock gene expression have 
been documented in the oral mucosa and skin cells of healthy human subjects 
(Bjamason et al., 2001). In both tissues CLOCK was expressed at a constant level 
with no rhythmicity across the circadian cycle (Bjamason et al., 2001), which is in 
accordance with the constitutive expression of CLOCK observed in the rodent SCN 
(Gekakis et al., 1998, Guilding and Piggins, 2007). On the other hand, BMAL1 and 
PERI expression was significantly rhythmic in both the oral mucosa and skin tissue, 
and a significant rhythm of CRY1 expression was detected in the oral mucosa 
(Bjamason et al., 2001). Furthermore measurement of peripheral clock gene 
expression in the oral mucosa has been employed to assess the impact upon the 
circadian clock of evening blue light, which is of the wavelength that is within the 
range of the photopigment melanopsin contained within the retinal ganglion cells 
(Cajochen et al., 2006). Here it was documented that blue light rapidly induced PER2 
expression, and hence the peripheral oscillator of the oral epithelial cells is 
responsive to the dominant Zeitgeber light (Cajochen et al., 2006). Circadian 
expression of the clock genes: BMAL1, PERI, PER2, REV-ERB a, DEC2 and DBP 
have been observed in fibroblast cell lines originating from human skin biopsies 
(Yang et al., 2009). Furthermore, a positive linear correlation has been demonstrated 
between the period length of fibroblast gene expression and human physiological 
period length as measured by melatonin concentrations (Pagani et al., 2010). Studies 
have also demonstrated rhythmic expression of the circadian clock genes in the 
peripheral blood mononuclear cells (Takata et al., 2002, Boivin et al., 2003, Teboul 
et al., 2005). Teboul et al., 2005 reported oscillations of BMAL1 and PER2 
expression, almost in phase with each other, and relatively constant expression of 
REV-ERB a across the circadian cycle. Additionally, two distinct molecular
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chronotypes were documented based upon two groups of subjects that exhibited 
differing phases of clock gene expression (Teboul et al., 2005). More recently 
circadian clock gene expression has been observed in the human hair follicle cells 
obtained from the head or the chin (Akashi et al., 2010). PER2 and DBP expression 
was reported to exhibit low amplitude oscillations, and the expression of BMAL1 and 
NPAS2 exhibited only a slight circadian oscillation (Akashi et al., 2010) The most 
robust and significant circadian rhythms of expression were observed for PER3, 
REV-ERB a, and REV-ERB /? (Akashi et al., 2010). Furthermore, the peak expression 
of PER3, REV-ERB a, and REV-ERB f3 was positively correlated with average 
wakefulness time as measured by actigraphy, and it was therefore concluded that the 
circadian rhythms of clock gene expression in the hair follicle cells correspond to the 
human behavioural rhythm (Akashi et al., 2010).
Entrainment o f the circadian clock
The dominant Zeitgeber that entrains the mammalian circadian clock is the light-dark 
cycle (Guilding and Piggins, 2007). Light is detected via the retina and photic 
information is conveyed to the SCN via the glutamatergic retinohypothalamic tract 
(RHT) which arises from widely distributed retinal ganglion cells (Moore et al., 
1995, Reppert and Weaver, 2001, Guilding and Piggins, 2007). Glutamate is die 
main neurotransmitter of the RHT and substance P and pituitary adenylate cyclise- 
activating peptide (PACAP) modulate entrainment (Ebling, 1996, Chen et al., 1999, 
Hamada et al., 1999, Reppert and Weaver, 2001). Glutamate is released as a 
consequence of photic stimulation and activates calcium-dependent signalling 
pathways (Reppert and Weaver, 2001, figure 1.3), and the extracellular-signal- 
regulated kinase (ERK) pathway has been implicated, which upon activation will 
result in the phosphorylation of cAMP response element binding protein (CREB) 
(Komhauser et al., 1996, Obrietan et al., 1998, Coogan and Piggins, 2003, Dziema et 
al., 2003, Lee et al., 2003, Coogan and Piggins, 2004, Antle et al., 2005, Guilding 
and Piggins, 2007). Phosphorylated CREB promotes transcription by binding to 
cAMP response elements (CRE) present in target genes, including PERI and PER2 
(Travnickova-Bendova et al., 2002, Guilding and Piggins, 2007). The circadian clock 
is able to regulate its responsiveness to inputs at specific points of the circadian 
cycle, through regulation of CREB phosphorylation whose light induction is limited
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to a nocturnal zone o f sensitivity (Ginty et al., 1993, Ding et al., 1997, Reppert and 
Weaver, 2001). Additionally, the immediate early genes c-FOS, FOSB  and JUNB  
also possess CRE sequences in their promoter regions and therefore are transcribed 
in response to night-time light pulses, in a similar manner to PERI and PER2 
(Greenberg et al., 1992, Perez-Albueme et al., 1993, Guilding and Piggins, 2007). c- 
FOS induction frequently occurs in parallel with a phase shift in response to various 
stimuli, however its induction in the SCN is not required for phase-shifting responses 
to light (Colwell et al., 1993, Weber et al., 1995, Honrado et al., 1996, Reppert and 
Weaver, 2001).
RHT
Glu 
!\
PACAP
SubP S C N  N e u r o n
cytoplasm
Ca2 +
MAPK
CaMK
PKA
PKC
PKG
S ' nucleus
ICREl IE box
U J
]CREl
Figure 1.3. The light input pathway to the SCN clockwork. Highlighted in red = 
elements known to be important for light activation o f pathways involved in the 
regulation o f behaviour. CLOCK = C, BMAL1 = B. Light stimulates glutamate (Glu) 
release from tenninals o f the RHT, which innervates the retinorecipient SCN. 
Glutamate differentially activates calcium-dependent signalling pathways; substance 
P (SubP) and PACAP released from the RHT modulate glutamate action. cAMP 
response element-binding protein (CREB) is phosphorylated by the kinases; MAP 
kinase (MAPK), protein kinase A (PKA), protein kinase C (PKC), protein kinase G 
(PKG) and CREB activates m PERl and mPER2 transcription via CRE sequences 
(blue) o f the PER gene promoter regions (Reppert and Weaver, 2001).
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Key components of the circadian system are the rhythmic output signals from the 
SCN, which are responsible for entrainment of the peripheral oscillators. The adrenal 
glucocorticoid stress hormone cortisol plays a key role in the hypothalamic-pituitary- 
adrenal (HPA) axis (Keller et al., 2006), but is also an important output of the master 
circadian pacemaker, and its secretion is regulated by output pathways of the SCN 
involving AVP and corticotropin-releasing hormone (Keller et al., 2006). Cortisol 
displays a circadian rhythm in its secretion consisting of an increase just before 
waking up in the morning, a peak within an hour of waking and then a decline over 
the rest of the 24-hour day (Van Someren and Riemersma-Van Der Lek, 2007). 
Environmental light exposure directly after awakening increases the amplitude of the 
morning peak, and so it can be postulated that a regular precise cortisol rhythm 
would be promoted by regular early morning light exposure (Van Someren and 
Riemersma-Van Der Lek, 2007). Cortisol is thought to be involved in the regulation 
of circadian rhythms (Keller et al., 2006) in particular the entrainment of the 
peripheral oscillators (Van Someren and Riemersma-Van Der Lek, 2007). Upon 
release from the adrenal glands cortisol binds predominantly with mineralocorticoid 
receptors (MRs) and to a lesser extent glucocorticoid receptors (GRs) (Keller et al.,
2006). The MRs are particularly involved in regulation of the evening-night nadir of 
the circadian rhythm (Kalman and Spencer, 2002, Otte et al., 2003, Young et al., 
2003, Keller et al., 2006), whereas the GRs are implicated in the feedback changes 
when cortisol levels are high, for example in response to stress, or during the peak of 
the circadian rhythm (Keller et al., 2006).
The pineal hormone melatonin is synthesised in the pinealocytes from tryptophan, 
which is taken up from the blood (Wiechmann and Summers, 2008) and the secretion 
of melatonin itself exhibits a clear circadian rhythm, with peak plasma levels usually 
between 02:00 and 03:00 am (Arendt and Skene, 2005, Pandi-Perumal et al., 2005). 
Input originating from the endogenous circadian pacemaker in the SCN via 
GABAergic mechanisms is thought to regulate melatonin synthesis (Reppert and 
Weaver, 2001). Furthermore input from the master pacemaker is essential for the 
synchronization of the circadian rhythm of melatonin to the light-dark cycle and the 
persistence of the rhythm (Macchi and Bruce, 2004). Melatonin also plays a role in 
mediating various circadian activities throughout the body through its antioxidant 
properties (Wiechmann and Summers, 2008). These include regulation of
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reproductive capacity, hormone secretion, immune responsiveness, daily rhythms of 
activity and entrainment of sleep/wake cycles (Wiechmann and Summers, 2008). 
The circadian rhythm of melatonin synthesis is closely linked to the sleep rhythm as 
demonstrated by the nocturnal onset of melatonin secretion, which usually occurs 2 
hours in advance of the individuals habitual bedtime, and correlates with evening 
sleepiness and the sleep promoting effect of exogenous melatonin (Tzischinsky et al., 
1993, Zhdanova et al., 1996, Zhdanova and Tucci, 2003, Pandi-Perumal et al., 2005). 
Melatonin is believed to have a strong entraining influence on the master circadian 
clock through its ability to directly feed back to the SCN (Pierce et al., 2008, Reppert 
and Weaver, 2001), where it is believed to have two main effects upon the SCN, 
acute neuronal inhibition and phase-shifting (Liu et al., 1997). Melatonin mediated 
inhibition of SCN neuronal firing is thought to promote sleep, via the activation of 
GABAergic mechanisms in the SCN (Golombek et al., 1996, Tenn and Niles, 1997, 
Pandi-Perumal et al., 2005). The firing rate of SCN neurons normally increases 
throughout the day, reaching a maximum in the evening, prior to the onset of 
melatonin production and this increase in electrical activity has been linked to the 
wakefulness-promoting effect of the circadian pacemaker (Pandi-Perumal et al., 
2005). Two subtypes of human G-protein coupled receptors (MTi and MT2) have 
been implicated in the sleep promoting and circadian effects of melatonin. MTi 
mRNA is expressed predominantly in the SCN, whereas MT2 mRNA is expressed in 
not only the SCN, but other areas of the CNS and the periphery (Reppert et al., 1988, 
Reppert et al., 1996, Pandi-Perumal et al., 2005). Both receptors are capable of 
mediating phase shifts (Reppert and Weaver, 2001) whilst just the SCN MTi 
receptors are related to amplitude of SCN circadian rhythmicity, the MT2 receptors 
are thought to be involved in entrainment of circadian rhythms (Liu et al., 1997, Hunt 
et al., 2001, Pandi-Perumal et al., 2005).
Interaction o f the circadian and catecholaminergic systems
The monoaminergic neurotransmitters, including dopamine and noradrenaline are 
involved in the regulation of a number of behaviours and physiological processes. 
The monoaminergic neurons are implicated in an arousal circuit involving 
noradrenergic neurons in the locus coeruleus, dopaminergic neurons in the ventral 
periaqueductal grey, serotonergic neurons in the dorsal raphe nucleus and the
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histaminergic neurons of the tuberomammilary nucleus, which project to the cerebral 
cortex (Mitchell and Weinshenker, 2010). These monoaminergic neurons receive 
input from the orexin neurons, which play a key role in the transitions between sleep 
stage and wakefulness (Lin et al., 1999, Carter et al., 2009, Mitchell and 
Weinshenker, 2010), and via the dorsal medial hypothalamus this system interacts 
with the SCN (Aston-Jones et al., 2001, Pace-Schott and Hobson, 2002). The 
noradrenergic system is also associated with the regulation of cortical functions 
including attention, alertness and vigilance (Biederman and Spencer, 1999). Whereas 
the neurotransmitter dopamine is involved in the regulation of mood (Nestler and 
Carlezon, 2006) and is also key to the brains reward system, with dopaminergic input 
from the ventral tegmental area (VTA) to the nucleus accumbens being involved in 
natural reward as well as the reward in response to drugs of abuse (Wise, 1998, Koob 
and Le Moal, 2001, Nestler and Carlezon, 2006). Characteristically many drugs of 
abuse will increase dopaminergic neurotransmission in the nucleus accumbens, 
which has been attributed to the rewarding effects of these drugs (Wise, 1998, Koob 
and Le Moal, 2001).
Furthermore, the extracellular concentrations of many neurotransmitters are known 
to exhibit a circadian rhythm in various brain regions, including dopamine and its 
metabolites in the striatum and nucleus accumbens (Smith et al., 1992, Paulson and 
Robinson, 1994, Paulson and Robinson, 1996, Castaneda et al., 2004) and 
noradrenaline in the SCN (Cagampang et al., 1994) and the pineal gland (Drijfhout et 
al., 1996). Furthermore, fibres containing tyrosine hydroxylase, the rate-limiting 
enzyme for dopamine biosynthesis, which hence has effects upon noradrenaline 
levels, have been located in the medial SCN (Cagampang et al., 1994). Many of 
these rhythms of extracellular neurotransmitter concentration appear to be 
endogenously regulated by the master circadian pacemaker, since they persist under 
constant conditions (Barassin et al., 2002, Castaneda et al., 2004). The 
catecholaminergic systems have also been implicated in regulation of the circadian 
system, with the dopamine system being involved in the entrainment of the master 
pacemaker, in particular the function of dopamine neurons in the regulation of light 
input in the retina (Witkovsky, 2004, McClung et al., 2005) and the essential role of 
D1 dopamine receptors in the synchronization of the SCN during prenatal 
development (Ferguson et al., 2000). Noradrenaline is known to influence
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spontaneous activity and photic responsiveness of the SCN neurons (Nishino and 
Koizumi, 1977, Liou et al., 1986, Rosenwasser, 1996), and it has been proposed as 
an entrainment signal originating from the SCN to entrain the peripheral oscillator of 
the pineal gland (Wongchitrat et al., 2009), since it has been observed in rodents that 
the expression of the clock genes PERI and CRY2 is regulated by nocturnal 
noradrenaline release in the pineal gland (Fukuhara et al., 2000, Simonneaux et al.,
2004). Noradrenaline is further implicated in the circadian system, by its regulation 
of melatonin production (Wongchitrat et al., 2009). Nocturnal noradrenaline release 
in the pineal gland causes an upregulation of arylalkylamine N-acetyltransferase 
(AA-NAT), the enzyme responsible for acetylation of serotonin, which along with 
methylation by hydroxyindole-O-methyltransferase, results in the production of 
melatonin (Wongchitrat et al., 2009). Since melatonin plays a key role in mediating 
various circadian activities including the sleep-wake cycle (Reppert and Weaver, 
2001, Pierce et al., 2008, Wiechmann and Summers, 2008), it can be postulated that 
noradrenaline levels could affect these processes also. Furthermore associations 
between altered behaviours that are controlled by these neurotransmitter systems and 
perturbations to the circadian system have been observed. For example, learning and 
memory are influenced by sleep and circadian disturbance (Dijk et al., 1992, 
Peigneux et al., 2004, Ellenbogen et al., 2006, Wright et al., 2006, Ruby et al., 2008, 
Wang et al., 2009). Moreover, the circadian rhythm of rodent locomotor activity is 
significantly disrupted by dopamine depletion due to a 6-hydroxydopamine lesion of 
the VTA (Isobe and Nishino, 2001), and dopamine P-hydroxylase knockout mice do 
not produce noradrenaline, and exhibit perturbed sleep and arousal rhythms (Mitchell 
and Weinshenker, 2010).
Interactions of the monoaminergic systems and the circadian clock are observed on 
the molecular level also. The rodent monoamine oxidase A (MAOA) promoter has 
been shown to be subject to regulation by BMAL1, NPAS2 and PER2 in the VTA, 
with BMAL1 being shown to bind the mMAOA promoter directly with circadian 
rhythmicity (Hampp et al., 2008). The dopamine receptors have also been shown to 
influence clock gene expression, with treatment of the striatal neurons with a D1 
receptor agonist causing an upregulation of the expression of the clock genes PERI, 
CLOCK, NPAS2 and BMAL1, whereas a D2/D3 receptor agonist suppressed CLOCK 
and PERI expression (Imbesi et al., 2009). Furthermore, daily dopaminergic
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activation of the D2 receptors is thought to be essential to the rhythmic expression of 
PER2 in the rodent dorsal striatum (Hood et al., 2010). A mechanism by which the 
monoamines may interact with circadian clock genes could be through the cAMP 
system (Uz et al., 2005), since the dopamine receptors are known to affect cAMP 
levels (Andersen et al., 1990). Furthermore, the phosphorylation of mitogen activated 
protein kinase (MAPK) and cAMP response element binding protein (CREB) is 
stimulated by both dopamine (Yan et al., 1999) and noradrenaline (Tamotsu et al., 
1995, Thonberg et al., 2002), and a number of clock genes are known to possess 
CRE binding sequences (Takahata et al., 2000, Travnickova-Bendova et al., 2002).
1.2 Circadian Rhythms in Psychiatry
Circadian rhythm disturbance is evident in psychiatry, and is observed in disorders 
including schizophrenia, unipolar depression and bipolar depression (Atkinson et al., 
1975, Wehr et al., 1983, Madjirova et al., 1995, Rausch et al., 2003, Yang et al., 
2009, Gouin et al., 2010, Lamont et al., 2010). The social Zeitgeber theory states that 
mood disorders can develop as a result of circadian rhythm disturbance, where 
circadian rhythm disruption may arise from life stresses, which perturb normal social 
routines and sleep/wake cycles, resulting in changes in biological rhythms and mood 
(McClung, 2007). This hypothesis is supported by evidence for the comorbidity of 
the circadian rhythm disorders familial advanced sleep phase syndrome (FASPS) and 
delayed sleep phase syndrome (DSPS) with depression and anxiety (Shirayama et al., 
2003, Xu et al., 2005, Hamet and Tremblay, 2006, McClung, 2007, Barnard and 
Nolan, 2008). Furthermore, therapies that stabilise or alter the circadian rhythm are 
successful in improving some of the symptoms of psychiatric illness (e.g. Wu and 
Bunney, 1990, Leibenluft and Wehr, 1992, Barbini et al., 1998, Benedetti et al., 
2001, Gould and Manji, 2005, Yin et al., 2006, Lamont et al., 2010).
Deficits in the sleep-wake cycle in psychiatry are widely documented, with 
polysomnographic and actigraphic studies revealing alterations in a number of 
circadian and sleep parameters in association with bipolar disorder, depression and 
schizophrenia. Insomnia and hyperinsomnia, early morning awakening, reduced 
sleep efficiency and most commonly reported altered REM sleep latency have been 
widely observed in bipolar disorder (Boivin, 2000, Lamont et al., 2010). The sleep-
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wake cycle also appears to play a role in the regulation of mood in bipolar disorder, 
as demonstrated by the association between the switch from mania/hypomania to 
depression or euthymia during or after sleep, whereas the switch from depression to 
mania/hypomania tends to occur after a period of wakefulness (Feldman-Naim et al., 
1997, Voderholzer et al., 2002, Lamont et al., 2010). Furthermore disturbances in the 
sleep-wake cycle, particularly sleep restriction, appears to increase the risk of a 
manic/hypomanic episode the following day (Leibenluft et al., 1996, Harvey, 2008, 
Boyce and Barriball, 2010, Lamont et al., 2010). Conversely, depression is 
associated with increased duration of sleep (Wehr, 1989, Leibenluft et al., 1996, 
Lamont et al., 2010). In unmedicated schizophrenics, polysomnography 
demonstrated poor sleep initiation and consolidation, impaired sleep homeostasis 
expressed as low levels of slow wave sleep and shortened REM sleep latency 
(Boivin, 2000, Chouinard et al., 2004, Lamont et al., 2010). Insomnia and a shorter 
REM stage latency after sleep onset has also been observed among depressed 
patients (Kupfer and Foster, 1972, Riemann et al., 2001), and a recent study reported 
that the severity of major depression correlates with circadian disturbance, therefore 
the greater the phase delay of the pacemaker relative to the timing of sleep, the more 
severe the symptoms of the disorder (Emens et al., 2009, de Bodinat et al., 2010).
The circadian rhythm of activity can be described by designation of chronotype, 
which refers to an individual’s innate preference to be active and alert either in the 
morning or the evening, accordingly known as “momingness” or “eveningness” 
(Home and Ostberg, 1977). The intrinsic period of the circadian clock is thought to 
be linked to diumal preference (Duffy et al., 2001, Johansson et al., 2003) and longer 
free-running circadian periods are associated and possibly causative of later phases 
of behaviour under the normal light-dark cycle, whilst shorter periods are associated 
with earlier phases (Brown et al., 2008). Extreme diumal preference has been linked 
with psychiatric illness, with associations between eveningness and both 
schizophrenia and bipolar disorder, and greater severity and increased cycling of 
mood in bipolar disorder (Mansour et al., 2006, Lamont et al., 2010).
A link of both depression and bipolar disorder with circannual rhythms, which are 
the yearly seasonal patterns observed in nature, has been widely documented (Boyce, 
1985, Westrin and Lam, 2007, Boyce and Barriball, 2010). Depression in seasonal
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affective disorder (SAD) is associated with the winter months, and a phase delay is 
the proposed circadian deficit responsible for the symptoms, as demonstrated by 
delayed temperature and melatonin secretion rhythms (Khalsa et a l, 2000, Boyce 
and Barriball, 2010). An increase in the number of bipolar episodes of depression or 
hypomania have been observed during certain times of the year, which it is thought 
to be due to failure in adaptation to the seasonal change in day length resulting in 
internal disorganisation of the circadian system, which causes mood problems 
(Boyce, 1985, Westrin and Lam, 2007, Boyce and Barriball, 2010).
The measurement of core body temperature and blood pressure both of which exhibit 
clear circadian rhythmicity, has been utilised as a key indicator of circadian clock 
functioning. An elevation in nocturnal body temperature has been associated with 
depression (Rausch et al., 2003, Gouin et al., 2010). Disturbance in core body 
temperature, blood pressure and pulse has been observed in schizophrenia 
(Madjirova et al., 1995, Lamont et al., 2010), and a shortened or lengthened circadian 
period has been associated with bipolar disorder (Atkinson et al., 1975, Wehr et al., 
1983, Yang et al., 2009).
As previously described, the molecular basis of the circadian clock consists of a 
number of transcriptional/translational feedback loops of circadian clock genes and 
their protein products (Boyce, 1985, Westrin and Lam, 2007, Boyce and Barriball, 
2010). Hence there have been a number of studies that have aimed to assess 
abnormalities in these clock components in psychiatric illness, including 
measurement of clock gene expression, screening of single nucleotide 
polymorphisms (SNPs), and investigation into the effects upon behaviour in rodent 
models deficient in one or more of these clock components, which will now be 
described.
A study of clock gene expression at a specific single time-point in the peripheral 
blood mononuclear cells revealed an upregulation of mCLOCK, mBMALl and 
mPERl expression in individuals with a history of unipolar depression in comparison 
to healthy controls, and levels of mCLOCK were found to predict history of the 
disorder (Gouin et al., 2010). Levels of mCRY2 have been assessed in bipolar 
depression before and after sleep deprivation, a key trigger for bipolar episodes
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(Lavebratt et al., 2010b). Lowered levels of mCRY2 at a single time-point in the 
peripheral blood mononuclear cells have been associated with bipolar disorder, and 
sleep deprivation was shown to prompt an increase in mCRY2 in the control subjects, 
but not in bipolar patients (Lavebratt et al., 2010b). Studies of gene expression at a 
single time-point are however limited by the inability to detect phase alterations in 
the rhythms of clock gene expression. Microarray analysis of post-mortem brain 
tissue has revealed a dampening of mPERl expression in schizophrenia (Aston et al., 
2004, Lamont et al., 2010). Clock gene expression in the fibroblasts of bipolar 
patients has been studied, and although the rhythmic expression of mBMALl, PERI, 
mPER2, mREV-ERB a, mDEC2 and mDBP was not significantly altered in bipolar 
disorder, there were trends towards reduced expression of mDBP and mDEC2, 
reduced phosphorylation of GSK3(3 and reduced amplitude of the BMAL1 expression 
rhythm in association with the disorder (Yang et al., 2009). DEC2 and DBP have 
been proposed to play a role in the core circadian clock (Yamaguchi et al., 2000b, 
Honma et al., 2002, Yang et al., 2009), although they are also known as clock 
controlled genes that could effect downstream gene regulation (Ripperger et al., 
2000, Noshiro et al., 2007, Yang et al., 2009). It could be postulated that such 
alterations in the expression of core clock components could have downstream 
effects upon clock controlled processes, and hence contribute to the pathogenesis of 
the disorder.
Associations of genetic variations in the core clock genes and both psychiatric and 
sleep disorders have been extensively investigated. Numerous studies have revealed 
an association between the rs 1801260 C/T SNP in the core circadian clock gene 
CLOCK and psychiatric illness. The SNP has been found to be associated with a 
higher number of bipolar episodes in bipolar patients (Benedetti et al., 2003, 
McClung, 2007), although this has not been replicated in other studies (Desan et al., 
2000, Johansson et al., 2003). Greater insomnia in bipolar patients and individuals 
undergoing antidepressant treatment has also been associated with the CLOCK SNP 
(Serretti et al., 2003, Serretti et al., 2005, McClung, 2007). An association between 
the C allele of the SNP and schizophrenia has been reported and it has been 
hypothesised that the CLOCK SNP along with aberrant dopaminergic transmission to 
the SCN could underlie the pathophysiology of the disorder (Takao et al., 2007, 
Lamont et al., 2010). The same SNP has also been implicated in diumal preference,
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with reports of an association between the C allele and evening preference 
(Katzenberg et al., 1998, Mishima et al., 2005), although no association has also been 
reported (Robilliard et al., 2002). Since this SNP is located in the 3’ flanking region 
of the CLOCK gene it can be postulated that it could effect processes integral in the 
regulation of translation efficiency, mRNA stability, and polyadenylation signals, 
(McClung, 2007).
Polymorphisms in other clock genes have also been associated with psychiatric 
illness including polymorphisms in BMAL1, PER3 and TIMELESS, which have been 
associated with bipolar disorder (Mansour et al., 2006, Nievergelt et al., 2006, Yang 
et al., 2009). It has also been suggested that the interaction of several clock gene 
polymorphisms may be necessary to disrupt circadian gene function (Lavebratt et al., 
2010b, Rosenwasser, 2010) as demonstrated by reports of the interaction of 3 clock 
gene polymorphisms in predicting bipolar disorder (Shi et al., 2008, Gouin et al., 
2010). In schizophrenia associations with polymorphisms in PERI, PER3 and 
TIMELESS have been reported (Aston et al., 2004, Mansour et al., 2006, 
Rosenwasser, 2010) and polymorphisms in PER2, NPAS2 and BMAL1 have been 
associated with depression in SAD (Johansson et al., 2003, Partonen et al., 2007, 
Lavebratt et al., 2010a).
Moreover, studies using rodent models for bipolar disorder have revealed circadian 
genes are candidate genes for mania and psychosis, including BMAL1, CRY2, 
GSK3/3, CKI3, and DBP (Niculescu et al., 2000, Ogden et al., 2004, Yang et al.,
2009). Also, the CRY1 gene is located near a linkage hotspot for schizophrenia on 
chromosome 12q24, and it is therefore suspected to be involved in the disorder (Peng 
et al., 2007, Lamont et al., 2010). Furthermore its expression impacts upon the 
activity of psychoactive drugs (Uz et al., 2005, Lamont et al., 2010).
Not only have the molecular properties of the circadian system been implicated in 
psychiatric disorders, but so have some of the key outputs of the master circadian 
pacemaker. Much research has addressed the role of potential abnormalities in the 
HPA-axis mediated response to stress via cortisol reactivity in psychiatric illness 
(Hong et al., 2003, Blomqvist et al., 2007, Sondeijker et al., 2007, Lackschewitz et 
al., 2008, Randazzo et al., 2008, Hastings et al., 2009). However, the potentially
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compromised role of cortisol in the circadian system has also been under scrutiny, 
and perturbed circadian profiles of cortisol secretion have been associated with 
psychiatric illness. Studies of the cortisol rhythm in depression have reported a wide 
range of alterations including an association of an earlier, elevated or reduced period 
of nadir with depression (Halbreich et al., 1985, Pfohl et al., 1985, Yehuda et al., 
1996, Keller et al., 2006). Furthermore, elevated evening cortisol levels have been 
associated predominantly with the psychotic symptoms of depression, and not the 
disorder generally (Rothschild et al., 1982, Keller et al., 2006) and it has been 
speculated that this could be due to reduced feedback inhibition of HP A axis activity, 
involving the mineralocorticoid receptors, due to their proposed role in the regulation 
of the HPA axis during the evening hours (Keller et al., 2006). Flattened diumal 
rhythms of cortisol secretion have been demonstrated in remitted bipolar disorder, 
with greater disturbance of the rhythm being associated with increased number of 
previous episodes (Havermans et al., 2010). Cortisol hypersecretion in bipolar 
patients during both depressed and hypomanic phases has been documented, but to 
the contrary there was no alteration in overall cortisol level detected in remitted 
bipolar patients (Cervantes et al., 2001). Other studies have reported advanced 
phases of cortisol secretion in bipolar disorder (Beck-Friis et al., 1985b, Linkowski et 
al., 1994, Lamont et al., 2010). The findings of studies of diumal cortisol profiles in 
schizophrenia are mixed. Basal HPA-axis functioning as measured by overall cortisol 
concentration throughout the day has been reported as normal in schizophrenia, 
whilst other studies have reported an association of normal diumal cortisol 
concentrations with both medicated and unmedicated patients (Kemali et al., 1985, 
Gil-Ad et al., 1986, Van Cauter et al., 1991, Jiang and Wang, 1998, Hempel et al., 
2010). To the contrary, heightened sensitivity of the HPA-axis as indicated by a 
steeper decrease in cortisol concentration during the day has been observed in 
schizophrenic patients (Hempel et al., 2010) as well as increased cortisol levels 
during the day of unmedicated schizophrenia patients (Monteleone et al., 1992, Ryan 
et al., 2004, Gunduz-Bruce et al., 2007, Hempel et al., 2010). It could be postulated 
that since the cortisol rhythm provides an entrainment signal from the SCN to the 
peripheral oscillators, any abnormalities in the cortisol rhythm could have 
implications for the synchronisation of the circadian system and consequently exert 
several physiological effects (Van Someren and Riemersma-Van Der Lek, 2007).
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It is well documented that an abnormal circadian rhythm of melatonin secretion is 
demonstrated in psychiatric illness. A number of abnormalities in the circadian 
rhythm of melatonin have been associated with bipolar disorder, including a phase 
advance in the rhythm, reduced amplitude of the melatonin rhythm and greater 
sensitivity to light suppression of melatonin (Beck-Friis et al., 1985b, Souetre et al., 
1989, Srinivasan et al., 2006, Lamont et al., 2010). Anomalies in the melatonin 
rhythm have also been documented in depression, particularly, lower concentrations 
of melatonin have been reported and delayed melatonin release has been observed in 
depressed patients (Parry and Newton, 2001, Macchi and Bruce, 2004, Gouin et al.,
2010), whilst the melatonin rhythm has been shown to be unaltered in depression by 
another study (Waldhauser et al., 1993). Additionally it has been demonstrated that 
plasma melatonin levels increase with improvement of clinical symptoms in patients 
suffering from major depressive disorder who are undergoing antidepressant 
treatment (Thompson et al., 1985, Golden et al., 1988, Pandi-Perumal et al., 2005). It 
is hypothesised that this occurs through photoperiodic dysregulation (Partonen, 1998, 
Macchi and Bruce, 2004), which is more likely to be associated with the phase of the 
melatonin rhythm relative to the day-night cycle rather than the amplitude or 
absolute level of melatonin (Lewy et al., 1987a, Macchi and Bruce, 2004). Several 
studies have reported perturbations of the melatonin rhythm in schizophrenia also, 
including a significantly longer period of the melatonin rhythm and a dampened 
nocturnal increase in melatonin secretion (Monteleone et al., 1992, Macchi and 
Bruce, 2004, Wulff et al., 2006). Due to the strong entraining influence melatonin 
has upon the master circadian clock, and its potential role in the entrainment of the 
peripheral oscillators (Wiechmann and Summers, 2008), it could be postulated that 
any abnormalities in the melatonin rhythm could impact particularly on the sleep- 
wake cycle, but also affect a number of other behavioural and physiological 
processes, thus contributing to the pathophysiology of psychiatric illness.
Various therapies for psychiatric illness have been implicated in some form of 
modulation of the circadian clock, including pharmacological treatments, bright light 
exposure and implementing enforced sleep patterns. Lithium is a pharmacological 
mood stabilizer predominantly used for the treatment of bipolar disorder, which 
appears to interact with the circadian clock in a number of ways. Firstly it was shown 
to reduce sensitivity to light suppression of melatonin in controls subjects (Hallam et
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al., 2005, Lamont et al., 2010). Secondly it lengthens the circadian period in rodents 
(LeSauter and Silver, 1993, Lamont et al., 2010), and also in SCN neuronal firing of 
cultured cells in a dose dependant manner (Abe et al., 2000, Lamont et al., 2010). It 
has been proposed that one of the mechanisms of action of lithium could be through 
the inhibition of GSK3J3, as GSK3(3 does function as a regulator of the circadian 
clock (Gould and Manji, 2005, Iitaka et al., 2005, Lamont et al., 2010). PER2 and 
REV-ERBa have both been shown to be modulated by lithium and GSK3(3, with 
knockdown of both lithium and GSK3p causing a lengthening of the period of PER2 
expression (Kaladchibachi et al., 2007, Lamont et al., 2010). Furthermore GSK3P 
affects the nuclear entry of PER2 (Iitaka et al., 2005, Lamont et al., 2010). Via the 
inhibition of GSK3P, lithium dampens REV-ERBa expression (Yin et al., 2006, 
Lamont et al., 2010). Moreover, it is thought that other mood stabilizers such as 
valproate may inhibit GSK3p, and other antidepressant therapies including 
serotonergic and dopaminergic agents may target GSK3p (Gould and Manji, 2005, 
Lamont et al., 2010), hence implicating it in the pharmacological treatment of a wide 
range of psychiatric disorders.
Light therapy and sleep deprivation have been shown to be efficacious in treating 
both depression in SAD and non-seasonal depression, and bipolar disorder during the 
depressive phase (Wehr et al., 1979, Wu and Bunney, 1990, Leibenluft and Wehr, 
1992, Barbini et al., 1998, Benedetti et al., 2001, Lamont et al., 2010). Bright light 
therapy normally consists of 10000 lux light every morning post waking, for 30-60 
minutes (Eastman et al., 1998, Lewy et al., 1998, Terman et al., 1998, Desan and 
Oren, 2001, Glickman et al., 2006). Morning light is more efficacious if timed 
appropriately to the melatonin rhythm, which in most clinical situations is 
approximated by chronotype (Terman, 2007). Dawn awakening therapy has also 
been used to treat seasonal depression, consisting of 300 lux light at the end of the 
sleep interval (Terman et al., 1989, Terman, 2007). Dawn simulation therapy appears 
to be as effective at treating seasonal depression as post awakening bright light 
therapy (Terman and Terman, 2006, Terman, 2007). Light therapy has also shown 
some effectiveness in the treatment of non-seasonal depression (Goel et al., 2005, 
Terman, 2007). However, mild seasonality, with depressive episodes occurring 
throughout the year but with increased prevalence during the winter months, has 
been reported for a considerable number of patients with non-seasonal depression
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(Terman, 2007). Therefore it could be the mildly seasonal component in these cases 
that is responsible for the positive effects of bright light therapy (Terman, 2007). The 
effects of light treatment on bipolar disorder have been more mixed, with some 
individuals showing improvement in clinical symptoms, whilst others are non- 
responsive, and it has been postulated that for it to be efficacious, a more sensitive 
dosing strategy would be required than that used for SAD (Leibenluft et al., 1995, Sit 
et al., 2007, Terman, 2007). However in combination with mood stabilizers and sleep 
deprivation, light therapy has shown some effectiveness in alleviating some of the 
symptoms of bipolar disorder (Benedetti et al., 2005, Benedetti et al., 2007). 
However light therapy does run the risk of triggering mood instability and a 
manic/hypomanic episode (Leibenluft et al., 1995, Leibenluft et al., 1996, Sit et al., 
2007, Lamont et al., 2010). Phase advancing the sleep time was also found to be an 
effective treatment during the depressive phase of bipolar disorder (Wehr et al., 
1979, Benedetti et al., 2001, Lamont et al., 2010).
Due to the observed abnormalities of the circadian rhythm of melatonin in depression 
and its effects upon the circadian clock, several studies have investigated the 
potential therapeutic use of exogenous melatonin in treating depression. Exogenous 
melatonin has been shown to exhibit a synchronising effect upon circadian rhythms, 
and has been used to facilitate adaptation to jet lag (Claustrat et al., 1992, Petrie et 
al., 1993, Dalton et al., 2000) and synchronizing the sleep-wake cycle of blind 
patients to an environmental light/dark cycle (Sack et al., 1991, Tzischinsky et al., 
1992, Dalton et al., 2000). Due to its hypnotic effects, melatonin has been shown to 
improve sleep duration and sleep maintenance as well as re-synchronize the sleep- 
wake rhythm in individuals suffering from chronic sleep onset insomnia, delayed 
sleep phase syndrome, and in elderly patients who suffer from insomnia (MacFarlane 
et al., 1991, Brown, 1994, Haimov and Lavie, 1995, Haimov et al., 1995, Dalton et 
al., 2000). In patients with major depressive disorder, exogenous melatonin was 
shown to result in a 50% increase in sleep quality although there was no 
improvement in the clinical symptoms of depression (Dolberg et al., 1998). 
Similarly, in patients suffering from treatment-resistant depression melatonin 
treatment reduced insomnia, but with no effect upon mood (Dalton et al., 2000).
More recently the effects of agomelatine, a novel non-monoaminergic antidepressant
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have been investigated in the treatment of depression. Agomelatine has been shown 
to resynchronize circadian disturbance in both nocturnal and diurnal rodent models 
of jet lag, DSPS, SAD and ageing, all of which displays depressive symptoms in 
association with circadian misalignement (Armstrong et al., 1993, Redman et al., 
1995, Van Reeth et al., 2001, Wirz-Justice et al., 2005, de Bodinat et al., 2010). In 
rodents it was shown that the action of agomelatine was sustained in rats that had 
undergone a pinealectomy, but in SCN lesioned rodents, the resynchronizing action 
of agomelatine was abolished, thus indicating its action was independent of the 
pineal gland, but dependant upon the SCN (Morgan et al., 1994, Redman and 
Francis, 1998, Pitrosky et al., 1999, Jockers et al., 2008, de Bodinat et al., 2010). In 
humans the main effect of agomelatine upon the circadian system has been a phase 
advance in the body temperature rhythm without affecting the level of melatonin in 
healthy human subjects (de Bodinat et al., 2010). Clinical trials have shown that 
agomelatine is effective in treating major depression in mildly and severely ill 
patients, producing an improvement in sleep quality (Kennedy and Emsley, 2006, 
Lemoine et al., 2007, Olie and Kasper, 2007, Kennedy et al., 2008, Kasper and 
Hamon, 2009, Kasper et al., 2010, de Bodinat et al., 2010). The main actions of 
agomelatine are to bind to the Ml and M2 melatonin receptors, suppress cAMP 
formation, and mimic the actions of melatonin by inhibiting SCN neuronal firing 
(Ying et al., 1996, de Bodinat et al., 2010). However, agomelatine also blocks 5-HT2c 
receptors, which are involved in the regulation of mood and the stress response 
(Giorgetti and Tecott, 2004, Millan, 2005, de Bodinat et al., 2010). The synthesis of 
serotonin is also under circadian regulation, and its pathways innervate the SCN and 
are implicated in the modulation of circadian rhythms (Kennaway and Moyer, 1998, 
Barassin et al., 2002, Varcoe and Kennaway, 2008, Cuesta et al., 2009, de Bodinat et 
al., 2010). Therefore, the action of agomelatine is thought to involve both agonistic 
effects upon the melatonin receptors and antagonist effects upon the 5-HT2c receptors 
(de Bodinat et al., 2010).
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1.3 Introduction to ADHD
Attention deficit-/hyperactivity disorder (ADHD) is a psychiatric condition that is 
characterised by inattention, hyperactivity, impulsivity and pervasiveness (Thome 
and Jacobs, 2004). ADHD can affect both children and adults (Biederman and 
Faraone, 2005). With the prevalence of ADHD in school aged children estimated at 
3-7% (van West et al., 2009) it is the most commonly diagnosed cognitive and 
behavioural disorder in children (Banerjee et al., 2007). Approximately half of those 
individuals suffering from childhood ADHD are thought to carry over their 
symptoms into adulthood (Biederman and Faraone, 2005). Although there is an age- 
dependant decline in ADHD symptoms (by the age of 30-40 years, the majority of 
individuals diagnosed with childhood ADHD will no longer meet the criteria to be 
diagnosed with the disorder), some individuals will still demonstrate impairing 
symptoms (Biederman and Faraone, 2005). There are clear differences in the 
symptomology of ADHD between children and adults, with the hyperactive- 
impulsive symptoms decreasing in adulthood, and individuals who were diagnosed 
with the combined subtype in their childhood, being re-diagnosed with the 
inattentive subtype in adulthood (McGough and Barkley, 2004). This however could 
be due to the DSM-IV diagnostic criteria for hyperactive and impulsive behaviour 
not being suitable for detection of these symptoms in adulthood (McGough and 
Barkley, 2004). Furthermore in adulthood secondary problems of the disorder can 
develop, such as emotional instability, delinquency and drug addiction (Rosier et al.,
2004).
ADHD is more commonly diagnosed in males, and this is thought to be 
predominantly due to gender differences between symptoms, with the symptoms in 
men being more obvious and so more easily diagnosed (Biederman and Faraone, 
2004, Biederman and Faraone, 2005). Furthermore, men are thought to be at 
increased risk of environmental causes of the disorder, for example head injury 
(Faraone et al., 2000b, Biederman and Faraone, 2005). Low socioeconomic status 
and young age are also associated with ADHD (Scahill and Schwab-Stone, 2000, 
Doyle, 2004, Biederman and Faraone, 2005). In the UK DSM-IV is accepted as the 
formal diagnostic criteria for childhood ADHD, from which three subtypes of 
ADHD can be diagnosed; hyperactive-impulsive, inattentive and the combined
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(McGough and Barkley, 2004, Biederman and Faraone, 2005). Diagnosis of adult 
ADHD requires both the use of DSM-IV criteria for diagnosis of retrospective 
childhood ADHD symptoms, along with additional scales including the Adult 
ADHD Self Report Scale (ASRS) and structured clinical interviews. There is 
evidence to suggest that the ADHD subtypes may not be manifestations of the same 
disorder but could be classed as completely separate conditions, although this 
hypothesis is still subject to debate (Faraone et al., 2000a, Smalley et al., 2000, 
Willcutt et al., 2000, McGough and Barkley, 2004).
It is widely believed that ADHD is a disorder that is caused by a dysfunction in the 
noradrenergic, dopaminergic and serotonergic systems, the neurotransmitters of 
which are intricately involved in the modulation of behaviours that are altered in 
ADHD (Comings, 2001, Biederman, 2005, Faraone and Khan, 2006, Chamberlain et 
al., 2007b, Nedic et al., 2010). This hypothesis is supported by a variety of evidence 
including that the targets of the pharmacological treatments for ADHD are 
components of these systems. The striatum contains a high degree of dopaminergic 
synapses and dopamine transporters, which are the targets of the stimulant 
methylphenidate, which is used to treat ADHD (Volkow et al., 1998, Volkow and 
Swanson, 2003, Biederman and Faraone, 2005). Rodents whose striatum is not intact 
exhibit hyperactivity and poor-inhibition control, which are characteristic behaviours 
of ADHD (Alexander et al., 1986, Biederman and Faraone, 2005). The 
spontaneously hypertensive rat is a well known rodent model for ADHD, and 
demonstrates abnormalities in dopamine release in the subcortical brain regions 
(Russell, 2000, Biederman and Faraone, 2005). The enzyme monoamine oxidase 
(MAO) is involved in the oxidative deamination of dopamine, noradrenaline and 
serotonin (Oreland, 2004, Nedic et al., 2010). An association has been reported of 
lowered platelet monoamine activity with the hyperactive, inattentive and impulsive 
symptoms of childhood ADHD patients (Nedic et al., 2010). Impairments in 
oxidative metabolism have also been observed in adult ADHD (Selek et al., 2008). 
Oxidative processes modulate brain function, for example the oxidant nitric oxide 
(NO) impacts upon catecholamine release, memory and learning and wakefulness 
(Akyol et al., 2004, Selek et al., 2008). Elevated levels of NO and decreased levels of 
the antioxidant superoxide dismutase (SOD) have been reported in adult ADHD, and
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it was speculated that via its oxidative impact upon dopamine this could affect the 
pathways that control attention and physical activity (Selek et al., 2008).
The frontal subcortical circuits have been strongly implicated in the manifestation of 
the disorder. These brain regions are responsible for mediating executive functions 
such as inhibition, working memory, planning and sustained attention (Robbins et al., 
1998, Miyake et al., 2000, Barkley et al., 2001, Castellanos and Tannock, 2002, 
Biederman and Faraone, 2005). A reduction in the volume of the front subcortical 
regions has been observed in ADHD by both structural and functional neuroimaging 
(Faraone and Biederman, 1998, Biederman and Faraone, 2005). Another study has 
revealed that in patients with ADHD there are significant patterns of frontal 
hypoactivity, affecting anterior cingulated, dorsolateral prefrontal, and inferior 
prefrontal cortices, and also related regions including the basal ganglia, thalamus, 
and portions of the parietal cortex (Dickstein et al., 2006, Ludolph et al., 2008b). The 
dopamine system in the midbrain, particularly the VTA and substantia nigra are 
thought to be important in the pathogenesis of ADHD (Viggiano et al., 2004), and 
PET scans have demonstrated a reduction in function of the brains dopamine reward 
circuit in ADHD (Volkow et al., 2010).
ADHD is a highly heritable disorder, with a 2 to 8 fold increase in the risk of 
developing the disorder in the parents and siblings of ADHD patients (Banerjee et 
al., 2007) and this is further demonstrated by twin and adoption studies (Faraone and 
Doyle, 2001, Faraone, 2004, Biederman and Faraone, 2005). It is also a 
multifactorial and heterogeneous condition (Nedic et al., 2010). Genetic variants of 
components involved in the dopaminergic, noradrenergic and serotonergic systems 
have been widely implicated in ADHD. A polymorphism in the dopamine D3 
receptor gene (DRD3), which is thought to alter receptor incorporation in the 
membrane, has been found to be associated with impulsive behaviours that are 
characteristic of ADHD (Retz et al., 2003). The dopamine D4 receptor gene (DRD4) 
is prevalent in the ffontal-subcortical networks, and dysregulation of this region has 
been associated with the ADHD (Faraone and Biederman, 1998, Biederman and 
Faraone, 2005). The exon III 7-repeat allele of DRD4 has been shown to cause an in- 
vitro dampened response to dopamine, and this variant has been associated with the 
disorder (Biederman and Faraone, 2005). A genetic variant of the dopamine 5
46
receptor gene (DRD5) has also been associated with the disorder (Lowe et al., 2004, 
Biederman and Faraone, 2005). Stimulant forms of ADHD medication have been 
shown to block the dopamine transporter (DAT) (Spencer et al., 2000, Biederman 
and Faraone, 2005) and reduced DAT binding has been demonstrated in adult ADHD 
(Dougherty et al., 1999, Dresel et al., 2000, Krause et al., 2000, Krause et al., 2002, 
Vies et al., 2003, Biederman and Faraone, 2005). Furthermore, a polymorphism of 
dopamine p hydroxylase, the enzyme predominantly responsible for converting 
dopamine to noradrenaline, has also been associated with ADHD (Biederman and 
Faraone, 2005). Variants in the noradrenaline transporter gene (SLC6A2) have been 
investigated by several studies and an A/T transversion of the rs28386840 SNP in the 
promoter region of SLC6A2 has been associated with ADHD and was found to 
decrease promoter function (Kim et al., 2006, Kim et al., 2010). Furthermore, it was 
shown that the same SNP is associated with response to methylphenidate as an 
ADHD treatment, with those individuals possessing the T/T genotype exhibiting a 
better response to treatment than the A/A genotype (Kim et al., 2010). The G1287A 
polymorphism (rs5569) of SLC6A2, has also been associated with methylphenidate 
response in the treatment of ADHD (Yang et al., 2004, Kim et al., 2010). Serotonin 
has been implicated in the regulation of impulsive, aggressive and violent behaviour 
(Retz et al., 2003, Nedic et al., 2010), and impaired maternal serotonin production 
has been associated with increased risk of the offspring developing ADHD (Halmoy 
et al., 2010). A functional variant of the serotonin transporter gene (SLC6A4) and a 
non functional marker of the serotonin IB receptor gene have been associated with 
ADHD (Biederman and Faraone, 2005). A positive association has also been found 
between ADHD and the synaptosomal-associated protein of 25 kDa (SNAP25) 
(Biederman and Faraone, 2005). This neuron-specific protein plays a role in 
synaptic-vesicle transport and release and SNAP25 knockout mutant mice display 
hyperactivity (Wilson, 2000, Biederman and Faraone, 2005), hence implicating the 
protein in the modulation of this behaviour.
ADHD is also believed to be a neurodevelopmental disorder and this is supported by 
the evidence for many risk factors for the disorder being associated with critical 
times of brain development. Foetal exposure to a number of environmental risk 
factors has been implicated in ADHD, including lead exposure, poor maternal health, 
maternal age, long duration of labour, prematurity, foetal distress, antepartum
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haemorrhage, and foetal exposure to nicotine and alcohol (Mick et al., 2002, Saigal 
et al., 2003, Hack et al., 2004, Indredavik et al., 2004, Biederman and Faraone, 2005, 
Banerjee et al., 2007). The basal ganglia is implicated in ADHD and is particularly 
sensitive to toxaemia, and this has been shown to impact upon dopaminergic 
functioning, thus implicating this mechanism in ADHD (Boksa and El-Khodor, 
2003, Biederman and Faraone, 2005, Banerjee et al., 2007). Behavioural, cognitive 
and learning problems have been associated with foetal exposure to alcohol (Boyd et 
al., 1991, Brown et al., 1991, Autti-Ramo, 2000, Biederman and Faraone, 2005). 
This is supported by evidence of foetal alcohol syndrome, which is caused by 
maternal alcohol consumption and displays some ADHD-like symptoms (Banerjee et 
al., 2007). Exposure to prenatal alcohol has been shown to be associated with 
hyperactive, disruptive, delinquent and impulsive behaviours in children, and an 
increased risk of developing psychiatric and psychosocial problems (Huizink and 
Mulder, 2006, Baneijee et al., 2007). Additionally, cognitive ability is impaired in 
children exposed to prenatal alcohol, this includes deficiencies in a number of 
characteristics including attention, learning and memory and social skills (Huizink 
and Mulder, 2006, Baneijee et al., 2007). Furthermore, functional magnetic 
resonance imaging (fMRI) has revealed that adults who were prenatally exposed to 
alcohol found it more difficult to perform a working memory task, and required 
increased involvement of the dorsolateral prefrontal cortex (Connor and Jarosz, 
2001, Baneijee et al., 2007). Foetal exposure to nicotine has been shown to damage 
the brain during neurodevelopment (Biederman and Faraone, 2005). In mice foetal 
exposure to nicotine is associated with an increase in hyperactive behaviours and 
cognitive impairment (Fung and Lau, 1989, Richardson and Day, 1994, van de Kamp 
and Collins, 1994, Biederman and Faraone, 2005). Not only can some of the 
ingredients of tobacco directly affect the foetal brain, in particular carbon monoxide 
and tar (Ernst et al., 2001, Baneijee et al., 2007), but cigarette smoke reduces uterine 
blood flow, and this leads to episodic foetal hypoxia-ischaemia and malnutrition 
(Suzuki et al., 1980, Baneijee et al., 2007). It is hypothesised that this could cause the 
intrauterine growth retardation frequently observed in children of mothers who 
smoke (Huizink and Mulder, 2006, Baneijee et al., 2007). Nicotine also reportedly 
causes abnormal cell proliferation and differentiation in the foetal brain of mice and 
rats (Slotkin and Bartolome, 1986, Baneijee et al., 2007). Nicotine stimulates the 
nicotinic acetylcholine receptors (Baneijee et al., 2007), which influence
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dopaminergic activity, and prenatal exposure has been shown to alter the 
dopaminergic and noradrenergic systems (Seidler et al., 1992, Slotkin, 1998, 
Biederman and Faraone, 2005, Banerjee et al., 2007).
A number of psychosocial factors have also been implicated in the risk of developing 
ADHD, including marital conflict, family dysfunction parental psychological 
problems and low social class (Palfrey et al., 1985, Biederman et al., 1995, 
Biederman et al., 2002, Biederman and Faraone, 2005). However it is thought to be 
the interaction of genetic predisposition and external environmental influence that is 
responsible for the development and phenotypic variability of ADHD (Banerjee et 
al., 2007). Recent studies have aimed to elucidate the interplay of these two sets of 
factors by examining the association between environmental risk factors and genetic 
variability. It has been demonstrated that in individuals that possessed the DAT1 440 
allele and were prenatally exposed to nicotine the risk of developing ADHD was 2.9 
times greater than in unexposed individuals who did not possess the risk allele ( 
Banerjee et al., 2007, Neuman et al., 2007). Furthermore an association has been 
described between an increase in hyperactive and impulsive behaviours in 
individuals who possessed the DAT1 480 allelic variant and had foetal exposure to 
nicotine (Kahn et al., 2003, Baneijee et al., 2007). Variants in this gene and prenatal 
exposure to alcohol have also been investigated, with the findings suggesting that the 
risk of developing ADHD was higher when possessing a haplotype of the gene if the 
foetus had been prenatally exposed to alcohol (Brookes et al., 2006, Banerjee et al.,
2007).
There is a high risk of comorbidity of childhood ADHD with other psychiatric and 
substance abuse disorders (Bird et al., 1993, Willcutt et al., 1999, Kadesjo and 
Gillberg, 2001, Lahey et al., 2002, Murphy et al., 2002, Biederman and Faraone,
2005), and adult ADHD with personality disorders (Modestin et al., 2001, Biederman 
and Faraone, 2005). Ludolph et al., 2008b, found that a considerable proportion of a 
population suffering from tourette syndrome also fulfilled the criteria for childhood 
ADHD, and the two disorders show comorbidity as characterised by the three main 
symptoms: impaired attention, hyperactivity and increased impulsivity which are 
shared by both disorders (Erenberg, 2005). The two disorders have also been found 
to be genetically linked (Comings, 2001) and it is speculated that the cause of both
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ADHD and tourette syndrome may involve a dysfunction in the neurotransmitter 
systems involving the frontal cortex, the thalamus and basal ganglia (Ludolph et al., 
2008b). In individuals diagnosed with comorbid ADHD and tourettes syndrome a 
reduction in the overall amygdalar volume has also been observed, and it was 
speculated that this may cause altered amygdala function thus contributing to the 
symptomology of ADHD (Ludolph et al., 2008b). There is considerable overlap in 
the symptomology of ADHD and autism, in particular difficulties in social 
interaction and communication (Luteijn et al., 2000, Hattori et al., 2006, Mulligan et 
al., 2009). It has been hypothesised that the similarity in the manifestation of the two 
disorders could be due to common aetiology or alternatively, autism could represent 
a subtype of ADHD (Mulligan et al., 2009). Comorbidity of ADHD with learning 
disability, conduct disorder and anxiety disorder has also been reported (McKay and 
Halperin, 2001, Rowland et al., 2002, Thome and Jacobs, 2004). There is an 
increased rate of conduct disorder (30-50%) in childhood ADHD patients in 
comparison to the control population (2-6%) (Kuhne et al., 1997, Disney et al., 1999, 
Matza et al., 2005, Jones and Foster, 2009), and in individuals suffering from 
comorbid ADHD and conduct disorder the risk of substance abuse and criminality 
problems is also increased (Babinski et al., 1999, Barkley et al., 2003, Jones and 
Foster, 2009).
The frontline pharmacological treatments for ADHD for many years have been the 
stimulants methylphenidate and amphetamine (Biederman and Faraone, 2005). Both 
amphetamine and methylphenidate exert their therapeutic action by raising dopamine 
levels in the striatum, nucleus accumbens, and both dopamine and noradrenaline in 
the prefrontal cortex (Shoblock et al., 2003b, Shoblock et al., 2004, Madras et al.,
2005). However amphetamine differs from the action of methylphenidate as its 
mechanism of increasing extracellular dopamine is to both inhibit dopamine re- 
uptake by DAT, through direct competition with dopamine, and to stimulate 
dopamine release into the cytoplasm (Madras et al., 2005). Methylphenidate on the 
other hand, predominantly acts via inhibition of DAT activity and to a lesser degree 
NET activity, to increase levels of extracellular dopamine (Madras et al., 2005, Kim 
et al., 2010). However, there has been concern over possible side effects of the 
stimulants, including tics, stunting of growth and substance abuse (Biederman and 
Faraone, 2005). Conversely studies have shown that stimulant treatment for ADHD
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reduces the risk of developing substance-use disorder, rather than causing the 
development of it (Faraone and Wilens, 2003, Wilens et al., 2003a, Biederman and 
Faraone, 2005). More recently, new ADHD treatments have been developed 
including slow-release methylphenidate and the anti-depressant non-stimulant 
atomoxetine (Biederman and Faraone, 2005). The benefits of slow-release 
methylphenidate is that it reduces the number of re-administrations of treatment per 
day, to fit in with the individuals daily schedule, thus reducing the embarrassment 
surrounding use of the medication in public and minimising the risk of missing a 
dose (Biederman and Faraone, 2005). The mechanism of action of atomoxetine is 
believed to be through selective inhibition of the noradrenaline transporter (NET) 
(with minimal affinity for the dopamine transporter (DAT), thus preventing 
noradrenaline re-uptake and causing its accumulation in the synapse (Kim et al.,
2010). DAT density is low, and NET density is high in the prefrontal cortex (Kim et 
al., 2010). Regardless of the differing selectivity and affinities, methylphenidate, 
amphetamine and atomoxetine all raise dopamine and noradrenaline levels in the 
prefrontal cortex, however these effects are distinct between the drugs in the striatum 
and nucleus accumbens (Bymaster et al., 2002, Shoblock et al., 2003b, Shoblock et 
al., 2003a, Shoblock et al., 2004, Madras et al., 2005).
Other pharmacological medications that have been used to treat ADHD but with 
lesser efficacy and various unwanted side-effects include the tricyclic 
antidepressants, buproprion, modanifil and the a2-adrenergic agonists clonidine and 
guanfacine (Biederman and Faraone, 2005). Buproprion is effective in reducing 
cigarette smoking, which is associated with ADHD, and it is thought it could be 
efficacious in treating diagnoses of ADHD comorbid with depression, bipolar 
disorder or substance abuse (Riggs et al., 1998, Daviss et al., 2001, Wilens et al., 
2003b, Biederman and Faraone, 2005). Modinifil is used as a treatment for 
narcolepsy, but has been shown to alleviate some of the symptoms of childhood and 
adult ADHD (Taylor and Russo, 2000, Rugino and Copley, 2001, Turner et al., 2004, 
Biederman and Faraone, 2005). Commonly, psychosocial therapy is implemented in 
conjunction with pharmacological treatment for ADHD, for example behavioural 
modification and cognitive-behaviour therapy (Biederman and Faraone, 2005). 
Although these therapies have proved therapeutic, pharmacological treatments show
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the greatest efficacy and are recommended as the predominant treatment for the 
disorder (Biederman and Faraone, 2005).
1.4 Circadian rhythms and sleep in ADHD
Sleep deficits are a prominent characteristic of ADHD, with up to 54% of children 
with ADHD reporting problems with sleep, (Tjon Pian Gi et al., 2003) and up to 83% 
of adult ADHD patients (Sobanski et al., 2008). Moreover sleep problems were 
recognised as a key characteristic included on a number of child rating scales in the 
diagnosis of ADHD in an earlier version of the DSM  and the Conners Rating Scale 
for parents (Goyette et al., 1978, Corkum et al., 1998, Gruber et al., 2000). Sleep 
problems have been widely documented through both self and parental sleep reports, 
and sleep and circadian parameters have been examined by actigraphic and 
polysomnographic studies. However, whilst sleep deficits are clearly symptomatic of 
ADHD and it could be argued that ADHD symptomology could reduce the ability of 
an individual to be settled enough to sleep effectively, it is also plausible that these 
sleep deficits may be contributing to the pathogenesis of the disorder.
It has been proposed that one of the mechanisms key to the development of ADHD is 
the impairment of cortical inhibitory control, resulting in dis inhibition of motor and 
frontal cortices (Castellanos, 1997, Berger and Posner, 2000, Moll et al., 2000, Moll 
et al., 2001, Kirov et al., 2004). This hypothesis would help to explain the sleep 
disturbance often observed in ADHD, since the prefrontal and frontal cortices are 
known to be essential for sleep regulation (Gottesmann, 1999, Muzur et al., 2002, 
Kirov et al., 2004). A role for sleep disturbance in the pathophysiology of ADHD is 
supported by the fact that some of the core symptoms of ADHD, inattention, 
impulsiveness and restlessness, are known characteristics of sleep deprivation 
(Corkum et al., 1998) and sleep deprivation has been shown to cause behavioural and 
cognitive problems (Bonnet, 1985, Babkoff et al., 1991, Gruber et al., 2000). 
Furthermore, the substantial influence of sleep deprivation upon mood is 
demonstrated by the efficacy of total sleep deprivation in treating depression 
(McClung, 2007), an association of mood problems with ADHD have been reported 
(McGough et al, 2005). Sleep disorders have also been associated with both 
childhood and adult ADHD (Cohen-Zion and Ancoli-Israel, 2004, Kirov et al., 2007,
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Van Veen et al., 2010) in particular Idiopathic Sleep Onset Disorder has been shown 
to be comorbid with ADHD (Van der Heijden et al., 2005, Neves and Reimao, 2007, 
Van Veen et al., 2010). ADHD has also been associated with periodic limb 
movement disorder (Picchietti et al., 1999, Boonstra et al., 2007) and sleep 
disordered breathing (Chervin et al., 1997, Boonstra et al., 2007). Furthermore the 
inattentive and hyperactive symptoms of ADHD have been associated with children 
who suffer from obstructive sleep apnoea (Chervin, 2005, Lim et al., 2008) and 
habitual snoring (Ali et al., 1993, Chervin et al., 2002a, Lim et al., 2008). Although, 
the inattentive and hyperactive symptoms can present themselves in patients 
suffering from these sleep disorders alone, without showing comorbidity for ADHD 
(Lim et al., 2008).
Parental and self reports of sleep in childhood ADHD have indicated a number of 
sleep deficits including reduced sleep duration (Lim et al., 2008) an increase in the 
degree of snoring (O'Brien et al., 2003a) and increased likelihood of suffering from 
nightmares (Chiang et al., 2010). Gender differences in sleep reports has been 
indicated, with female ADHD patients reporting more difficulties sleeping, however 
the authors speculate that this finding could be due to parental expectations of girls 
finding it easier to sleep than boys (Lim et al., 2008). Sub-type differences in 
childhood ADHD of sleep disturbance has been assessed via self-report 
questionnaires (Chiang et al., 2010). The combined and hyperactive-impulsive 
subtypes were reported to exhibit increased sleep duration in comparison to the 
inattentive subtype and healthy controls, whereas daytime sleepiness and napping, 
early insomnia, middle insomnia, sleep terrors and snoring was increased in the 
combined and inattentive subtypes in comparison to the hyperactive-impulsive 
subtype (Chiang et al., 2010). Furthermore, circadian rhythm disturbance, sleep- 
talking, nightmares and nightmare disorders, and circadian rhythm sleep disorders 
were more predominant in the combined subtype than the inattentive subtype of 
childhood ADHD (Chiang et al., 2010).
Actigraphy and polysomnography have been utilised as methods of measuring the 
sleep/wake cycle and sleep and activity parameters (Littner et al., 2003a, Littner et 
al., 2003b). Actigraphs store data on levels of activity via measurement of 
movement, whereas polysomnography can also collect data on sleep quality and
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other sleep-related disorders. Actigraphic analysis has shown daytime activity of 
children with ADHD in a clinical setting to be greater than that of individuals who do 
not have the disorder, however no subtype differences in activity levels have been 
detected (Dane et al., 2000). In conjunction with sleep diaries, actigraphy has 
demonstrated increased variance in a number of sleep measures in childhood ADHD, 
including sleep onset time, sleep duration and true sleep time, thus indicating greater 
sleep instability in childhood ADHD (Gruber et al., 2000). In adult ADHD, 
actigraphy has revealed greater daytime activity than in the control population, 
although nocturnal activity as measured during the 5 hour period of least activity 
(L5) did not differ significantly between the two groups (Boonstra et al., 2007). 
Reduced sleep efficiency, longer sleep onset latency and shorter durations of 
uninterrupted sleep were also demonstrated in adult ADHD with or without 
comorbid sleep onset insomnia (Boonstra et al., 2007, Van Veen et al., 2010).
Polysomnographic studies have revealed reduced sleep efficiency, and increased 
awakenings and percentage wakefulness after sleep onset in adult ADHD (Sobanski 
et al., 2008). This is in accordance with other studies showing reduced sleep 
efficiency (Dagan et al., 1997, Sobanski et al., 2008) and increased nocturnal 
awakenings in childhood ADHD (Ramos Platon et al., 1990, Picchietti et al., 1998, 
O'Brien et al., 2003b, Sobanski et al., 2008). These findings are however 
contradicted by previous studies of adult and childhood ADHD (Busby et al., 1981, 
Greenhill et al., 1983, Philipsen et al., 2005, Sobanski et al., 2008). The percentage 
of rapid-eye movement (REM) sleep has also been shown to be reduced in adult 
ADHD (Sobanski et al., 2008). Therefore this could have implications for 
behavioural functioning, since REM sleep is associated with learning and 
performance, including attention, memory and language (Siegel, 2001, Sobanski et 
al., 2008). A reduction in % REM sleep has also been observed in childhood ADHD, 
along with an increase in REM sleep latency (O'Brien et al., 2003a).
Since the circadian clock is key to the regulation of the sleep-wake cycle as 
previously described, studies have aimed to establish if circadian deficits are evident 
in ADHD. A recent study has shown that adult ADHD is associated with evening 
preference, with more than 40% of the ADHD study population exhibiting evening 
preference, whereas only 18.5% exhibited morning preference, which is in stark
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contrast to findings that in the general population that only 10.8% exhibit evening 
preference and 40.2% exhibit morning preference (Rybak et al., 2007). In addition, it 
was found that greater eveningness correlated with increased difficulty in sustaining 
attention and a higher level of impulsive behaviour (Rybak et al., 2007). It was 
suggested that the inattention aspect of ADHD symptomology may be due to 
lowered arousal levels as a consequence of a sleep deficit that the individual may be 
experiencing (Rybak et al., 2007), hence implicating sleep disturbance as a factor in 
the psychopathology of the disorder. The mechanism responsible for the formation of 
chronotype has been proposed to involve the interaction of sleep homeostasis and 
circadian rhythms in the hypothalamus (Schmidt et al., 2009). This hypothesis would 
explain the evening decrease in alertness of morning chronotype individuals as being 
due to either a greater negative influence of sleep homeostasis on the anterior 
hypothalamus regions involved in circadian regulation or reduced influence of the 
circadian clock on sleep homeostasis arising from the anterior hypothalamus 
(Schmidt et al., 2009). Circadian disturbance is further implicated in ADHD by 
findings that seasonal affective disorder is comorbid with ADHD in some cases 
(Levitan et al., 1999, Amons et al., 2006, Van Veen et al., 2010).
As previously described, melatonin is a key output and regulator of the circadian 
clock (Reppert and Weaver, 2001, Pierce et al., 2008, Wiechmann and Summers, 
2008), and plays an important role in the modulation of the sleep-wake cycle 
(Tzischinsky et al., 1993, Zhdanova et al., 1996, Zhdanova and Tucci, 2003, Pandi- 
Perumal et al., 2005). A delay in dim light melatonin onset, and also sleep and wake 
time, as measured by actigraphy, has been associated with both childhood and adult 
ADHD when comorbid with sleep onset insomnia, whereas both child and adult 
ADHD patients, who did not suffer from the sleep disorder, displayed normal dim 
light melatonin onset timing (Van der Heijden et al., 2005, Van Veen et al., 2010). 
This delay in circadian timing of the sleep/wake cycle observed in sleep onset 
insomnia is characteristic of delayed sleep phase disorder (DSPS), and therefore it 
has been proposed that sleep onset insomnia is a circadian rhythm disorder that is 
comorbid with ADHD (Van der Heijden et al., 2005, Van Veen et al., 2010). 
Furthermore subtype differences in the prevalence of sleep onset insomnia have been 
indicated, with a decreased number of the inattentive ADHD subtype of adults 
displaying symptoms of sleep onset insomnia in comparison to the other subtypes
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(Van Veen et al., 2010). As expected the inattentive subtype patients that did not 
suffer from sleep onset insomnia exhibited longer sleep duration and more stable 
sleep/wake rhythms in comparison to those individuals diagnosed with the sleep 
disorder, and this is in accordance with previous reports that inattentive subtypes of 
ADHD are sleepier during the day and sleep for longer durations at a time (Gau et 
a l, 2007, Mayes et al., 2009, Van Veen et al., 2010), and it could be postulated that 
disturbance in the melatonin rhythm could exacerbate behavioural and cognitive 
problems via the effects this has upon the sleep/wake cycle. Furthermore, the 
potential for abnormalities in the melatonin rhythm to have downstream effects upon 
the peripheral oscillators and other behavioural and physiological processes that 
contribute to the pathophysiology of the disorder, is demonstrated in rodents where a 
constantly high level of melatonin in rats causes a reduction in the amplitude of the 
circadian rhythms of temperature and heart-rate (Simon et al., 2002).
It has been proposed that dysfunction of the behavioural inhibition system could be 
responsible for some of the altered behaviours characteristic of ADHD (Quay, 1997, 
Lackschewitz et al., 2008). The HPA-axis is involved in stress response and 
regulation (Hastings et al., 2009) and levels of the adrenal hormone cortisol are 
widely used as an indicator of HPA-axis reactivity, as HPA-axis activation in 
response to stress initiates the release of the adrenal hormone cortisol (Chrousos and 
Gold, 1992, Randazzo et al., 2008). Therefore it has been postulated that if a 
dysfunctional behaviour inhibition system is a causative factor of ADHD then an 
abnormal HPA axis response to stress should be observed in ADHD (Hong et al., 
2003).
Lowered circulating cortisol levels in response to stress has been associated with 
many of the characteristics of childhood ADHD including maladaptive behaviour 
(Hastings et al., 2009) and poorer cognitive performance (Hanna et al., 1996, Hong 
et al., 2003), as well as being associated with a decreased degree of anxiousness in 
childhood ADHD (Hastings et al., 2009). These findings have been replicated in a 
study of adult ADHD, which found that lower cortisol levels in response to stress 
were associated with ADHD (Lackschewitz et al., 2008). Due to the considerable 
differences in symptomology, ADHD is a disorder that can be divided into three 
subtypes (McGough and Barkley, 2004, Biederman and Faraone, 2005), and
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therefore ADHD subtype differences in the stress response have also been 
investigated, but with contradictory results. Under-reactivity of the HPA-axis in 
response to stress has been associated with the hyperactive/impulsive subtype of 
ADHD (Virkkunen, 1985, Moss et al., 1995, Hong et al., 2003, Blomqvist et al., 
2007). However, the inattentive ADHD subtype has also been shown to display 
blunted cortisol levels and hence impaired HPA-axis functioning in response to stress 
(Randazzo et al., 2008). Other studies have shown that low-cortisol responsivity to 
psychosocial stress is associated with childhood ADHD-combined, but not for those 
with ADHD-inattentive (van West et al., 2009). Possible reasons for this discrepancy 
could be effects of treatment, comorbidity and study design, since measurement of 
stress response in a laboratory setting could itself alter stress levels. Furthermore, 
gender differences in the stress response have been identified in childhood ADHD, 
with elevated early morning cortisol levels in boys, and decreased levels in girls 
(Sondeijker et al., 2007). It was postulated that this could be due to the gender 
differences in symptomology, with lower levels of hyperactivity and other 
externalizing behaviours being associated with female ADHD patients (Gaub and 
Carlson, 1997, Gershon, 2002, Sondeijker et al., 2007).
Studies of the circadian rhythm of cortisol secretion in ADHD are somewhat 
contradictory with a normal rhythm being demonstrated in adult ADHD (Hirvikoski 
et al., 2009). Furthermore no difference in the diurnal profile of cortisol was detected 
between two ADHD groups of high-post stress cortisol and low-post stress cortisol 
(Hirvikoski et al., 2009). An association of high-post stress cortisol concentrations 
were found with impulsivity, depression and anxiety (Hirvikoski et al., 2009), but 
since no alteration in diurnal cortisol profiles were detected, it can be assumed that 
these symptoms are related to the role cortisol plays in the HPA-axis response to 
stress rather than the circadian clock. The finding of a normal diurnal rhythm of 
cortisol in ADHD is in agreement with a previous studies carried out in a laboratory 
setting, of both adult ADHD (Lackschewitz et al., 2008), and childhood ADHD 
(White and Mulligan, 2005). However, abnormal cortisol rhythms have been 
associated with the hyperactive component of childhood ADHD (Kaneko et al., 
1993) and dampened cortisol awakening response (Blomqvist et al., 2007), although 
a later study has demonstrated no childhood ADHD subtype differences in the 
cortisol rhythm (Hastings et al., 2009). The cortisol awakening response has also
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been studied in children suffering from ADHD with comorbid disruptive behaviour 
disorder, and it has been shown that whilst childhood ADHD patients exhibit a 
normal cortisol awakening response (Snoek et al., 2004, Freitag et al., 2009), those 
ADHD patients with comorbid oppositional defiant disorder exhibited a dampened 
cortisol awakening response, hence indicating dysfunction in the HPA-axis in 
association with the symptoms of disruptive behaviour disorder (Freitag et al., 2009).
The association of the T-allele of the rs 1801260 SNP in CLOCK with adult ADHD 
provides further evidence for a putative role of the circadian clock in the 
pathogenesis of the disorder (Kissling et al., 2008, Xu et al., 2010). In healthy 
populations the C allele of the polymorphism has also been shown to be associated 
with evening preference and delayed sleep timing (Katzenberg et al., 1998, Mishima 
et al., 2005). Therefore the association of the rs 1801260 C/T SNP with chronotype 
and sleep disturbance in psychiatric illness further implicates this polymorphism in 
sleep regulation. Since this SNP is located in the 3’ flanking region of CLOCK it can 
be postulated that the presence of either the T or C allele may exert effects upon 
polyadenylation or mRNA stability (Beelman and Parker, 1995, Ross, 1996, 
Benedetti et al., 2003, McClung, 2007) with possible effects upon the level of 
protein being translated (Benedetti et al., 2003).
The treatment of sleep-related disorders have been shown to improve daytime 
function in children with ADHD (Van der Heijden et al., 2007), and several therapies 
that interact with the circadian clock have been trialled for the treatment of ADHD. 
A three week trial of daily morning bright light therapy for adult ADHD has been 
shown to cause a shift towards an earlier chronotype and to improve the core 
symptoms of the disorder, and this improvement appeared to be independent of any 
therapeutic effect on depressive symptoms (Rybak et al., 2006, Terman, 2007). 
Melatonin treatment in childhood ADHD patients suffering from insomnia has been 
shown to improve a number of sleep measures including an increase in the mean 
total time asleep and sleep efficiency, and a decrease in sleep latency, nocturnal 
restlessness and difficulty falling asleep (Van der Heijden et al., 2007). Furthermore 
sleep onset and dim light melatonin onset was advanced to that of values found in 
healthy children not suffering from insomnia, and this effect was more pronounced in 
individuals who exhibited more extreme delays in dim light melatonin onset at
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baseline (Van der Heijden et al., 2007). However, whilst these sleep deficits were 
improved, no improvement of behaviour, cognitive function or quality of life was 
observed in these individuals, and it was suggested that the sleep improvements were 
not great enough to impact upon the core ADHD symptoms, for which longer 
treatment duration would be required (Van der Heijden et al., 2007).
The spontaneous hypertensive rat (SHR) is a well documented rodent model for 
ADHD since it displays all the behavioural symptoms of the disorder when 
compared to the normotensive Wistar-Kyoto (WKY) control rat (Russell, 2007). A 
number of anomalies in the dopaminergic and noradrenergic systems have been 
observed in SHR, including reduced DAT expression in the prenatal SHR midbrain 
and elevated DAT expression in the adult SHR (Watanabe et al., 1997, Leo et al., 
2003, Russell, 2007). A disturbance in dopaminergic and noradrenergic 
neurotransmission in the prefrontal cortex of SHR has been documented, with a 
reduction in dopamine release, and an increase in noradrenaline, not only in the 
prefrontal cortex but the locus coeruleus and substantia nigra also (de Villiers et al., 
1995, Russell, 2002, Russell, 2007). These findings are consistent with reports of 
hypofunctional dopamine systems and hyperfunctional noradrenaline systems in the 
prefrontal cortex in childhood ADHD (Solanto, 1998, Russell, 2002, Russell, 2007). 
The expression of VEP mRNA has been shown to be elevated in the SHR brain in 
comparison to WKY, and therefore an impact upon the circadian system could be 
postulated, since VIP has been implicated in entrainment to the LD cycle (Peters et 
al., 1994). Moreover, significant alterations in the circadian rhythm of locomotor 
activity of SHR in comparison to WKY have been demonstrated, with a phase 
advance in wheel running behaviour under LD, and under constant light and constant 
darkness conditions the free-running locomotor rhythm was significantly shorter for 
SHR than for the WKY controls (Peters et al., 1994). Additionally, SHR differ in 
their responses to phase advances and delays of the LD cycle in comparison to the 
control, with SHR taking significantly longer to entrain to a phase delay, whilst being 
significantly quicker to entrain to a phase advance than the WKY control rats (Peters 
et al., 1994). SHR has also been found to differ to WKY in its light sensitivity 
(Rosenwasser, 1993), and sleep alterations in the SHR model in comparison to the 
WKY control model have been observed, including more frequent interruptions to 
sleep being associated with SHR (Kuo et al., 2004).
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1.5 The effects of ADHD medication upon sleep and the circadian clock
There are mixed reports of the effects of methylphenidate upon sleep in ADHD, with 
actigraphy and polysomnography studies revealing improvements including a 
reduced number of actigraphically assessed nocturnal awakenings and a significant 
reduction in sleep onset latency and improved sleep efficiency in patients undergoing 
methylphenidate treatment (Boonstra et al., 2007, Sobanski et al., 2008). However in 
contrast, there have been reports of increased sleep onset latency in adult ADHD 
patients undergoing methylphenidate treatment (Boonstra et al., 2007), and insomnia 
has been documented in both methylphenidate medicated childhood and adult 
ADHD patients (Sangal et al., 2006). Improvement in some sleep parameters by 
atomoxetine treatment has also been documented in ADHD, including a reduction in 
both the onset of sleep and difficulty to settle down, and an improvement in ease of 
getting up in the morning (Sangal et al., 2006). Comparisons of the effects upon 
sleep by atomoxetine and methylphenidate have indicated that atomoxetine generally 
appears to produce less adverse side effects upon sleep than methylphenidate and it 
has been postulated that the high specificity of atomoxetine for the noradrenaline 
transporter, with little affinity for other monoaminergic transporters or receptors 
could be responsible for the reduced negative impact upon the sleep/wake cycle than 
the psychostimulants (Sangal et al., 2006). Moreover the same study demonstrated an 
improvement in childhood ADHD symptoms in the morning and evening when 
undergoing atomoxetine treatment as oppose to methylphenidate (Sangal et al., 
2006), and thus it could be postulated that the improvement in behaviour could be 
partly due to the improvement in sleep. However, it is worth noting that to the 
contrary it could be argued that an improvement in sleep could be a consequence of 
an improvement in behaviour, since presumably a reduction in hyperactive and 
restless behaviour for example, would improve the ability of the individual to settle 
down to sleep.
Investigations of the effects of the psychostimulants methamphetamine and 
methylphenidate upon the rodent circadian system have revealed significant 
alterations of the rodent locomotor rhythm by chronic administration of both 
treatments (Honma et al., 1986, Honma et al., 1988, Tataroglu et al., 2006, Honma et 
al., 2008, Algahim et al., 2009, Algahim et al., 2010, Lee et al., 2010). The presence
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of a methamphetamine sensitive oscillator is well documented, and evidence for its 
existence stem from the observations that chronic methamphetamine treatment de­
synchronizes the locomotor rhythm of SCN intact rodents from the LD cycle and 
produces a significant rhythm of locomotor activity in otherwise arrhythmic SCN 
lesioned rodents (Honma et al., 1986, Tataroglu et al., 2006, Honma et al., 2008). 
Furthermore, chronic methamphetamine treatment of SCN-lesioned rodents has been 
shown to alter a number of physiological rhythms, including feeding, body 
temperature and plasma corticosterone levels (Honma et al., 1988). Moreover, 
chronic methamphetamine treatment has been shown to alter circadian clock gene 
expression in the hippocampus (Yamamoto et al., 2005), and in the striatum where 
this was associated with shift in the behavioural rhythm (Masubuchi et al., 2000). 
Chronic methylphenidate treatment has also been shown to shift the rodent 
locomotor rhythm (Algahim et al., 2009, Algahim et al., 2010, Lee et al., 2010), 
although effects upon the molecular circadian clock have not been documented to 
date. Although significant effects of the antidepressant, atomoxetine, upon sleep 
architecture and other sleep measures in ADHD have been documented (Sangal et 
al., 2006), as of yet the effects of atomoxetine upon rodent locomotor activity or the 
molecular circadian clock have not been investigated.
Collectively the research to date would suggest a role of the circadian clock in 
manifestation of psychiatric illness including ADHD, and furthermore a potential 
mechanism of pharmacological treatments to produce both therapeutic and adverse 
side effects by interaction with the circadian clock.
Therefore it is hypothesised firstly that deficiencies of the circadian timing system 
are associated with adult ADHD, which could contribute to the psychopathology of 
the disorder, and secondly that ADHD medications modulate the functioning of the 
circadian system, which contributes to the therapeutic and adverse side effects of 
these medications. The main aims of this work were therefore firstly to develop a 
non-invasive method of sampling the human circadian clock, secondly to utilise this 
method to assess circadian rhythms in behaviour, endocrine parameters and circadian 
clock gene expression in adults with ADHD in comparison to matched controls. 
Thirdly, to assess whether alterations in these parameters are associated with
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alterations in objectively observed sleep parameters, and lastly to assess how ADHD 
medications affect circadian clock protein expression in the rodent brain.
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Chapter 2: The development of a non-invasive technique for the
assaying of human circadian clock function
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Chapter 2; Development of a non-invasive technique for the assaying of human
circadian clock function
2.1 Introduction 
Actigraphy
Actigraphy is a well validated method of assessing the rest-activity rhythm, from 
which information regarding a number of activity and sleep measures can be gleaned 
(Littner et al., 2003b). Actigraphy has previously been utilized successfully to define 
alterations in circadian activity patterns in a number of medical conditions including 
psychiatric illness and sleep disorders (Sadeh et al., 1995, Littner et al., 2003b, 
Wiggs and Stores, 2004, Jones et al., 2005, Boonstra et al., 2007). A measure of 
circadian preference is provided by chronotype which refers to the time of day of an 
individuals innate preference to be active and can be accurately assessed by means of 
the Home-Ostberg momingness/eveningness questionnaire (Home and Ostberg, 
1977). This scale designates individuals preference as one of three categories; 
morning, evening or intermediate (Home and Ostberg, 1977), with the majority of 
healthy individuals being of intermediate chronotype (Paine et al., 2006). However, 
there is a disadvantage to the use of this questionnaire, due to the time-line format of 
the answers that can be selected to the questions. This does not allow for precise time 
estimation, but rather the choice of a time-range, and therefore it is thought that this 
could skew the distribution of the data (Neubauer et al, 1992).
Salivary concentrations of the hormones cortisol and melatonin are widely 
documented to exhibit circadian rhythmicity and these hormones are key outputs of 
the master circadian pacemaker, influencing peripheral oscillator entrainment to the 
master circadian clock (Keller et al., 2006, Wiechmann and Summers, 2008). 
Assaying of the 24 hour profiles of salivary cortisol and melatonin levels therefore 
provide indication of circadian phase and indirectly of the functional status of the 
circadian clock on the master level. The assaying of the human molecular circadian 
clock poses a number of practical problems including firstly the accessibility of 
tissue. Since the assaying of the human SCN is only possible in post mortem tissue, 
the circadian system could be subject to disturbance as observed in various disease
64
states (eg. Wu et al., 2006, Hoffman et al., 2010, Tseng et al., 2010) and with aging 
(eg Ando et al. 2010, Wyse and Coogan, 2010). Secondly, alterations to an 
individuals sleep/wake cycle and sleep quality may be caused by unnatural schedules 
imposed upon subjects who partake in a circadian study within a research facility or 
hospital. Thirdly, it is not clearly defined how the oscillatory nature of the peripheral 
clocks relate to that of the SCN, and therefore the molecular clockwork of the 
peripheral oscillators may not be representative of that of the SCN. More recently, 
laboratories have been utilising the presence of molecular circadian clocks in 
peripheral and easily accessible human tissues as a method of assessing human 
circadian clock functioning, these tissues include peripheral blood mononuclear cells, 
fibroblasts, hair follicle cells and the oral mucosa (Bjamason et al., 2001, Takata et 
al., 2002, Boivin et al., 2003, Teboul et al., 2005, Cajochen et al., 2006, Archer et al., 
2008, Yang et al., 2009, Akashi et al., 2010, Pagani et al., 2010).
Assessing RNA integrity
When assaying gene expression in any tissue RNA integrity is essential for accurate 
quantification of gene expression by quantitative RT-PCR (Fleige and Pfaffl, 2006). 
The 28S: 18S ribosomal RNA (rRNA) ratio provides an indicator of RNA 
degradation, with a ratio of 2.0 being indicative of intact, high quality RNA, and an 
elevated threshold baseline and decreased 28S:18S ratio both being indicative of 
degradation (Imbeaud et al., 2005). Other measures of RNA integrity are the RNA 
integrity number (RIN) and RNA quality index (RQI) numbers, which are equivalent 
measures of RNA degradation that are calculated by analogous automated 
electrophoresis systems (Godler et al., 2009). In both cases a value of 10 is predictive 
of intact RNA, and 1 represents total mRNA degradation (Imbeaud et al., 2005, 
Taylor et al., 2010).
Normalisation o f gene expression
Since the central principal of gene expression quantification by quantitative RT-PCR 
is that the greater the number of copies of the target present in the sample, the fewer 
amplification cycles that will be required for the fluorescence to reach the threshold 
of detection, there are therefore a number of factors that it is essential are controlled
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for by normalisation to ensure reliable measurement of gene expression (Bustin et 
a l, 2005). These factors include, polymerase inhibitors, quantity of sample RNA, 
differing amplification efficiencies and between sample variation (Bustin et al., 
2005).
However, there is currently much controversy surrounding the most appropriate 
method of normalisation (Bustin, 2002). The most commonly used normalisation 
method is the quantification of housekeeping gene expression, use of which is based 
upon the idea that its expression will reflect the quantity and quality of the target 
gene mRNA, whilst being minimally effected by experimental conditions (Godler et 
al., 2009). However it has been proposed that all house-keeping genes probably do 
vary in their levels of expression, due to various factors such as the developmental 
stage, cell cycle stage and experimental conditions (Bustin, 2000, Tricarico et al., 
2002). Both (3-actin and most commonly glyceraldehyde-3 phosphate dehydrogenase 
(GAPDH) have been widely used as housekeeping gene controls for the 
normalisation of gene expression (Lupberger et al., 2002, Tricarico et al., 2002), and 
in a study to assess the effects of experimental conditions upon housekeeping gene 
expression, serum stimulation was shown to increase the expression of both (3-actin 
and GAPDH in human fibroblasts (Schmittgen and Zakrajsek, 2000).
Other methods of normalisation include using total mRNA or rRNA amounts as a 
standard (Bustin et al., 2005, Godler et al., 2009). However, disadvantages of 
normalising to total mRNA amounts are firstly that accurate quantification of total 
mRNA amounts is compromised when extracting RNA from small samples. 
Secondly, normalisation of gene expression to total mRNA amounts does not allow 
for consideration of RT-PCR inhibitors, as this measurement is not subject to this 
inhibitor, in contrast to the co-amplification of a housekeeping gene alongside the 
target gene (Bustin, 2002). Additionally transcriptional activity may differ between 
individuals and between different types of tissue (Bustin, 2002, Tricarico et al., 
2002), with total mRNA amounts being known to be elevated in highly proliferating 
cells (Bustin et al., 2005). Although in tissues such as nucleated blood cells minimal 
variation of total mRNA between individuals has been observed (Bustin, 2002). 
rRNA however, is thought to vary to a lesser degree than mRNA in human tissue 
samples (Bustin et al., 2005) and to be more reliable than normalising against the
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expression of a panel of housekeeping genes in human skin fibroblasts (Mansur et 
al., 1993). Although, there are a number of drawbacks of this approach including that 
additional PCR protocols would be required to assay the amount of rRNA (Bustin et 
al., 2005), there may be between sample imbalances between rRNA and mRNA 
amounts (Solanas et al., 2001, Bustin et al., 2005), differing kinetics in the 
amplification of rRNA and mRNA due to the considerable difference in their 
abundance and in their degradation kinetics (Godler et al., 2009) and possible effects 
of biological factors and drugs upon rRNA expression (Spanakis, 1993, Bustin et al., 
2005).
Human oral mucosa consists of rapidly proliferating cells, since it is subject to 
frequent injury and it is thought to have a requirement for more rapid healing in 
comparison to other tissues, such as cutaneous tissue (Angelov et al., 2004, 
Warburton et al., 2005), in order to minimise infection caused by oral pathogens 
(Warburton et al., 2005). As previously mentioned total mRNA amounts may be 
elevated in tissues that undergo rapid cell proliferation (Bustin et al., 2005), such as 
the oral mucosa. Cell cycle proteins have been shown to be under circadian control in 
the oral mucosa (Bjamason et al., 1999) and cell proliferation involves activation of a 
number of transcriptional pathways involving inflammation and healing (Warburton 
et al., 2005) various aspects of which have been shown to be under some circadian 
modulation in various human and rodent tissues (Lavker et al., 1991, Irwin et al., 
2006, Wang et al., 2006). Both (3-actin and GAPDH have previously been utilised as 
housekeeping genes in the normalisation of clock gene expression in the human oral 
mucosa (Bjamason et al., 2001, Cajochen et al., 2006) with GAPDH expression 
having been shown to be constitutively expressed in this tissue under both wound 
and repair conditions (Warburton et al., 2005, Cajochen et al., 2006).
Aims
The main aims of this work were therefore to firstly develop a non-invasive 
technique of sampling RNA in the oral mucosa for subsequent clock gene analysis 
and secondly to ascertain the most appropriate method of normalisation of clock 
gene expression in this tissue by comparing normalisation to total mRNA and to 
GAPDH expression.
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2.2 Method
Subjects
Adult healthy subjects (n=19) were recruited from the university staff, hospital staff 
and a student population. Average age of the participants was 27.83±9.43 years, and 
consisted of 30% male and 70% female participants. Only subjects that were not 
showing evidence of suffering from a current psychiatric or sleep disorder were 
included in the study. Each participant was assessed using a semi-structured clinical 
interview supplemented by the Research Version of the Structured Clinical Interview 
for DSM-IV-TR- Axis I Disorders (SCID-RV), in addition to ADHD questionnaires 
and psychometric tests; (WHO’s Adult ADHD Self Report Scale (ASRS), Conners 
scales (CAARS-Self-Report Long Version and CAARS-Observer Long Version) and 
the Wender-Utah Rating Scale (WURS) for retrospective information on childhood 
ADHD. Chronotype was assessed by completion of the Home-Ostberg questionnaire.
Actigraphy
Subjects wore an ActiWatch Light (Cambridge Neurotech, UK) on their non­
dominant wrist for at least 7 days, the last day of which was when mucosal/salivery 
samples were collected. Data was transferred for analysis from the ActiWatch to a 
PC, upon which the Sleep analysis software (Cambridge Neurotech, UK) was 
installed. Data analysis excluded the first and last days of data collection. Wake 
times were calculated from actigraphic data by means of the “auto” detection of 
minimal activity threshold above which an epoch is defined as being during waking 
time (Sleep analysis software, Cambridge Neurotech). Analysis of actigraphic data 
was via non parametric circadian rhythm analysis (Van Someren et al, 1999) as well 
as by 24 hour co-sinor analysis. These methods yielded a number of measures:
Intradaily variability: This is an index of fragmentation of the rhythm, and assesses 
frequency of transitions between periods of activity and inactivity.
Interdaily stability: This is a measure of the stability of the rhythm between days, and 
is taken as a measure of the strength of entrainment of the endogenous circadian 
clock to environmental Zeitgebers.
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L5: This is the amount of activity counts that occurs in the least active 5 hours of the 
24 hour cycle.
L5o: This is the time of onset of the least active five hour period.
M10: This is the amount of activity in the most active 10 hour period.
MlOo: This is the time of onset of the most active 10 hour period.
Relative amplitude: Indicates quantity of activity, derived from the normalized 
difference between M10 and L5 hour period in an average 24 hour pattern. Values 
range between 0 and 1, 1 representing the greatest difference between the most and 
least active phases, and thus the best temporal organisation of the activity cycle. 
Amplitude: This is the peak-to-trough difference in terms of activity counts.
Period: This is the period that shows best fit to the data by means of a chi-squared 
periodogram.
Acrophase: This is the time of the peak of the best fit periodogram.
The ActiWatch also recorded a number of light measures including daily average 
illumination (lux), maximum illumination (lux) and time spent above the baseline 
level of light (100 lux). Sleep measures recorded included sleep efficiency, sleep- 
onset latency, sleep start and end, and total length of sleep.
Clock gene analysis
Buccal samples were collected every four hours over a 24 hours period using foam 
tipped swabs (Whatman International Ltd, UK) and the material was stored on FTA 
cards (Whatman International Ltd, UK) at room temperature. RNA was extracted 
from the FTA cards using the Magmax viral RNA isolation kit (Ambion, UK) and 
concentrated using carrier RNA and the micro-magnetic beads provided within the 
kit. RNA concentrations were measured in duplicate using the NanoDrop 8000 
spectrophotometer (Thermo Scientific, USA), with purity assessed by the 
A260/A280 ratio and adequate values rated as between 1.8 and 2 (Taylor et al., 
2010). The quality and quantity of total mRNA isolated was confirmed using the 
experion RNA HighSens analysis kit (Bio-Rad, UK) and the experion automated 
electrophoresis system (Bio-Rad, UK). RNA integrity was assessed by measurement 
of both the 28S:18S ribosomal RNA ratio with the highest value of 2 indicating 
intact RNA, and the RNA quality indicator (RQI), which gives a rating of 1 to 10,
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with 1 being degraded RNA, and 10 being intact RNA (Taylor et al., 2010). There 
was no evidence of variations of mRNA quality according to time of sampling.
One-step quantitative real-time PCR was performed using the Light Cycler 3.5 
(Roche Diagnostics, Germany) with SYBR-Green I dye amplimer detection.
For amplification of the target RNA the following primers were used:
PER2 forward: 5 ’ -GCATCCATATTTCACTGTAAAAGA-3 ’,
PER2 reverse: 5’ -AGTAAAAGAATCTGCTCCACTG-3 ’, (Cajochen et al., 2006), 
BMAL1 forward: 5’-AAGGATGGCTGTTCAGCACATGA-3’,
BMAL1 reverse: 5’-CAAAAATCCATCTGCTGCCCTG-3’ (Bjamason et al., 2001), 
PERI forward: 5 ’-CTGAGGAGGCCGAGAGGAAAGAA-3 ’
PERI reverse: 5’-AGGAGGAGGAGGCACATTTACGC-3’ (Bjamason et al., 
2001),
GAPDH forward: 5’-GAAGGTGAAGGTCGGAGT-3\
GAPDH reverse: 5 ’ -GAAGATGGTGATGGGATTTC-3 ’.
RNA was added to a reaction mixture of final volume 20 pi containing one-step 
RT-PCR kit components (RNA Master SYBR Green I, Roche Diagnostics, UK) 
with appropriate primers at 0.5pm and 2.5mM MnOAc2. The following PCR 
conditions were used. PER2 and PERI: 20 min at 61°C, 30 s at 95°C, followed 
by 50 cycles of 1 s at 95°C, 5 s at 55°C, 13 s at 72°C and 1 s at 75°C. BMAL1: 20 
min at 61°C, 30 s at 95°C, followed by 50 cycles of 1 s at 95°C, 5 s at 60°C, 13 s 
at 72°C and 1 s at 78°C, GAPDH: 20 min at 61°C, 30 s at 95°C, followed by 50 
cycles of 1 s at 95°C, 5 s at 57°C, 13 s at 72°C and 1 s at 78°C. All samples were 
amplified in duplicate, and all PCR reactions included duplicate water blank 
samples as a negative control. Melting curve analysis followed each of these 
protocols.
To ascertain the most appropriate normalisation method, clock gene expression 
levels were normalised both to relative mRNA abundance and to the levels of the 
GAPDH gene using the 2~AACT method (eg. Cajochen et al, 2006).
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Melatonin and cortisol analysis.
Saliva samples were collected every four hours over a 24 hours period (at the 
same time periods as buccal sampling), by chewing on a cotton swab (Salivettes, 
Buhlmann Laboratories, Schonenbuch Switzerland) and subsequently stored at - 
20°C prior to analysis. Subjects were asked to collect night time samples under 
dim illumination. Prior to analysis saliva samples were thawed at room 
temperature and centrifuged at 2000-3000 x g for 10 minutes to remove 
particulate material. Both the levels of cortisol and melatonin of the spun saliva 
samples were assayed in duplicate by ELISA, according to the manufacturer’s 
protocol (IBL international, Germany). The optical density of each well was 
determined using a microplate spectrophotometer at 450 nm (reference 
wavelength 600-650 nm). A standard curve of the optical densities against their 
corresponding concentrations of the standards supplied within the kit was 
calculated using a 4 parameter logistics fit, and the concentrations of the samples 
were subsequently calculated from the standard curve.
Statistical Analysis
The statistical software SPSS (IBM Corporation, USA) installed on a PC was used to 
carry out analysis of correlations between actigraphic measures and chronometric 
parameters using Pearson’s product moment correlation, two-tailed. Clock gene 
expression and hormone data was fitted by the method of single co-sinor analysis to 
determine whether significant circadian rhythms were present, by means of the 
Chronolab software (Mojon et al., 1992). This involved fitting a curve with a 24 
period to the observed data by the least squares method, with the fit deemed 
significant if the 95% confidence interval for the fitted amplitude did not include 
zero. y(ti)=M+Acos(coti +<J))+Si was the formula for curve fitting, where f(f) was the 
expression of the factor of interest across time for individual i, M was the MESOR, 
the time series mean around which expression oscillates, A was the amplitude of the 
rhythms, co was the period of the fitted rhythm and was the acrophase of the rhythm 
and £i the error term. The regression fitting also produced an r-squared statistic,
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which was then used to compute the percentage of variance in an individuals time- 
series data that is accounted for by the fitted 24hour curve.
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2.3 Results
2.3.1 Actigraphy and Chromotype
Each subject wore an actiwatch to record various activity and sleep parameters and 
levels of light intensity. The 5 hours of least activity commenced in the very early of 
the morning (figure 2.1), with the amount of activity exhibited in these 5 hours (L5) 
being 1250.81±726.42, and an actigraphically calculated time of onset (L5o) of 
1.76±1.14 hours (table 2.14 figures 2.1 and 2.2). The amplitude of the rest-activity 
rhythm was 20012.90±4740.50 and the activity during the 10 hours of most activity 
(M10) was calculated as 21263.67±4740.40, with a time of onset (MlOo) during mid 
morning, 10.43±1.69 hours (figure 2.1) and an acrophase of 15.43±1.36 hrs (table 
2.1, figures. 2.1 and 2.2). The average activity rhythm exhibited a period length of 
23.88±0.33 hrs, with period deviation calculated as 0.17±0.18 hours (table 2.1, figure
2.3). Interdaily stability (IS) and intradaily variability (IV) were calculated as 
0.54±0.15 and 0.77±0.21 respectively, and the relative amplitude of the rest-activity 
rhythm was 0.89±0.05. The average bed time was 23:45±00:55, with an average time 
of sleep start at 00:19±01:00 hrs (table 2.2). The average time of sleep end was 
07:59±00:47 hrs, and get up time was 08:20±00:45 with the wake time calculated as 
8.09±1.59 hrs (tables 2.1 and 2.2). The actual duration of sleep (07:01 ±00:40 hrs, 
table 2.2) was just under an hour shorter than the assumed duration of sleep 
(07:57±00:46 hrs, table 2.2) and the actual duration of time spent awake was 
00:59±00:13 hrs (table 2.2) with the proportion of time spent in bed asleep and 
awake 87.15±2.46% and 12.85±2.46% respectively (table 2.2). The number of wake 
bouts during the period of sleep was 41.15±9.25, and the average duration of wake 
bouts and sleep bouts were 01:30±0.61 mins and 15.75±22.08 mins respectively 
(table 2.2). Average sleep efficiency was 79.09±4.88%, and the latency to sleep onset 
was on average 0.44±0.37 hrs (table 2.2). According to the Home-Ostberg 
momingness/eveningness questionnaire the average score of the participants was 
53.84±11.09 (table 2.1), which is assigned as intermediate chronotype (morning 
chronotype = 59-86, intermediate chronotype = 42-58 and evening chronotype <42). 
Both average and maximum light illumination were greatly reduced during the hours 
of midnight to 6am (2.29±4.27 lux and 706.23± 1804.96 lux respectively), in
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comparison to the full 24 hour period (366.42±458.22 lux and 14800.21±7977.85 lux 
respectively) (table 2.3).
IS 0.54 ±0.15
IV 0.77 ± 0.21
M10 21263.67 ± 4740.50
MlOo (h) 10.4311.69
L5 1250.81 ± 726.42
L5o (h) 1.76 ±1.14
Amplitude 20012.9014799.96
Relative amplitude 0.89 ± 0.05
Period (h) 23.88 ± 0.33
Period deviation (h) 0 .1710.18
Acrophase (h) 15.43 ±1.36
Wake time (h) 8 .0911.59
HO MEQ Score 53.841 11.09
Table 2.1. Chronometrics of the actigraphic circadian rhythm and the Home-Ostberg 
momingness/eveningness (HO MEQ) score (means and standard deviations). IS = 
Interdaily stability; IV = intradaily variability; M10 = activity counts in the 10 most 
active hours; MlOo = time of onset of the ten most active hours; L5 = activity counts 
in the five least active hours; L5o = time of onset of the least active five hours; 
Amplitude = peak amount of activity; Relative amplitude = difference between L5 
and M10; Period = duration of 1 full cycle of the rest-activity rhythm; Period 
deviation = difference in period length from 24 hours; Acrophase = peak phase of 
rhythm; Wake time = actigraphically determined wake time.
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Figure 2.1. Example actograms of the daily activity levels measured by the 
actiwatch. Both subjects exhibit decreased activity during the hours o f 12am-6am. 
(Activity = black, light illumination = yellow).
Subject 1 Subject 2
00:00 06:00 12:00 18:00 00:00 00:00 06:00 12:00 18:00 00:00
Figure 2.2. Example o f the average daily activity profiles measured by the actiwatch. 
(Activity = black, light illumination = yellow).
Subject 1 Subject 2
Peak correlation is at 23:59
— i— i— i— i— i— i— i— i— i— i— i—  — i— i— i— i— i— i— i— i— i— i— i—
Peak correlation is at 24:05
10:00 13:22 16:44 20:06 23:28 26:50 30:00 10:00 13:22 16:44 20:06 23:28 26:50 30:00 
Tim e (hh:mm) Tim e (hh:mm)
Figure 2.3. Example periodograms o f the average period length o f the activity 
rhythm, measured by the actiwatch. Peak correlation = average period o f the activity 
rhythm.
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Bedtime (h) 23:45 ±00:55
Get up time (h) 08:20 ± 00:45
Time in bed (h) 08:45 ±00:41
Sleep start (h) 00:19 ±01:00
Sleep end (h) 07:59 ±00:47
Assumed sleep time (h) 07:57 ±00:46
Actual sleep time (h) 07:01 ±00:40
Actual sleep % (%) 87.15 ±2.46
Actual wake time (h) 00:59 ±00:13
Actual wake % (%) 12.85 ±2.46
Wake bouts (#) 41.15 ±9.25
Sleep bout duration (min) 15.75 ±22.08
Wake bout duration (min) 01.30 ±0.61
Sleep efficiency (%) 79.09 ±4.88
Sleep latency (h) 0.44 ±0.37
Table 2.2. Summary of the actigraphically assessed sleep parameters (means and 
standard deviations). Time in bed = difference between get up time and bed time; 
Assumed sleep time = difference between sleep end and sleep start, Actual sleep time 
= assumed sleep minus periods of wakefulness during the night; Actual sleep % = 
percentage of sleep between sleep start and sleep end. Actual wake time = hours of 
wakefulness during assumed sleep time; Actual wake % = percentage of wakefulness 
during assumed sleep time; Wake bouts (number of) = number of times participant 
wakes during sleep; Sleep bout duration = average length of uninterrupted sleep 
between two consecutive awakenings; Wake bout duration = mean duration of 
periods of wakefulness; Sleep efficiency = percentage of sleep between bed time and 
sleep end; Sleep latency = the time it takes from bed time to sleep start.
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24 Hours 12am - 6am
Time above Time above
Average Maximum 100 lux / Average Maximum 100 lux /
illumination illumination, minutes, mean illumination illumination minutes, mean
mean ± SD mean ± SD ± SD mean ± SD mean ± SD ± SD
366.42 ± 14800.21 ± 292.30 ± 2.29 ± 706.23 ± 1.84 ±
458.22 7977.85 187.27 4.27 1804.96 4.73
Table 2.3. Light exposure (lux) measured by the actiwatches worn by study 
participants (means and standard deviations).
2.3.2 Endocrine circadian rhythms
Subjects were assayed for salivary cortisol and melatonin and rhythmicity was 
assessed by co-sinor analysis. Salivary cortisol levels were significantly rhythmic 
(P<0.05), with 59.5% rhythm and an acrophase of 9.17 hrs (n=10, figure 2.4, table
2.4). Salivary melatonin did not exhibit significant rhythmicity (P=0.268), although 
percentage rhythm was 67.6% (n=4, figure 2.5, table 2.4).
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N
Percentage 
Rhythm (%) P
Mesor
(a.u)
Amplitude
(a.u)
C.I.
Amplitude
(a.u)
Acrophase
(h)
CJ.
Acrophase
(a.u)
Cortisol 10 59.5 <0.05 0.24±0.03 0.24±0.1 0.0,0.5 9.17 5.27,11.4
Melatonin 4 67.6 0.269 3.78±0.81 3.94±1.4 0.0,0.0 5.08 0.0,0.0
Total RNA 
Concentration
14 49.6 <0.01 23.686
±3.260
9.739
±2.363
2.932,
16.620
4.69 1.92, 6.8
Non-normalised
GAPDH
6 52.8 <0.05 27.06±0.39 0.94±0.3 0.0,2.2 18.38 14.85, 1.4
Non-normalised BMAL1 13 48.5 <0.05 3.75±0.63 3.00±1.1 0.1,6.2 4.8 3.08, 11.82
BMAL1 normalised to 
GAPDH
6 50.8 0.577 3.05±1.84 1.83±1.5 0.0,0.0 8.3 0.0,0.0
BMAL1 normalised to 
total RNA concentration
8 42.0 0.133 3.17±0.66 1.82±1.1 0.0,0.0 4.2 0.0, 0.0
Non-normalised PER2 6 53.1 0.134 8.80±3.31 9.65±4.9 0.0,0.0 3.59 0.0,0.0
PER2 normalised to 
GAPDH
5 48 0.699 6.04±4.96 4.53±4.6 0.0, 0.0 13.31 0.0,0.0
PER2 normalised to 
total RNA concentration
5 40.5 0.608 4.85±1.69 5.28±4.3 0.0,0.0 5.51 0.0,0.0
Non-normalised PERI 4 52.1 0.297 3.46±1.15 1.18±0.8 0.0, 0.0 5.57 0.0, 0.0
PERI normalised to 
total RNA concentration
3 73.3 0.672 2.78±0.40 0.89±1.0 0.0,0.0 11.83 0.0, 0.0
Table 2.4. Chronometrics of the average 24-hour profiles of cortisol, melatonin, 
GAPDH, BMAL1, PER2, PERI and total mRNA concentration, assessed by co-sinor 
analysis. For the BMAL1 and PER2 profiles, non-normalised, and normalised data to 
both GAPDH expression and total mRNA are shown. For PERI non-normalised data 
and data normalised to total mRNA concentration are shown. The profiles of cortisol, 
total mRNA concentration, and non-normalised GAPDH and BMAL1 expression are 
significantly rhythmic. a.u.=arbitrary units.
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I Figure 2.4. Co-sinor analysis of salivary cortisol. (A) Chronogram of salivary
j  cortisol across the 24 hour cycle. The fitted dark line represents the co-sine wave of
i
I best fit with a 24 hour period. The horizontal line represents the MESOR. (B)
I
I Polargram of the phase/amplitude relationship for salivary cortisol. Length of the
I dotted black vector indicates amplitude of circadian rhythm and the orientation of
! this vector represents the acrophase for the control group. 95% confidence interval
| for the combined amplitude and acrophase are represented by elliptical area around
the vector tip, indicated by lightly dashed line. The error ellipse does not overlap the 
zero point, indicating a significant co-sinor fit for the data on a 24h time-base. (C) 
Chronometrics of salivary cortisol 24-hour profile. % rhythm refers to the percentage 
of variance in the population data that is explained by regression with the 24h co-sine 
wave of best fit. AMP is the amplitude of the rhythm, Cl AMP is the 95% confidence 
interval for the amplitude, Acrophase is the time of the peak of the rhythm, Cl 
Acrophase is the 95% confidence interval for the amplitude.
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Figure 2.5. Co-sinor analysis of salivary melatonin. (A) Chronogram of salivary 
melatonin across the 24 hour cycle. The fitted dark line represents the co-sine wave 
of best fit with a 24 hour period. The horizontal line represents the MESOR. (B) 
Polargram of the phase/amplitude relationship for salivary melatonin. Length of the 
dotted black vector indicates amplitude of circadian rhythm and the orientation of 
this vector represents the acrophase for the control group. 95% confidence interval 
for the combined amplitude and acrophase are represented by elliptical area around 
the vector tip, indicated by lightly dashed line. The error ellipse covers the zero point 
of amplitude, indicating a non-significant circadian fit for the observed data. (C) 
Chronometrics of salivary melatonin 24-hour profile. Abbreviations are as figure 2.4.
2.3.3 RNA analysis
Experion electrophoresis analysis measured an average concentration of total mRNA 
extracted from the oral mucosa samples across all of the time-points of 24.31 ± 12.88 
ng/pl. RNA integrity was assessed by means of assessment of the 28S:18S ratio and 
the RQI score. The average 28S:18S ratio was 1.80 ± 0.95 and the average RQI was 
2.33 ± 0.54. The total concentration of RNA across the time-course of sampling 
exhibited significant rhythmicity (P<0.01) with an acrophase of 4.69 hrs and a
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percentage rhythm of 49.6%, as assessed by co-sinor analysis (n=14, figure 2.6). 
Although no variation in the degree of degradation was observed (figure 2.7).
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Figure 2.6. Co-sinor analysis of total mRNA concentration. (A) Chronogram of the 
RNA concentration of the oral mucosa samples across the 24 hour cycle. The fitted 
dark line represents the co-sine wave of best fit with a 24 hour period. The 
horizontal line represents the MESOR. (B) Polargram of the phase/amplitude 
relationship for RNA concentration. Length of the dotted black vector indicates 
amplitude of circadian rhythm and the orientation of this vector represents the 
acrophase for the control group. 95% confidence interval for the combined amplitude 
and acrophase are represented by elliptical area around the vector tip, indicated by 
lightly dashed line. The error ellipse does not overlap the zero point, indicating a 
significant co-sinor fit for the data on a 24h time-base. (C) Chronometrics of the total 
mRNA concentration profile. Abbreviations are as figure 2.4.
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Figure 2.7. Example chromatograms obtained from the Experion electrophoresis 
analysis o f the RNA samples collected over the 24 hour period, showing the degree 
of RNA degradation did not vary considerably over the 24 hour period. A lower 
threshold baseline and 5S peak, and greater 28S:18S ratio and RQI is indicative o f 
intact RNA (Perfectly intact RNA: 28S: 18S=2.0, RQI=10). Average 28S:18S and 
RQI o f all the samples was 1.80 ± 0.95 and 2.33 ± 0.54 respectively.
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2.3.4 Normalisation o f clock gene expression
Expression levels o f the house-keeping gene GAPDH  and clock genes were 
quantified by RT-PCR and the data was tested for significant rhythmicity by co-sinor 
analysis. Non-normalised raw GAPDH  expression showed a significant oscillation 
(P<0.05), with an acrophase o f 18.38 hrs and percentage rhythm o f 52.8% (n=6, 
figure 2.8, table 2.4). Prior to normalisation, the raw non-normalised BMAL1 data 
was significantly rhythmic, (P<0.05) with an acrophase o f 4.8hrs and a percentage 
rhythm o f 48.5% (n=13, figure 2.9, table 2.4). Non-normalised PER2 expression did 
not show significant rhythmicity (P=0.134) although percentage rhythm o f the data 
was 53.1% (n=6, figure 2.10, table 2.4). Non-normalised PERI  expression also did 
not show significant rhythmicity (P=0.297), and the percentage rhythm o f the data 
was 52.1% (n=4, figure 2.11, table 2.4).
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Figure 2.8. Co-sinor analysis o f non-normalised raw GAPDH  expression levels. (A) 
Chronogram o f GAPDH  expression levels in the oral mucosa samples across the 24 
hour cycle. The fitted dark line represents the co-sine wave o f best fit with a 24 hour 
period. The horizontal line represents the MESOR. (B) Polargram o f the 
phase/amplitude relationship for GAPDH  expression levels. Length o f the dotted
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black vector indicates amplitude of circadian rhythm and the orientation of this 
vector represents the acrophase. 95% confidence interval for the combined amplitude 
and acrophase are represented by elliptical area around the vector tip, indicated by 
lightly dashed line. The error ellipse does not overlap the zero point, indicating a 
significant co-sinor fit for the data on a 24h time-base. (C) Chronometrics of the 
GAPDH expression profile. Abbreviations as outlined in figure 2.4.
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Figure 2.9. Co-sinor analysis of non-normalised raw BMAL1 expression levels. (A) 
Chronogram of BMAL1 expression levels in the oral mucosa samples across the 24 
hour cycle. The fitted dark line represents the co-sine wave of best fit with a 24 hour 
period. The horizontal line represents die MESOR. (B) Polargram of the 
phase/amplitude relationship for BMAL1 expression levels. Length of the dotted 
black vector indicates amplitude of circadian rhythm and the orientation of this 
vector represents the acrophase. 95% confidence interval for the combined amplitude 
and acrophase are represented by elliptical area around the vector tip, indicated by 
lightly dashed line. The error ellipse does not overlap the zero point, indicating a 
significant co-sinor fit for the data on a 24h time-base. (C) Chronometrics of the 
BMAL1 expression profile. Abbreviations as outlined in figure 2.4.
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Figure 2.10. Co-sinor analysis of non-normalised raw PER2 expression levels. (A) 
Chronogram of PER2 expression levels in the oral mucosa samples across the 24 
hour cycle. The fitted dark line represents the co-sine wave of best fit with a 24 hour 
period. The horizontal line represents the MESOR. (B) Polargram of the 
phase/amplitude relationship for PER2 expression levels. Length of the dotted black 
vector indicates amplitude of circadian rhythm and the orientation of this vector 
represents the acrophase. 95% confidence interval for the combined amplitude and 
acrophase are represented by elliptical area around the vector tip, indicated by lightly 
dashed line. The error ellipse covers the zero point of amplitude, indicating a non­
significant circadian fit for the observed data. (C) Chronometrics of the PER2 
expression profile. Abbreviations as outlined in figure 2.4.
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Figure 2.11. Co-sinor analysis of non-normalised raw PERI expression levels. (A) 
Chronogram of PERI expression levels in the oral mucosa samples across the 24 
hour cycle. The fitted dark line represents the co-sine wave of best fit with a 24 hour 
period. The horizontal line represents the MESOR. (B) Polargram of the 
phase/amplitude relationship for PERI expression levels. Length of the dotted black 
vector indicates amplitude of circadian rhythm and the orientation of this vector 
represents the acrophase. 95% confidence interval for the combined amplitude and 
acrophase are represented by elliptical area around the vector tip, indicated by lightly 
dashed line. The error ellipse covers the zero point of amplitude, indicating a non­
significant circadian fit for the observed data. (C) Chronometrics of the PERI 
expression profile. Abbreviations as outlined in figure 2.4.
To compare the use of normalisation to GAPDH expression to total mRNA 
concentration, the expression of the clock genes BMAL1, PER2 and PERI were 
normalised via both methods. BMAL1 expression normalised to both GAPDH 
expression (n=6 ) and to total mRNA concentration (n=8 ) did not exhibit significant 
rhythmicity (P=0.577 and P=0.133 respectively, figures 2.12-2.13, table 2.4). 
Although percentage rhythm of the data was 50.8% when normalised to GAPDH 
expression and 42.0% when normalised to total mRNA concentration (figures 2.12-
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2.13, table 2.4). PER2 expression also did not exhibit significant rhythmicity when 
normalised by either method (P=0.669 and P=0.608 respectively, n=5 in both cases, 
figures 2.14-2.15, table 2,4). Percentage rhythm of the data was again greater when 
normalised to GAPDH expression (48%) in comparison to total mRNA 
concentration (40.5%, figures 2.14-2.15, table 2.4). Only two sets of PERI 
expression data normalised to GAPDH expression were available and therefore the 
data was assessed by co-sinor analysis individually (table 2.5). Data set 1 exhibited a 
significant circadian rhythm (P<0.01), with an acrophase of 4.52hrs and 97.1% 
rhythm (table 2.5). Whereas data set 2 did not exhibit rhythmic PERI expression 
(P=0.102), with a percentage rhythm of 78.2% (table 2.5). PERI expression 
normalised to total mRNA concentration was also not significantly rhythmic 
(P=0.672), although the data had a percentage rhythm of 73.3% (n=3, figure 2.16, 
table 2.4).
Although in almost all cases neither normalisation method produced significantly 
rhythmic data, (apart from GAPDH normalised PERI expression of data set 1, 
P<0.01, table 2.5), the expression of each clock gene showed the greatest percentage 
rhythm when normalised to GAPDH expression as oppose to total mRNA 
concentration (figures 2.12-2.16, table 2.4 and 2.5).
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Figure 2.12. Co-sinor analysis of BMAL1 expression normalised to GAPDH 
expression. (A) Chronogram of BMAL1 expression in the oral mucosa samples 
across the 24 hour cycle. The fitted dark line represents the co-sine wave of best fit 
with a 24 hour period. The horizontal line represents the MESOR. (B) Polargram of 
the phase/amplitude relationship of the BMAL1 expression levels. Length of the 
dotted black vector indicates amplitude of circadian rhythm and the orientation of 
this vector represents the acrophase. 95% confidence interval for the combined 
amplitude and acrophase are represented by elliptical area around the vector tip, 
indicated by lightly dashed line. The error ellipse covers the zero point of amplitude, 
indicating a non-significant circadian fit for the observed data. (C) Chronometrics of 
the profile of BMAL1 expression. Abbreviations as outlined in figure 2.4.
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Figure 2.13. Co-sinor analysis of BMAL1 expression normalised to total mRNA 
concentration. (A) Chronogram of BMAL1 expression in the oral mucosa samples 
across the 24 hour cycle. The fitted dark line represents the co-sine wave of best fit 
with a 24 hour period. The horizontal line represents the MESOR. (B) Polargram of 
the phase/amplitude relationship of the BMAL1 expression level. Length of the 
dotted black vector indicates amplitude of circadian rhythm and the orientation of 
this vector represents the acrophase. 95% confidence interval for the combined 
amplitude and acrophase are represented by elliptical area around the vector tip, 
indicated by lightly dashed line. The error ellipse covers the zero point of amplitude, 
indicating a non-significant circadian fit for the observed data. (C) Chronometrics of 
the profile of BMAL1 expression. Abbreviations as outlined in figure 2.4.
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Figure 2.14. Co-sinor analysis of PER2 expression normalised to GAPDH 
expression. (A) Chronogram of PER2 expression in the oral mucosa samples across 
the 24 hour cycle. The fitted dark line represents the co-sine wave of best fit with a 
24 hour period. The horizontal line represents the MESOR. (B) Polargram of the 
phase/amplitude relationship of the PER2 expression level. Length of the dotted 
black vector indicates amplitude of circadian rhythm and the orientation of this 
vector represents the acrophase. 95% confidence interval for the combined amplitude 
and acrophase are represented by elliptical area around the vector tip, indicated by 
lightly dashed line. The error ellipse covers the zero point of amplitude, indicating a 
non-significant circadian fit for the observed data. (C) Chronometrics of the profile 
of PER2 expression. Abbreviations as outlined in figure 2.4.
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| Figure 2.15. Co-sinor analysis of PER2 expression to total mRNA concentration.
I (A) Chronogram of PER2 expression in the oral mucosa samples across the 24 hour
I
! cycle. The fitted dark line represents the co-sine wave of best fit with a 24 hour
i
| period. The horizontal line represents the MESOR. (B) Polargram of the
| phase/amplitude relationship of the PER2 expression level. Length of the dotted
black vector indicates amplitude of circadian rhythm and the orientation of this 
vector represents the acrophase. 95% confidence interval for the combined amplitude 
and acrophase are represented by elliptical area around the vector tip, indicated by 
lightly dashed line. The error ellipse covers the zero point of amplitude, indicating a 
non-significant circadian fit for the observed data. (C) Chronometrics of the profile 
of PER2 expression. Abbreviations as outlined in figure 2.4.
Cosinor Fit % Rhythm MESOR AMP CIAMP Acrophase Cl
Acrophase
Data Set 1 P=0.005 97.1 0.97±0.01 0.13±0.01 (0.1,0.2) 4.52±0.38 (3.4, 5.7)
Data Set 2 P=0.102 78.2 1.03±0.12 0.57±0.16 (0.0,0.0) 4.2911.16 (0.0,0.0)
Table 2.5. Co-sinor analysis of PERI expression to GAPDH expression. (A) 
Chronometrics of the profile of PERI expression for data set 1 and 2. Abbreviations 
as outlined in figure 2.4. No chronogram or polargram were available due to the co- 
sinor analysis of individual data sets.
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Figure 2.16. Co-sinor analysis of PERI expression to total mRNA concentration. 
(A) Chronogram of PERI expression in the oral mucosa samples across the 24 hour 
cycle. The fitted dark line represents the co-sine wave of best fit with a 24 hour 
period. The horizontal line represents the MESOR. (B) Polargram of the 
phase/amplitude relationship of the PERI expression level. The vector indicating 
amplitude and acrophase is not visible due to the low amplitude (0.89±1.0). 95% 
confidence interval for the combined amplitude and acrophase are represented by 
elliptical area around the vector tip, indicated by lightly dashed line. The error ellipse 
covers the zero point of amplitude, indicating a non-significant circadian fit for the 
observed data. (C) Chronometrics of the profile of PERI expression. Abbreviations 
as outlined in figure 2.4.
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2.3.5 Correlations o f the behavioural data with the endocrine and molecular 
measures
To investigate the relationship of the rest-activity rhythm and actigraphically 
assessed sleep measures with the profiles of the molecular and endocrine circadian 
rhythms, correlations between actigraphic measures and the chronometrics of the 
GAPDH normalised clock gene expression and salivary melatonin and cortisol 
profiles were examined by two-tailed Pearson’s product moment correlation. An 
inverse relationship was demonstrated between L5o and the acrophase of PER2 
expression (r=-0.950, P<0.05, figure 2.17A). The acrophase of BMAL1 significantly 
correlated with percentage of actual sleep (r=0.883, PO.05, figure 2.17B), and hence 
there was an inverse relationship of the acrophase of BMAL1 expression with 
percentage of actual time awake (r=-0.883, PO.05, figure 2.17C). The acrophase of 
the salivary cortisol rhythm was inversely correlated with the actigraphic period 
deviation (r=-0.890, PO.Ol, figure 2.17D) and significantly correlated with the time 
of sleep start (r=0.842, PO.Ol, figure 2.17E).
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Figure 2.17. Significant correlations between the chronometrics of the actigraphic 
circadian rhythm and the chronometrics of the BMAL1, PER2 and cortisol. (331 
correlations between the chronometrics of the actigraphic rhythm and the 
chronometrics of the BMAL1, PER2, cortisol and melatonin rhythms did not reach 
significance). L5o = time of onset of the least active five hours; Actual sleep duration 
% = percentage of time spent in bed asleep; Actual wake duration % = percentage of 
time spent in bed awake; Period deviation = difference in period length from 24 
hours.
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2.4 Discussion
2.4.1 Actigraphy and chronotype
Although not identical, the actigraphic measurements of the rest and activity periods 
are correlated with sleep and wakefulness periods (Boonstra et al., 2007). Based 
upon previous actigraphy studies, all the average activity and sleep measures of the 
subjects in the present study were comparable to those reported of healthy subjects 
(Jones et al., 2005, Boonstra et al., 2007). These included indicators of sleep 
continuity and quantity; sleep bout and wake bout durations, number of wake bouts, 
assumed and actual sleep durations, actual wake duration and percentages of sleep 
and wakefulness during the sleep time. The time spent awake and asleep, in 
comparison to the time spent in bed, and the sleep efficiency and sleep latency 
measures all indicated that the proportion of sleep during the period of rest and the 
time taken to fall asleep were within the normal range. The amount of activity 
exhibited over the 24 hours period was also as expected in healthy individuals, as 
demonstrated by the amplitude, and the activity exhibited in the least 5 active hours 
and the 10 most active hours. Furthermore the intradaily variability and relative 
amplitude measures demonstrated a robust rhythm of the rest-activity rhythm. L5o, 
MlOo and the acrophase of the rest-activity rhythm indicated that the phase of the 
behavioural rhythm was as expected in healthy individuals, with onset of the rest 
period just after midnight, onset of the most active period in the mid morning and 
peak activity in the mid afternoon. This was further confirmed by the calculated 
sleep measures, which demonstrated time of sleep end, wake time and get up time in 
the early morning and bed time and sleep start just before midnight. The average 
intrinsic period in humans is estimated to be just over 24 hours at 24.18 hours 
(Czeisler et al., 1999), and the average period of the rest-activity rhythm in the 
present study fell just short of 24 hours. Importantly the period deviation from 24 
hours observed was minimal, and the interdaily stability was within the range of 
healthy adults, thus indicating efficient coupling of the behavioural rhythm to the 24 
hours environmental cycle. The subjects were on average of intermediate 
chronotype, which is to be expected of healthy adults, as it is documented as the most 
common chronotype of the healthy human population (Paine et al., 2006), and 
extremes in chronotype have been associated with psychiatric illness (Mansour et al.,
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2005, Lamont et al., 2010). Normal patterns of light exposure were also 
demonstrated by average and maximum light illumination being minimal during the 
normal hours of sleep of 12am -  6 am in comparison to the full 24 hour period.
2.4.2 Endocrine circadian rhythms
Salivary cortisol levels exhibited a characteristic diurnal rhythm that was significant, 
with an acrophase in the morning as is widely documented in healthy individuals 
(Van Someren and Riemersma-Van Der Lek, 2007, Dockray and Steptoe, 2010). 
Salivary melatonin levels are known to also display a significant diurnal rhythm, 
with peak levels at ~3am (Arendt and Skene, 2005, Pandi-Perumal et al., 2005). In 
the present study however a significant rhythm of salivary melatonin was not 
detected, which is most likely due to the low sample number, although the 
measurement of percentage rhythm indicated a robust rhythm of melatonin.
2.4.3 RNA analysis
In the present study a non-invasive technique was developed for the simple sampling 
of oral mucosa for the monitoring of clock gene expression. The advantages of this 
protocol being that it allows for self-sampling, and so does not require laboratory 
based sampling and thus, when applied with actigraphy in order to gain objective 
sleep and motor activity measurements and reference points, allows for a more 
naturalistic monitoring of these circadian processes The reliability of the 28S: 18S 
ratio as an indicator of RNA quality is questionable as incorrect identification of the 
start and end points of the 28S and 18S peaks leads to inaccurate calculations of area 
resulting in highly variable 28S: 18S calculations between identical samples 
evaluated on independent runs (Imbeaud et al., 2005). Therefore both the 28S:18S 
ratio and RQI measurements were evaluated in the present study and in both cases 
this indicated that the RNA extracted from the oral mucosa was of relatively low 
integrity, although the degree of RNA degradation did not vary greatly across the 
circadian cycle or between subjects. It is not surprising that the RNA was relatively 
degraded since it originates from the oral mucosa, a tissue that is subject to regular 
abrasion (Warburton et al., 2005) and surrounded by an environment of high RNase 
activity (Driemel et al., 2007). Furthermore it has been acknowledged in the
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literature that a 28S:18S ratio of 2.0 indicating completely intact rRNA is veiy 
difficult to meet in RNA derived from clinical samples (Imbeaud et al., 2005).
2.4.4 Normalisation o f clock gene expression
The concentration of total mRNA extracted from the oral mucosa in the present study 
was shown to oscillate over the 24 hour period with a significant rhythm. This could 
be explained in part by the high degree of abrasion and hence cell proliferation of the 
oral mucosa (Angelov et al., 2004, Warburton et al., 2005). Total mRNA is known to 
be increased in highly proliferating tissues (Bustin et al., 2005) and a number of 
aspects of the cell cycle, inflammatory and healing processes have been shown to be 
in part under circadian control (Lavker et al., 1991, Bjamason et al., 1999, Irwin et 
al., 2006, Wang et al., 2006), and so it could therefore be postulated that total mRNA 
amounts may oscillate over the 24 hour cycle as a consequence of this. Prior to 
normalisation, the profiles of the housekeeping gene GAPDH and the clock gene 
BMAL1 were also shown to oscillate, whilst both PER2 and PERI expression were 
not significantly rhythmic prior to normalisation. It is quite probable that the 
oscillation in total mRNA quantity could play a role in this significant rhythm of 
GAPDH expression, which may otherwise not be expressed with significant 
rhythmicity. However GAPDH expression has been reported to be under circadian 
regulation (Shinohara et al., 1998), and furthermore a circadian profile in its 
expression has been documented in the rodent retinal tissue (Kamphuis et al., 2005). 
To the contrary however, GAPDH has been shown to be constitutively expressed in 
the human oral mucosa, and is therefore an appropriate house-keeping gene for 
normalisation of gene expression in this tissue (Warburton et al., 2005, Cajochen et 
al., 2006).
To further investigate the merits of normalising to a housekeeping gene or to total 
mRNA amounts, the effects of both methods of normalisation upon the expression of 
the clock genes; BMAL1, PER2 and PERI were assessed. The expression of all three 
clock genes was not significantly rhythmic after normalisation to either GAPDH 
expression or total mRNA amounts, which can most probably be attributed to the 
low samples numbers in each case. However, the percentage rhythms of clock gene 
expression were relatively high, indicating the potential usefulness of the technique
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when applied to a larger sample population. Furthermore, the percentage rhythms of 
BMAL1 and PER2 were greatest when GAPDH normalisation was implemented as 
oppose to normalisation to total mRNA amounts, which may be a direct consequence 
of the robust oscillation of total mRNA amounts across the circadian cycle. It was 
therefore concluded that due to the increased robustness of clock gene expression 
rhythmicity when normalised to GAPDH expression and the observed circadian 
oscillation of total mRNA concentration in the oral mucosa, that normalising to the 
expression of GAPDH was a more appropriate method of normalisation than using 
total mRNA concentration. This is in agreement with previous reports that suggest 
quantification of GAPDH expression is an adequate method of normalisation of gene 
expression in the oral mucosa, since it is constitutively expressed in this tissue 
(Warburton et al., 2005, Cajochen et al., 2006).
2.4.5 Correlations o f the behavioural data with the endocrine & molecular measures
Correlations were observed between a number of actigraphic parameters and the 
acrophases of the profiles of PER2 and BMAL1 expression and salivary cortisol. This 
therefore indicated potential interactions of the molecular and endocrine circadian 
rhythms with the circadian rhythm of behaviour, and therefore the potential 
usefulness of these rhythms as markers of the circadian clock pacemaker, as also 
demonstrated by the circadian rhythms of clock gene expression in human hair 
follicle cells (Akashi et al., 2010). Correlations observed in the present study 
included an inverse relationship of PER2 acrophase with the time of onset of least 
activity, indicating that as the acrophase of the PER2 rhythm increases the time of 
onset of the rest period becomes earlier. The significant correlation of BMAL1 
acrophase with percentage duration of sleep and the inverse relationship of BMAL1 
acrophase with percentage duration of wakefulness both indicate that the later the 
BMAL1 acrophase the longer the duration of time asleep will be. These correlations 
therefore indicate a potential interaction of the circadian rhythm of clock gene 
expression with sleep timing and duration. A correlation of the acrophase of the 
cortisol rhythm with the time of sleep start was observed, thus indicating that as the 
acrophase of the cortisol rhythm becomes later so too does the time of sleep onset. 
This observation can be explained by the fact that cortisol plays a key role in the 
awakening response, with a clear morning peak in cortisol occurring just after
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waking (Van Someren and Riemersma-Van Der Lek, 2007). Therefore in individuals 
exhibiting later phases of behaviour, not only would their time of sleep onset occur 
later, but so too would their time of waking the following day, in conjunction with a 
later acrophase of the cortisol rhythm. An inverse relationship was also revealed 
between the acrophase of the cortisol rhythm and the actigraphic period deviation, 
which suggests that the further the period of the rest-activity rhythm deviates from 24 
hours, the earlier the acrophase of the cortisol rhythm will occur. This would suggest 
that there is a possible link between the phase of the cortisol rhythm with 
synchronisation of the circadian activity rhythm to the environmental 24 hour cycle, 
an assumption which could be plausible due to the known roles of cortisol in the 
awakening response as mentioned earlier and also its role in the entrainment of the 
peripheral oscillators (Van Someren and Riemersma-Van Der Lek, 2007). It could 
therefore be postulated that altered timing of the phase of the cortisol rhythm could 
not only impact upon the behavioural rhythm, but also perturb the synchronisation of 
the peripheral oscillators to the master circadian pacemaker.
2.4.6 Conclusions
The subjects included in this study exhibited normal diurnal patterns of rest and 
activity as indicated by actigraphic measures and intermediate chronotype. The phase 
of the cortisol rhythm further corroborated this, and actigraphic measures of light 
illumination revealed that the subjects were exposed to normal patterns of light 
exposure over the 24 hour period. It can therefore be assumed that the circadian 
system was intact in these individuals who were exposed to normal patterns of light 
and social Zeitgebers. RNA extraction from the oral mucosa using the protocol 
developed in the current study produced RNA of adequate integrity for successful 
analysis of clock gene expression. The normalisation of clock gene expression to the 
expression of the housekeeping gene GAPDH was shown to be superior to that of 
total mRNA amounts in the oral mucosa as indicated by the comparison of 
robustness of clock gene rhythmicity. The relevance of sampling clock gene 
expression in the oral mucosa was highlighted by the significant correlations 
observed between a number of actigraphic parameters and the chronometrics of the 
circadian rhythms of clock gene expression. These findings therefore demonstrated
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the usefulness of the technique for further clock gene analysis in a wider clinical 
population.
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Chapter 3: Circadian rhythms in adult Attention deficit- 
/hvperactivitv disorder
Chapter 3: Circadian rhythms in adult Attention deficit-Zhyperactivitv disorder
3.1 Introduction
Attention deficit-Zhyperactivity disorder (ADHD) is a psychiatric condition that can 
affect both children and adults, with an estimated prevalence of 3 -  7% in school 
aged children (van West et al., 2009) and 3.4% in adults (Fayyad et al., 2007, 
Lackschewitz et al., 2008). The disorder is characterised by behavioural and attention 
difficulties, which can lead to secondary problems such as drug addiction and 
delinquency in adults (Rosier et al., 2004). Sleep deficits are a prominent 
characteristic of the disorder, with up to 54% of children and up to 83% of adults 
with ADHD reporting problems with sleep (Tjon Pian Gi et al., 2003, Sobanski et al., 
2008). Actigraphy and polysomnography studies of sleep disturbance in ADHD have 
demonstrated significant association of sleep disturbance with both childhood and 
adult ADHD, including delayed sleep onset and difficulties in awakening, increased 
variability in sleep onset time, sleep duration and true sleep time, increased nocturnal 
activity, reduced sleep efficiency, more nocturnal awakenings and reduced 
percentage of REM sleep (Gruber et al., 2000, Boonstra et al., 2007, Rybak et al., 
2007, Sobanski et al., 2008). Furthermore, the core symptoms of ADHD; inattention, 
impulsiveness and restlessness, are known characteristics of sleep deprivation 
(Corkum et al., 1998) and sleep deprivation has been shown to cause behavioural and 
cognitive problems (Bonnet, 1985, Babkoff et al., 1991, Gruber et al., 2000). 
Moreover, the sleep disorder, Idiopathic Chronic Sleep Onset Disorder has been 
shown to be associated with childhood ADHD (Van der Heijden et al., 2005, Neves 
and Reimao, 2007).
The circadian clock is responsible for the generation of rhythms of behaviour and 
physiology on a near twenty-four period base, and plays a key role in determining the 
rhythm of the sleep/wake cycle (McClung, 2007). The master clock is located in the 
suprachiasmatic nuclei (SCN) of the anterior hypothalamus and it is entrained to the 
24 hour day by receiving light pulses via the retinohypothalamic tract, with further 
slave oscillators present throughout the brain and periphery (Piggins and Loudon,
2005). SCN output is responsible for driving circadian rhythms in a number of
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hormones, including melatonin and cortisol (Reppert and Weaver, 2001, Keller et al., 
2006).
The pineal hormone, melatonin, plays a key role in regulating daily rhythms of 
activity and entrainment of sleep/wake cycles (Wiechmann and Summers, 2008). 
The nocturnal onset in its secretion, which usually occurs 2 hours in advance of the 
individuals habitual bedtime, correlates with evening sleepiness and the sleep 
promoting effect of exogenous melatonin (Tzischinsky et al., 1993, Zhdanova et al., 
1996, Zhdanova and Tucci, 2003, Pandi-Perumal et al., 2005). Abnormal rhythms of 
melatonin secretion have been correlated with childhood ADHD, with children 
suffering from both ADHD and chronic sleep onset insomnia being shown to exhibit 
a delayed sleep phase and delayed dim-light melatonin onset (DLMO) (Van der 
Heijden et al., 2005). Adult ADHD patients suffering from chronic sleep onset 
insomnia have also been shown to exhibit a delayed DLMO in comparison to adult 
ADHD patients not suffering from this sleep condition (Van Veen et al., 2010).
In addition to its key role in the hypothalamic-pituitary-adrenal (HPA) axis (Keller et 
al., 2006), the adrenal glucocorticoid stress hormone cortisol is thought to be 
involved in the regulation of circadian rhythms (Keller et al., 2006) in particular the 
entrainment of the peripheral oscillators (Van Someren and Riemersma-Van Der 
Lek, 2007). The circadian rhythm of cortisol secretion consists of an increase just 
before waking up in the morning, with a peak within an hour of waking, followed by 
a decline over the rest of the 24-hour day (Van Someren and Riemersma-Van Der 
Lek, 2007). Cortisol circadian profiles have been reported to be either unaltered in 
ADHD (Hirvikoski et al., 2009) or altered in association primarily with the 
hyperactive subtype of ADHD (Kaneko et al., 1993; Blomqvist et al., 2007).
The molecular basis of circadian rhythm generation consists of positive and negative 
transcriptional/translational feedback loops of “clock” genes and their protein 
products (Guilding and Piggins, 2007), which gives rise to twenty-four hour 
molecular oscillations in a number of behavioural and physiological processes. The 
transcription factors CLOCK and BMAL1 form a heterodimer thus activating the 
transcription of mPer and mCty (Gekakis et al., 1998, van der Horst et al., 1999, 
Guilding and Piggins, 2007). PER and CRY accumulate thus inhibiting their
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CL0CK-BMAL1-dependent transcriptional activation, and the degradation of PER 
and CRY then leads to a restart of the process, (Reppert and Weaver, 2002, Hastings 
and Herzog, 2004, Hirota and Fukada, 2004). The rs 1801260 C/T single nucleotide 
polymorphism in the 3’-UTR of the circadian clock gene CLOCK has also recently 
been found to be associated with adult ADHD, where the T-allele was found to be a 
risk allele for ADHD (Kissling et al., 2008, Xu et al., 2010).
A very apparent behavioural manifestation of circadian phenotypes in humans is 
diurnal preference, an individuals preference for activity in the morning or evening 
(Home and Ostberg, 1977). It has been hypothesised that in individuals with extreme 
diumal preferences conflicts between the internal biological clock and 
environmental/social clocks occur, which could result in the disruption of 
homeostatic processes and behaviours (Barnard and Nolan, 2008). Presumably de- 
synchronisation of the internal biological clock with the environmental light-dark 
cycle could occur in individuals with extreme diumal preference due to an altered 
exposure to environmental light, the dominant Zeitgeber responsible for entrainment 
of the circadian system to a 24-hour period. Furthermore, greater eveningness has 
been associated with self-reported symptoms of ADHD (Rybak et al., 2007).
Based upon these indications that the circadian clock may be compromised in adult 
ADHD, the aims of this study were therefore to examine for the first time circadian 
rhythmicity at the molecular, endocrine and behavioural levels in adult ADHD.
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3.2 Methods
Subjects
Adult ADHD patients were recruited from the Adult ADHD clinic at Cefn Coed 
hospital, Swansea, Wales, (n=14), and age & gender-matched healthy controls 
(n=30) were recruited from the university staff, hospital staff and a student 
population. Additionally two of the subjects included as ADHD patients were 
originally recruited as controls, but were diagnosed with adult ADHD when 
screened. During the course of the study four of the ADHD patient cohort were 
undergoing pharmacological treatment for ADHD (dex-amphetamine n=2, 
methylphenidate n=l, atomoxetine n=l). Only control subjects that were not 
showing evidence of suffering from a current psychiatric or sleep disorder were 
included in the study. Participants included in both the ADHD patient cohort and 
control cohort were recruited across the year. Each participant was assessed using a 
semi-structured clinical interview supplemented by the Research Version of the 
Structured Clinical Interview for DSM-IV-TR- Axis I Disorders (SCED-RV), in 
addition to ADHD questionnaires and psychometric tests; (WHO’s Adult ADHD 
Self Report Scale (ASRS), Conners scales (CAARS-Self-Report Long Version and 
CAARS-Observer Long Version) and the Wender-Utah Rating Scale (WURS) for 
retrospective information on childhood ADHD (table 3.1). Chronotype was assessed 
by completion of the Home-Ostberg questionnaire.
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ADHD 
n = 14
Controls 
n = 3 0
Age in Years, mean ± SD 31.5 ± 11.7 30.6 ± 12.3
Male, n (%) 9 (64.3%) 15 (50%)
Childhood ADHD symptoms Wurs-K score, mean ± SD 119.5 ±28.7 42.8 ± 17.3
Adult ADHD Self-Report Scale (ASRS-vl.l), mean ± SD 51.3 ± 13.9 19.3 ±9.3
CAARS-Self-Report: Long Version
ADHD Index, mean ± SD 72.5 ± 9.7 42.3 ± 7.9
DSM-IV ADHD symptoms total score, mean ± SD 80.8 ± 12.2 43.5 ± 8.4
DSM-IV ADHD inattentive symptoms score, mean ± SD 82.2 ±9.1 46.5 ±8.5
DSM-IV ADHD hyperactive-impulsive symptoms score, mean ± SD 71.7 ±9.9 41.4 ± 6.8
CAARS-Observer: Long Version
ADHD Index, mean ± SD 71.9 ± 14.7 44.6 ±7.6
DSM-IV ADHD symptoms total score, mean ± SD 69.9 ± 13.7 44.2 ±6.3
DSM-IV ADHD inattentive symptoms score, mean ± SD 71.3 ± 11.4 43.6 ±5.4
DSM-IV ADHD hyperactive-impulsive symptoms score, mean ± SD 63.5 ± 15.3 45.7 ±7.0
Table 3.1 Demographic and clinical data
Actigraphy
Subjects wore an ActiWatch Light (Cambridge Neurotech, UK) on their non­
dominant wrist for at least 7 days, during which mucosal/salivary samples were 
collected. Data was transferred for analysis from the ActiWatch to a PC, upon which 
the Sleep analysis software (Cambridge Neurotech, UK) was installed. Data analysis 
excluded the first and last days of data collection. Wake times were calculated from 
actigraphic data by means of the “auto” detection of minimal activity threshold 
above which an epoch is defined as being during waking time (Sleep analysis 
software, Cambridge Neurotech). Analysis of actigraphic data was via non 
parametric circadian rhythm analysis (Van Someren et al, 1999) as well as by 24 
hour co-sinor analysis. These methods yielded a number of measures:
Intradaily variability: This is an index of fragmentation of the rhythm, and assesses 
frequency of transitions between periods of activity and inactivity.
Interdaily stability: This is a measure of the stability of the rhythm between days, and 
is taken as a measure of the strength of entrainment of the endogenous circadian 
clock to environmental Zeitgebers.
L5: This is the amount of activity counts that occurs in the least active 5 hours of the 
24 hour cycle.
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L5o: This is the time of onset of the least active five hour period.
M10: This is the amount of activity in the most active 10 hour period.
MlOo: This is the time of onset of the most active 10 hour period.
Relative amplitude: Indicates quantity of activity, derived from the normalized 
difference between M10 and L5 hour period in an average 24 hour pattern. Values 
range between 0  and 1, 1 representing the greatest difference between the most and 
least active phases, and thus the best temporal organisation of the activity cycle. 
Amplitude: This is the peak-to-trough difference in terms of activity counts.
Period: This is the period that shows best fit to the data by means of a chi-squared 
periodogram.
Acrophase: This is the time of the peak of the best fit periodogram.
The ActiWatch also recorded a number of light measures including daily average 
illumination (lux), maximum illumination (lux) and time spent above the baseline 
level of light (100 lux). Sleep measures recorded included sleep efficiency, sleep- 
onset latency, sleep start and end, and total length of sleep.
Clock gene analysis
Buccal samples were collected every four hours over a 24 hours period using 
foam tipped swabs (Whatman International Ltd, UK) and the material was stored 
on FTA cards (Whatman International Ltd, UK) at room temperature. RNA was 
extracted from the FTA cards using the Magmax viral RNA isolation kit 
(Ambion, UK) and concentrated using carrier RNA and the micro-magnetic 
beads provided within the kit. The quality and quantity of total RNA isolated was 
confirmed using the experion RNA HighSens analysis kit (Bio-Rad, UK) and the 
experion automated electrophoresis system (Bio-Rad, UK). There was no 
evidence of variations of RNA quality according to time of sampling.
One-step quantitative real-time PCR was performed using the Light Cycler 3.5 
(Roche Diagnostics, Germany) with SYBR-Green I dye amplimer detection.
For amplification of the target RNA the following primers were used:
PER2 forward: 5 ’-GCATCCATATTTCACTGTAAAAGA-3 ’,
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PER2 reverse: 5’-AGTAAAAGAATCTGCTCCACTG-3’, (Cajochen et a l, 2006), 
BMAL1 forward: 5 ’-AAGGATGGCTGTTCAGCACATGA-3 ’,
BMAL1 reverse: 5 ’-CAAAAATCCATCTGCTGCCCTG-3 ’ (Bjamason et a l, 2001), 
GAPDHforward: 5’-GAAGGTGAAGGTCGGAGT-3’,
GAPDH reverse: 5 ’-GAAGATGGTGATGGGATTTC-3 ’.
RNA was added to a reaction mixture of final volume 20pl containing one-step 
RT-PCR kit components (RNA Master SYBR Green I, Roche Diagnostics, UK) 
with appropriate primers at 0.5pm and 2.5mM MnOAc2. The following PCR 
conditions were used. PER2: 20 min at 61°C, 30 s at 95°C, followed by 50 cycles 
of 1 s at 95°C, 5 s at 55°C, 13 s at 72°C and 1 s at 75°C. BMAL1: 20 min at 61°C,
30 s at 95°C, followed by 50 cycles of 1 s at 95°C, 5 s at 60°C, 13 s at 72°C and 
1 s at 78°C, GAPDH: 20 min at 61°C, 30 s at 95°C, followed by 50 cycles of 1 s 
at 95°C, 5 s at 57°C, 13 s at 72°C and 1 s at 78°C. All samples were amplified in 
duplicate, and all PCR reactions included duplicate water blank samples as a 
negative control. Melting curve analysis followed each of these protocols.
Expression levels were normalised to the levels of the GAPDH gene and relative 
mRNA abundance was calculated using the 2'MCT method (e.g. Cajochen et al,
2006).
Melatonin and cortisol analysis.
Saliva samples were collected every four hours over a 24 hours period (at the 
same time periods as buccal sampling), by chewing on a cotton swab (Salivettes, 
Buhlmann Laboratories, Schonenbuch Switzerland) and subsequently stored at - 
20°C prior to analysis. Subjects were asked to collect night time samples under 
dim illumination. Prior to analysis saliva samples were thawed at room 
temperature and centrifuged at 2000-3000 x g for 10 minutes to remove 
particulate material. Both the levels of cortisol and melatonin of the spun saliva 
samples were assayed in duplicate by ELISA, according to the manufacturer’s 
protocol (IBL international, Germany). The optical density of each well was 
determined using a microplate spectrophotometer at 450 nm (reference 
wavelength 600-650 nm). A standard curve of the optical densities against their
corresponding concentrations of the standards supplied within the kit was 
calculated using a 4 parameter logistics fit, and the concentrations of the samples 
were subsequently calculated from the standard curve.
PCR Amplification o f target DNA in the 3 ’ UTR o f the Clock gene
Amplification of the target DNA containing the rs 1801260 polymorphic site was 
performed using PCR (BioRad, UK) with the following primers:
Clock forward: 5 ’ -CCAGCAGTTTCATGAGATGC-3 ’ and 
Clock reverse: 5’-GAGGTCATTTCATAGCTGAGC-3 ’ (Katzenberg et al., 1998, 
Kissling et al., 2008). The reaction was performed in a final volume of 25pi 
consisting of the target DNA present in the buccal cell samples, and a reaction mix of 
dNTPs (Applied Biosystems, UK), 2.5mM MgC^ and components supplied within 
the HotStarTaq DNA polymerase kit (Qiagen, UK). The following PCR protocol was 
used: 10 min at 95°C, then 35 cycles of 30 s at 94°C, 30 s at 58°C and 30 s at 72°C, 
followed by 2 min at 72°C. All PCR reactions included water blank samples as a 
negative control for DNA contamination. The amplicon (221 bp) was visualized on a 
2% agarose gel stained with SYBRsafe (Invitrogen, UK), following separation at 
1 0 0 V in tris-borate electrophoresis buffer.
Restriction Digest
lOpl of the PCR product was digested in a final volume of 20pl with Bspl286I (New 
England Biolabs, UK) and reaction buffers at 37°C overnight. The resulting digested 
samples (unrestricted TT genotype = 221 bp, complete restriction CC genotype = 
125 and 96 bp, partial restriction TC genotype = 221, 125 and 96bp fragments) were 
visualized using electrophoresis as previously described and scored for genotypes. 
All RFLP assays were run with a positive control (CC genotype), that was amplified 
by PCR and subsequently the amplicon underwent total restriction upon incubation 
with the Bsp12861 restriction endonuclease (New England Biolabs, UK) as described 
above.
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Data analysis
Clock gene and hormone data is presented as standardised Z-scores, to allow for the 
direct inter-variable comparison of amplitudes between genes and hormones 
measured in different units (Archer et al, 2008). Z-scores were calculated for each 
participants set of time-course samples. This calculation can be described as the 
subtraction of the average data across the time-points from each individual time-
point value, divided by the standard deviation. The hormone data was Z-scored from
the raw data, the clock gene data was Z-scored from GAPDH-noimalised data.
Further description of changes in the rhythm of the time-course data (clock gene 
expression and hormone rhythms) were carried out by measuring the area under the 
curve. This is a well documented method of estimating ultradian/circadian changes in 
time-course data (Pruessner et al., 2003). Two methods of calculating the area have 
been devised and were used: the area under the curve with respect to ground (0 , 
AUCq) and the area under the curve with respect to increase (the lowest data point, 
AUCi), both of which have been derived from the trapezoid formula (Pruessner et al., 
2003). These formulas are summarized as:
AWir, V* 1) + mt) ' ri
a u c g = 2 - ---------- ^-----------
(—1
n — I
AUCi — AUCq — ^  tj
j-1
Where m is measurement, t is the time-interval between two consecutive data points 
and i is the individual data point and n is the total amount of measures (Pruessner et 
al., 2003).
Statistical Analysis
The statistical software SPSS (IBM Corporation, USA) installed on a PC was used to 
carry out group-wise comparisons of actigraphic, sleep and light parameters and 
A UC measurements by Mann-Whitney U tests, as the majority of the data did not 
conform to the normal distribution. Correlations between the DSM ADHD index
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score and chronometric parameters was by Pearson’s product moment correlation, 
one-tailed to test the hypothesis that increasing clinical scores would be correlated 
with decreasing robustness of rhythmic parameters. Allele frequencies of the 
rs 1801260 polymorphism were tested for Hardy Weinberg equilibrium and 
differences between groups using the Chi Square test. Clock gene expression and 
hormone data was fitted by the method of single co-sinor analysis to determine 
whether significant circadian rhythms were present, by means of the Chronolab 
software (Mojon et al., 1992). This involved fitting a curve with a 24 period to the 
observed data by the least squares method, with the fit deemed significant if the 95% 
confidence interval for the fitted amplitude did not include zero. f(t1)=M+Acos(ot1 
+(j))+Si was the formula for curve fitting, where f(h) was the expression of the factor 
of interest across time for individual i, M was the MESOR, the time series mean 
around which expression oscillates, A was the amplitude of the rhythms, co was the 
period of the fitted rhythm and was the acrophase of the rhythm and £i was the error 
term. The regression fitting also produced an r-squared statistic, which was then used 
to compute the percentage of variance in an individuals time-series data that was 
accounted for by the fitted 24hour curve. For between group comparisons of 
chronometrics derived by this method we used the Bingham test (Bingham et al., 
1982), which compared the amplitude, MESOR, acrophase, and amplitude/acrophase 
pair between groups, with p<0.05 considered significant. Z-scored data was 
examined, although the data was also analysed by the above methods prior to Z- 
scoring, with no meaningful differences observed between the two methods.
I l l
3.3. Results
3.3.1 Actigraphy and Diurnal Preference
Non-parametric analysis of the actigraphic circadian rhythms revealed no significant 
difference in the interdaily stability (IS) and intradaily variability (IV) between the 
control and ADHD groups (table 3.2). Both the amount of activity in the least active 
five hours of the 24 h cycle, L5, and the amount of activity in the most active ten 
hour period, M10, were increased in the ADHD cohort, therefore resulting in an 
increase in the rhythm amplitude in the ADHD group (table 3.2, figures 3.1 and 3.2). 
There were however, no between groups differences in the relative amplitudes 
(normalised difference between M10 and L5), the time of M10 and L5 onset (MlOo 
and L5o respectively) or the acrophase of the actigraphic rhythm. Analysis of the 
period of best fit showed that the ADHD group display significantly shorter period 
than the controls, as demonstrated by both direct estimation of the period (PO.Ol, 
table 3.2, figure 3.3) and by deviation of the period from 24h (0.17h for controls vs. 
0.40h for ADHD, PO.05, table 3.2). Non-parametric analysis of the sleep parameters 
measured by actigraphy revealed a significant difference in the actual sleep time and 
sleep efficiency between the control and ADHD groups (PO.05 for both, table 3.3). 
The ADHD group exhibited a shorter duration of sleep (06:08 ± 01:22) in 
comparison to the control group (07:11 ± 00:40), and reduced sleep efficiency 
(79.7% for controls vs. 72.14% for ADHD group), although there were no significant 
differences between the two groups in the other sleep parameters measured and the 
objectively assessed wake-times (table 3.2).
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Control ADHD Control Vs. 
ADHD
IS 0.579 ± 0.03 0.546 ± 0.03 n.s.
IV 0.785 ± 0.05 0.707 ± 0.05 n.s.
M10 19620 ± 1156 25302 ± 1430 P 0 .0 0 1
MlOo (h) 9.52 ± 0.32 10.80 ± 1.01 n.s.
L5 841 ± 98 1647 ± 295 P 0 .0 0 1
L5o(h) 2.2 ±1.1 4.45 ± 1.6 n.s.
Amplitude 18785 ± 1156 23696± 1273 PO.Ol
Relative amplitude 0.904 ±0.015 0.879 ±0.015 n.s.
Period (h) 23.95 ± 0.07 23.76 ±0.14 PO.Ol
Period deviation (h) 0.17 ± 0.15 0.40 ± 0.29 PO .05
Acrophase (h) 14.62 ±0 .29 14.83 ± 0.66 n.s.
Wake (h) 7.96 ± 0.27 8.61 ± 0.47 n.s.
HO MEQ Score 52.6 ± 1.4 41.5 ±2.1 P 0 .0 0 5
Table 3.2. Chronometrics of the actigraphic circadian rhythm, and the Home- 
Ostberg momingness/eveningness (HO MEQ) score. IS = Interdaily stability; IV = 
intradaily variability; M10 = activity counts in the 10 most active hours; MlOo = 
time of onset of the ten most active hours; L5 = activity counts in the five least active 
hours; L5o = time of onset of the least active five hours; Amp = amplitude of the 
rhythm in activity counts; Rel. Amp. = Relative amplitude of the circadian rhythm; 
Period = period of best fit; Aero. = Acrophase (peak phase of rhythm); Wake = 
actigraphically determined wake time. n.s. = not significant. Between group 
differences of actigraphic parameters were assessed by non-parametric Mann- 
Whitney U tests (Control Vs ADHD) and this revealed significant between group 
differences in M10, L5, amplitude, period, period deviation and HO MEQ score.
113
Control A Control B
00 00 00 00 □R 00 12 0 000 00 06 00 12 0 0 18 00
, . iEj , , <iiMiiiii i,
. l.Jutiikt ^  Jl;1i - 1..Day 2 Day 2
Day 4
Day 5
Day 6 Day 6
Patient A Patient B
00:00 06 00 12:00 18 00
DO 00
111 li' >iHMLl I i .. . . . i -  i l K i > i lM lU l i l* tk , .  1
. . . . . .  „
iiuji un.iDay 3
Day 4
Day 1
■ _____ J ■ t d h l l  l l j l w i l  II
Day 2
,—J l. i i . j l  .U . . .  . . i . i iL .Jk
Day 3
.  1 - i r l  , ,  . . . . j  jWMuUftriadU. .^ .k .. j j
Day 4
•o ^-ujL  .  |____ . .. . . n l
Day 5
. .  . . . . . . . . . . i l a a  JL iL JltiU iiJhL . n ■
Day 6
.4. .  ........ ................... lk .L lilU ,.4. 4 l.
Figure 3.1. Example actograms of the daily activity levels measured by the 
actiwatch. Patient A exhibits a bimodal activity rhythm over the 24 hour period, 
whereas patient B exhibits a 4-6 hour delay in the phase o f the activity rhythm 
compared to the controls subjects A and B. Both patients exhibit increased activity 
during the hours o f least activity o f the control subjects (12am-6am). (Activity = 
black, light illumination = yellow).
Control A Control B
__
Patient BPatient A
I
Figure 3.2. Example o f average daily activity profiles as measured by the actiwatch. 
(Activity = black, light illumination = yellow).
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Control A
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Figure 3.3. Example periodograms o f the average period length o f the activity 
rhythm as measured by the actiwatch. Note that the average period length (peak 
correlation) is greater in the control group than the ADHD group.
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Control ADHD Control Vs. 
ADHD
Bedtime (h) 23:14 ±00.55 00:34 ±02:19 n.s
Get up time (h) 07:40 ± 00:56 07:50 ±02:01 n.s
Time in bed (h) 08:58 ± 00:39 08:27 ±01:13 n.s
Sleep start (h) 23:43 ±00:55 01:25 ±02:29 n.s
Sleep end (h) 07:53 ± 00:53 07:40 ±01:59 n.s
Assumed sleep time (h) 08:15 ±00:40 07:26 ±01:21 n.s
Actual sleep time (h) 07:11 ±00:40 06:08 ±01:22 P<0.05
Actual sleep % (%) 87.13 ±4.21 82.34 ± 8.83 n.s
Actual wake time (h) 01:04 ± 00:22 01:16 ±00:35 n.s
Actual wake % (%) 12.87 ±4.21 17.66 ± 8.83 n.s
Wake bouts (#) 40.40 ± 9.05 44.93 ± 13.20 n.s
Sleep bout duration (min) 14:39 ± 16:00 09:11 ±03:16 n.s
Wake bout duration (min) 01:38 ±00:30 01:41 ±00:34 n.s
Sleep efficiency (%) 79.7 ± 7.42 72.14 ±10.92 P<0.05
Sleep latency (h) 00:27 ±00:18 00:34 ± 00:20 n.s
Table 3.3. Summary of the actigraphically assessed sleep parameters (means and 
standard deviations). Time in bed = difference between bed time and get up time; 
Assumed sleep time = difference between sleep start and sleep end, Actual sleep time 
= assumed sleep minus periods of wakefulness during the night; Actual sleep % = 
percentage of sleep in the duration between sleep start and sleep end. Actual wake 
time = hours of wakefulness during assumed sleep time; Actual wake % = 
percentage of wakefulness during assumed sleep time; Wake bouts (number of) = 
number of times participant wakes during sleep; Sleep bout duration = average 
length of uninterrupted sleep between two consecutive awakenings; Wake bout 
duration = mean duration of periods of wakefulness; Sleep efficiency = percentage of 
sleep between bed time and sleep end; Sleep latency = the time it takes from bed 
time to sleep start. Non-parametric Mann-Whitney U tests revealed significant 
between group differences in actual sleep time and sleep efficiency, n.s. = not 
significant.
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Levels of light exposure were also examined and whilst there was no overall 
difference in the average illumination across a 24 hour period, a significant increase 
in the average illumination in the six hours between midnight and 6 am in ADHD 
subjects compared with controls was observed, which is in accordance with the 
increase in L5 observed in ADHD (table 3.4).
Group
24 Hours 12am - 6am
Average 
illumination  
mean ± SD
Maximum  
illumination 
mean ± SD
Time above 
100 lu x / 
minutes, mean 
±  SD
Average 
illumination  
mean ±  SD
Maximum  
illuminationm  
ean ±  SD
Time above 
100 lux / 
minutes, mean 
± SD
ADHD 251.2 ±274 .9
12626.0 ±  
9949.9 256.5 ± 125.6 12.1 ± 3 1 .4 325.1 ± 685 .9 7.9 ± 21 .8
Controls 301.6 ±418 .8
11556.0 ± 
7764.7 294.5 ± 160.6 1.2 ± 1.7 96.8 ± 159.4 0.8 ± 1.2
Control 
Vs. ADHD n.s. n.s. n.s. P<0.05 n.s. n.s.
Table 3.4. Light exposure (lux) as measured by the actiwatches worn by study 
participants. Average nocturnal light exposure was significantly greater in the ADHD 
group, P<0.05. n.s. = not significant.
Analysis of the Home-Ostberg (HO) momingness/eveningness questionnaire data 
showed that the ADHD subjects scored significantly lower than the controls, 
indicating a shift to eveningness in ADHD (table 3.5). Further, when subjects were 
assigned a chronotype according to their HO scores (morning types scoring 59-86, 
intermediate 42-58 and evening types less than 42), chi-squared analysis revealed a 
significant difference (p<0.05) between the control and ADHD groups, with 50% of 
the ADHD being classified as evening oriented, compared to 13% for the controls 
(table 3.5). Moreover there were significant inverse correlations between the DSM 
index ADHD scores and the HO score and the actigraphic period (r=-0.619 and - 
0.534 respectively, both P<0.005, figure 3.4A-B). There were also significant 
correlations between the DSM index ADHD scores and the actigraphic period 
deviation and the wake-time according to the actigraphic data (r=0.570 P<0.005, 
r=0.372 P<0.05 respectively, figure 3.4C-D).
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C h r o n o ty p e C o n tr o l A D H D
M o r n in g 8 (26% ) 2 (14% )
In te r m e d ia te 19 (61% ) 5 (36% )
E v e n in g 4  (13% ) 7 (50% )
7 .1 8 9
p < 0 .0 5
Table 3.5. Chronotype assigned according to the Home-Ostberg 
momingness/eveningness questionnaire. Chi-square analysis revealed a significant 
difference in chronotype between the groups.
A number of significant correlations between the DSM index ADHD score and 
actigraphically assessed sleep parameters were observed including get up time 
(r=0.512, PO.Ol), sleep end (r=0.465, PO.Ol) and percentage wake time (r=0.352, 
P<0.05) (figures 3.4E, 3.4H and 3.4K respectively). Inverse correlations were 
demonstrated between the DSM index ADHD score and bed time (r=-0.443, 
PO.Ol), sleep start (r=-0.339, PO.05), actual sleep duration (r=-0.365, PO.05), 
percentage sleep duration (r=-0.352, PO.05) and sleep efficiency (r=-0.379, PO.05) 
(figures 3.4F- G, 3.4J-M respectively).
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Figure 3.4. Significant correlations between the DSM index ADHD score and 
activity and sleep parameters. HO MEQ score = Home-Ostberg 
momingness/eveningness score; Wake time = actigraphically determined wake time; 
Period = duration o f 1 full cycle o f the rest-activity rhythm; Period deviation = 
difference in period length from 24 hours; Actual sleep duration = assumed sleep 
minus periods o f wakefulness during the night; Actual sleep duration % = percentage
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of sleep between sleep start and sleep end; Actual wake duration % = percentage of 
wakefulness during assumed sleep time; Sleep efficiency = percentage of sleep 
between bed time and sleep end. Increasing DSM index ADHD score is indicative of 
increasing ADHD symptom severity.
3.3.2 Clock gene and hormone rhythms
BMAL1 exhibited rhythmic expression in the oral mucosa in the control group, as 
judged by co-sinor analysis, with the peak of the rhythm present ~13 hours after 
waking (figure 3.5A and 3.5D, table 3.6). This rhythmicity was lost in the ADHD 
group, which did not display significant circadian fluctuation in BMAL1 expression 
levels (figure 3.5B and 3.5D, table 3.6). The two groups were compared by means of 
the Bingham test, and the amplitude and amplitude/acrophase relationship was found 
to be significantly different between the control and ADHD groups (PO.Ol for 
amplitude, PO.05 for amplitude/acrophase) although there was no difference for 
MESOR, acrophase (figure 3.5C and 3.5D, table 3.6) or the area under the curve of 
the BMAL1 expression profile (figure 3.5E and D).
BMAL1 PER2 Melatonin Cortisol
Control ADHD Control ADHD Control ADHD Control ADHD
Percentage 
Rhythm (%)
56.8 33.9 63 53 63 53 60 50
P 0.002 0.617 <0.001 0.11 <0.001 0.11 <0.001 0.003
M esor
(a.u)
-0.03
±0.0
-0.03
±0.03
0.06 ± 0.4 -0.01
±0.2
0.06 ± 0.4 -0.01
±0.2
0.01
±0.03
0.03
±0.04
Amplitude (a.u) 0.61 0.10 0.62 0.25 0.62 0.25 0.87 0.65
C.I. Amplitude 
(a.u)
0.3, 0.9 0,0 0.4, 4.5 0 ,0 0.4, 4.5 0 ,0 0.7, 1.0 0.3, 1.0
Acrophase (h) 13.26 12.88 18.9 19 18.9 19 1.37 3.37
C.I. Acrophase 
(a.u)
11.5,
15.0
0,0 17.5,21.3 0,0 17.5,21.3 0,0 0.73, 2.0 1.53,
5.27
Table 3.6. Chronometrics of the BMAL1, PER2, melatonin and cortisol rhythms, as 
assessed by co-sinor analysis. The profiles of BMAL1 and PER2 expression and 
melatonin and cortisol secretion of the control group were significantly rhythmic. 
The profile of cortisol secretion of the ADHD group was significantly rhythmic also. 
a.u. = arbitrary units.
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Figure 3.5. Analysis o f the rhythmic expression o f BMAL1. (A) Chronogram of the 
BMAL1 profile o f the control group. (B) Chronogram o f the BMAL1 profile o f the 
ADHD group. Fitted dark line = co-sine wave o f best fit with a 24 hour period. 
Horizontal line = MESOR. (C) Polargram o f the phase/amplitude relationship for 
BMAL1 expression for the control (black ellipse) and ADHD (hatched ellipse) 
groups. Length o f the dotted white vector indicates amplitude o f circadian rhythm 
and the orientation o f this vector represents the acrophase for the control group. 95% 
confidence interval for the combined amplitude and acrophase are represented by 
elliptical areas around the vector tips, indicated by lightly dashed line. The error 
ellipse for the ADHD group covers the zero point o f amplitude, indicating a non­
significant circadian fit for the observed data, whilst the error ellipse o f the control 
group does not overlap the zero point, indicating a significant co-sinor fit for the data 
on a 24h timebase. (D) Chronometrics o f the BMAL1 expression profile for both 
groups. % rhythm = variance in the population data that is explained by regression 
with the 24h co-sine wave o f best fit. AM P=amplitude o f the rhythm, Cl AMP = 
95% confidence interval for the amplitude, Aero. = time of the peak o f the rhythm, 
Cl Aero. = 95% confidence interval for the amplitude. * = Significant group-wise 
difference assessed by the Bingham test (P<0.05). Area under the curve o f the 
BMAL1 profile calculated using the AUCg method (E) and the AUCi method (F).
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Expression of the clock gene PER2 was also analysed in the same samples. 
Rhythmic circadian expression o f PER2 was again demonstrated by the control 
group, with a peak o f the rhythm occurring ~12hours after waking (Figure 3.6A and 
3.6D, table 3.6). The ADHD group did not display a significant circadian rhythm in 
PER2 expression (P=0.83 for the 24h co-sine fit; figure 3.6B and 3.6D, table 3.6), 
although the Bingham test for between groups comparisons o f the chronometrics did 
not reveal any significant differences (figure 3.6C and 3.6D, table 3.6), and there was 
no significant between group differences in the area under the curve measured by 
both the AUC g and AUCj methods (Figures 3.6E and F).
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Figure 3.6. Analysis o f the rhythmic expression o f PER2. (A) Chronogram o f the 
PER2 profile o f the control group and (B) chronogram o f the PER2 profile o f the 
ADHD group. The fitted dark line represents the co-sine wave o f best fit with a 24 
hour period. The horizontal line represents the MESOR. (C) Polargram o f the 
phase/amplitude relationship for PER2 expression o f the control (black ellipse) and 
ADHD (hatched ellipse) groups. Length o f the dotted white vector indicates 
amplitude o f circadian rhythm and the orientation o f this vector represents the 
acrophase for the control group. Note that the error ellipse for the ADHD group 
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observed data. (D) Table summarising the chronometrics o f the rhythmic expression 
of PER2. Abbreviations are as described in figure 3.5. Average area under the curve 
of the PER2 profile calculated using the AUCg method (E) and the AUCj method 
(F).
As expected, melatonin was strongly rhythmic in the control group, with a peak of 
secretion occurring 19 hours after waking (approximately 3am; figure 3.7A and D, 
table 3.6). The ADHD group displayed a rhythm that appeared to be broadly similar, 
with a peak in secretion in the early morning, but with dampened amplitude, and thus 
the rhythm was not deemed significant by co-sinor analysis (figure 3.7 B and D, 
table 3.6). However, between groups comparisons by the Bingham test did not reveal 
significant differences in any o f the parameters (figure 3.7C, table 3.6) and there was 
no significant between group differences in the area under the curve measured by 
both the AUCg and AUCj methods (figures 3.7E and F).
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Figure 3.7. Analysis o f the rhythmic salivary melatonin profile. (A) Chronogram of 
the melatonin profile o f the control group and (B) chronogram o f the melatonin 
profile o f the ADHD group. The fitted dark line represents the co-sine wave o f best 
fit with a 24 hour period. The horizontal line represents the MESOR. (C) Polargram
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of the phase/amplitude relationship for melatonin in controls (black ellipse) and 
ADHD subjects (hatched ellipse). Length of the dotted white vector indicates 
amplitude of circadian rhythm and the orientation of this vector represents the 
acrophase for the control group. Note that the error ellipse for the ADHD group 
covers the zero point of amplitude, indicating a non-significant circadian fit for the 
observed data. (D) Table summarising the chronometrics of the melatonin profile for 
both groups. Abbreviations are as for figure 3.5. Average area under the curve of the 
melatonin profile calculated using the AUCg method (E) and iheAUCi method (F).
When salivary cortisol was examined, again as expected the control group showed a 
robust circadian rhythm with a peak in expression approximately 1 hour after waking 
(figure 3.8A, table 3.6). The ADHD group also exhibited rhythmic salivary cortisol, 
although in this group the peak of secretion was phase-delayed relative to wake time 
and occurred ~ 3hours after waking (figures 3.8B-D, table 3.6). This difference in 
acrophase was found to be significant by the Bingham test, as was the 
amplitude/acrophase relationship (P<0.05 for both; figure 3.8C, table 3.6) and the 
area under the curve of the cortisol profile, which was significantly elevated in 
ADHD (P<0.05 when measured using both the AUCg and AUCj methods, figures 
3.8E-F). It therefore appeared that the rhythm in salivary cortisol was present in the 
ADHD group, although it was significantly phase-delayed, and cortisol levels were 
increased.
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Figure 3.8. Analysis o f the rhythmic salivary cortisol profile. (A) Chronogram o f the 
cortisol profile o f the control group and (B) chronogram o f the cortisol profile o f the 
ADHD group. The fitted dark line represents the co-sine wave o f best fit with a 24 
hour period. The horizontal line represents the MESOR. (C) Polargram o f the 
phase/amplitude relationship for cortisol in controls (black ellipse) and ADHD 
subjects (hatched ellipse). Length o f the dotted white vector indicates amplitude o f 
circadian rhythm and the orientation o f this vector represents the acrophase for the 
control group, whilst the black dotted vector represent that for the ADHD group. 
The rhythms in both groups were significant, but note the phase-delay o f the cortisol 
profile in ADHD subjects compared to controls. (D) Table summarising the 
chronometrics o f the salivary cortisol profile for both groups. Abbreviations are as 
for figure 3.5. *= Significant group-wise difference assessed by the Bingham test 
(P<0.05). Average area under the curve o f the cortisol profile calculated using the 
AUCg method (E) and using the A UCj method (F).
Correlations were examined between the DSM-IV-index ADHD score for each 
subject with a number o f chronometrics from the individual profiles for BMAL1, 
PER2, melatonin and cortisol (the amplitude o f the individual rhythms, the 
percentage o f variance explained by the fitted 24h co-sine wave and the acrophase).
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The hypothesis was that increasing DSM-IV ADHD scores would be correlated with 
weakening o f rhythmic measures (percentage rhythm and amplitude). By this method 
a significant inverse correlation was uncovered between DSM-IV ADHD score and 
BMAL1 amplitude (r=-0.331, P<0.05, figure 3.9A) BMAL1 percentage rhythm (r= - 
0.344, P O .05 , figure 3.9B), PER2 amplitude (r=-0.314, PO .05 , figure 3.9C) and the 
percentage o f variance explained by the 24h co-sine wave for cortisol (r=-0.444, 
P O .O l, figure 3.9D). No significant correlations were uncovered between the DSM- 
index ADHD score and the chronometrics o f the melatonin profile.
A B C
30 40 50 60 70 80 90 30 40 50 60 70 30 90 30 40 50 60 70 80 90
DSM Index ADHD S co re  DSM Index ADHD Score DSM Index ADHD S co re
D
io w r = -0 444
|  80- .
% ' '  / *
K 6 0 ' . * •
3* .
8  40 ' * . .
t . ~
5  20-
01
30 40 50 60 70 80 90 
DSM Index ADHD Score
Figure 3.9. Significant correlations between the DSM index ADHD score and the 
chronometrics o f the BMAL1, PER2 and cortisol profiles. Increasing ADHD score is 
indicative o f increasing ADHD symptom severity.
Correlations between the actigraphic measures and the chronometrics o f the BMAL1, 
PER2, melatonin and cortisol profiles were also examined. Inverse correlations 
between BMAL1 amplitude and both M10 (r=-0.371, P O .05 , figure 3.10A) and 
MlOo were observed (r=-0.383, P O .05 , figure 3.10B). BMAL1 acrophase correlated 
with the period (r=0.402, P<0.05, figure 3 .10C) and relative amplitude o f the 
actigraphic rhythm (r=0.492, P O .O l, figure 3.10D). Whereas there was an inverse 
relationship o f BMAL1 acrophase with MlOo (r=-0.515, P O .O l, figure 3.10E) with
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L5 (r=-0.527, PO.Ol, figure 3.10F) and with actigraphic period deviation (r=-0.417, 
PO.05, figure 3.10G). A significant correlation between the actigraphic period and 
% PER2 rhythm (r=0.489, PO.Ol, figure 3.10H) and PER2 amplitude (r=0.535, 
PO.Ol, figure 3.10J), and an inverse correlation between the actigraphic period 
deviation and % PER2 rhythm (r=-0.451, PO.Ol, figure 3.1 OK) and PER2 amplitude 
(r=-0.490, PO.Ol, figure 3.10L) were demonstrated.
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Figure 3.10. Significant correlations between the parameters o f the behavioural and 
the molecular rhythms. M10 = activity counts in the 10 most active hours; MlOo = 
time of onset o f the 10 most active hours; L5 = activity counts in the 5 least active 
hours; Period = duration o f 1 full cycle o f the rest-activity rhythm; Period deviation = 
difference in period length from 24 hours; Relative amplitude = difference between 
L5 and M10; (Black filled squares = control, clear circles = ADHD).
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A significant inverse relationship of cortisol % rhythm with actigraphic period 
deviation (r=-0.408, PO.05, figure 3.11 A) and with actigraphic acrophase (r=-0.440, 
PO.Ol, figure 3.1 IB) was observed. There was a significant correlation of cortisol 
acrophase with a number of actigraphic measures including with L5 (r=0.507, 
PO.Ol, figure 3.11C), L5o (r=0.427, PO.05, figure 3.1 ID), M10 (r=0.498, PO.Ol, 
figure 3.1 IE), MlOo (r=0.545, PO.Ol, figure 3.1 IF) and amplitude (i=0.460, 
PO.05, figure 3.11G). There was also an inverse correlation of cortisol acrophase 
with the acrophase of the actigraphic rhythm (r=-0.389, PO.05, figure 3.11H).
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Figure 3.11. Significant correlations between the actigraphic circadian rhythm 
measures and the chronometrics of the salivary cortisol rhythm. M10 = activity 
counts in the 10 most active hours; MlOo = time of onset of the ten most active 
hours; L5 = activity counts in the five least active hours; L5o = time of onset of the 
least active five hours; Amplitude = peak amount of activity; Acrophase = peak 
phase of rhythm; Period deviation = difference in period length from 24 hours (Black 
filled squares = control, clear circles = ADHD).
A number of significant correlations were demonstrated between the actigraphically 
assessed sleep parameters and the chronometrics of the BMAL1, PERI, melatonin 
and cortisol profiles. BMAL1 acrophase significantly correlated with sleep bout 
duration (r=431, P<0.05, figure 3.12A) and with actual % sleep (r=413, P<0.05, 
figure 3.12B). Then in turn, a significant inverse correlation between BMAL1
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acrophase and actual % wake (r=-0.413, P<0.05, figure 3.12C) was observed. There 
were significant correlations between sleep bout duration and both PER2 % rhythm 
(r=0.428, P<0.05, figure 3.12D) and PER2 amplitude (r=0.451, P<0.05, figure 
3.12E). An inverse correlation between get up time and PER2 amplitude (r=-0.367, 
P<0.05, figure 3.12F) was demonstrated.
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Figure 3.12. Significant correlations between the actigraphically assessed sleep 
parameters and the chronometrics o f circadian clock gene expression. Sleep bout 
duration = average length o f uninterrupted sleep between two consecutive 
awakenings; Actual time asleep % = percentage o f sleep between sleep start and 
sleep end; Actual time awake % = percentage o f wakefulness during assumed sleep 
time (Black filled squares = control, clear circles = ADHD).
Melatonin % rhythm significantly correlated with the time spent in bed (r=0.384, 
P<0.05, figure 3.13A) and with assumed sleep duration (r=0.394, P<0.05, figure 
3.13B). The amplitude of the melatonin rhythm also significantly correlated with 
both assumed sleep and actual sleep (r=0.417, P<0.05 and r=0.441, P<0.01 
respectively, figures 3.13C and 3.13D). There was a significant correlation o f 
melatonin acrophase with actual sleep (r=0.362, P<0.05, figure 3.13E) and with 
actual % sleep (r=0.404, P<0.05, figure 3.13F) and a significant inverse relationship
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between actual % wake duration and melatonin acrophase (r=-0.404, P<0.05, figure 
3.13G).
100- r = 0.384
.E 80-
60
£ 40
£ 20
4 6 8 10 12
1 50- r =  0 .4 1 7r = 0 394
Q . =  1 .0 0 -
”  ^ 0 . 7 5
o  j a  0 . 5 0
®  2 0
0 00
T i m e  s p e n t  in  b e d  (h )
A s s u m e d  s l e e p  d u r a t i o n  
(h)
r = 0.441 r = 0.362
A c t u a l  s l e e p  d u r a t i o n  
( h )
0 2 4 6 8 10
A c tu a l  s l e e p  d u r a t i o n  (h )
A s s u m e d  s l e e p  
d u r a t i o n  ( h )
24
r = 0.404
I8­
60 70 80 90 100
A c tu a l  s l e e p  d u r a t i o n  (% )
24-
r = -0.347
18-1
0 20 30 4010
A c tu a l  w a k e  d u r a t i o n  (% )
Figure 3.13. Significant correlations between sleep parameters and chronometrics of 
the salivary melatonin rhythm. Time spent in bed = difference between get up time 
and bed time; Assumed sleep duration = difference between sleep end and sleep start, 
Actual sleep duration = assumed sleep minus periods o f wakefulness during the 
night; Actual sleep duration % = percentage o f  sleep between sleep start and sleep 
end; Actual wake duration % = percentage o f wakefulness during assumed sleep time 
(Black filled squares = control, clear circles = ADHD).
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Cortisol % rhythm significantly correlated with bed time (r=0.419, P<0.05, figure 
3.14A), and an inverse correlation of time of sleep end with cortisol % rhythm was 
observed (r=-0.394, P<0.05, figure 3.14B). Significant inverse correlations between 
cortisol acrophase and assumed sleep (r=-0.456, PO.Ol, figure 3.14C) actual sleep 
(r=-0.404, PO.05, figure 3.14D) and time spent in bed (r=-0.543, PO.Ol, figure 
3.14E) were also demonstrated. A significant correlation was shown between get up 
time and the area under the cortisol curve, AUCg, (r=0.339, PO.05, figure 3.14F), 
whereas time of sleep start was inversely correlated with both cortisol AUCg (r=- 
0.446, PO.Ol, figure 3.14G) and cortisol AUCj (r=-0.589, PO.Ol, figure 3.14H). 
Cortisol AUCi was also inversely correlated with actual sleep (r=-0.412, PO.05, 
figure 3.14J). There was an inverse relationship between cortisol AUCi and sleep 
efficiency (r=-0.468, PO.Ol, figure 3.14K).
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Figure 3.14. Significant correlations between the actigraphically assessed sleep 
parameters and the chronometrics o f the salivary cortisol rhythm. Time spent in bed 
= difference between get up time and bed time; Assumed sleep duration = difference 
between sleep end and sleep start, Actual sleep duration = assumed sleep minus 
periods o f wakefulness during the night; Cortisol AUCg = area under the curve o f the 
cortisol profile calculated with respect to ground; Cortisol AUCj = area under the
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curve of the cortisol profile calculated with respect to increase (Black filled squares = 
control, clear circles = ADHD).
3.3.3 rs1801260polymorphism in CLOCK
Chi-square analysis revealed that there were no significant genotype differences of 
the rs 1801260 polymorphism between groups (table 3.7). However, when the 
relationship between genotype and the chronometrics of the circadian rhythms were 
examined by ANOVA, there was a significant main effect of genotype upon BMAL1 
amplitude (df=2, F=4.620, P<0.05), cortisol amplitude (df=2, F=5.994, PO.Ol) and 
% rhythm of cortisol (df=2, ^=3.481, PO.05).
C ontrol A D H D
TT 12 (63.5%) 4 (30.8%)
TC 7(36.8% ) 8(61.5% )
CC 0 (0 ) 1 (7.7%)
T allele 31 (81.6%) 16(61 .5)
C allele 7(18.4% ) 10 (38.5)
%2 3.18
P 0.07
Table 3.7. Genotype and allele frequencies (%) of the CLOCK rs l801260 
polymorphism of the adult ADHD patient and control groups. Chi-squared analysis 
revealed no significant difference in genotype frequencies between the groups.
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3.4 Discussion
The main findings of this study demonstrate fundamental changes in a number of 
circadian parameters of behavioural, endocrine and molecular rhythms in adult 
ADHD.
3.4.1 Actigraphy & diurnal preference
Actigraphic analysis demonstrated significantly greater levels of activity during the 5 
least active hours and the 10 most active hours were associated with adult ADHD, 
and significantly increased amplitude of the activity rhythm was associated with 
adult ADHD. These measures therefore demonstrate hyperactivity of the ADHD 
patients across the circadian cycle. Boonstra et al (2007) reported increases in M10 
in adult ADHD, but not in L5, although the same study does indicate diminished 
bouts of prolonged nocturnal sleep in ADHD, and that methylphenidate treatment did 
not alter either L5 or M10, but did alter the onset of L5. Conversely, it has been 
reported in childhood ADHD that methylphenidate treatment was associated with an 
increase in nocturnal activity (Ironside et al., 2010). Boonstra et al (2007) did not 
observe significant differences in adult ADHD in IS, IV or RA, similar to the present 
results. However in a further study, Van Veen et al., (2010), reported that IV, but not 
IS, was altered in adult ADHD, and that when adults with ADHD were subdivided 
according to whether sleep-onset insomnia was present or not, there was a 
strengthening of the rhythm, as measured by IS, in those with ADHD, but without 
sleep-onset insomnia, compared to healthy controls. A significant deviation of the 
period of the activity rhythm away from 24 hours in the ADHD group was observed 
in the present study, although there was not a significant difference in the time of the 
acrophase. These results may indicate a measure of altered entrainment to external 
Zeitgebers in ADHD, which has also been proposed as an explanation for the 
significant phase-delay of the dim-light melatonin onset in adult ADHD (Van Veen 
et al., 2010). This is further supported by the shift towards eveningness associated 
with adult ADHD measured by the Home-Ostberg momingness/eveningness 
questionnaire, a finding that is in agreement with a previous study (Rybak et al., 
2007). A strong positive correlation was also observed between the DSM index 
ADHD score and the deviation of the period from 24 hours and an inverse
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relationship between the DSM-IV-ADHD score and the period length, therefore 
suggesting that the period of the activity rhythm would shorten with the severity of 
the disorder.
The average illumination during the hours of midnight to 6 am was significantly 
increased in the ADHD group in comparison to the control group, which is most 
probably due to the use of artificial lighting. Along with the observed increase in L5 
also associated with adult ADHD, this observation reflects increased activity during 
the normal hours of sleep. Furthermore, actigraphic analysis revealed that a reduction 
in both the duration of actual sleep and sleep efficiency were associated with adult 
ADHD. Previous studies have reported shorter bouts of uninterrupted sleep in adult 
ADHD (Boonstra et al., 2007, Van Veen et al., 2010), although in both studies actual 
sleep duration was unaltered in ADHD. The association of reduced sleep efficiency 
in adult ADHD reported in the present study is in agreement with previous findings 
by both actigraphy (Boonstra et al., 2007, Van Veen et al., 2010) and 
polysomnography studies (Sobanski et al., 2008).
The present findings of positive correlations of the DSM index ADHD score with get 
up time and with sleep end were in accordance with the shift to eveningness 
observed in the ADHD cohort of the present study. Sleep efficiency, percentage 
sleep and actual sleep duration were inversely correlated with the DSM index ADHD 
score, whilst time to go to bed, time of sleep start and percentage duration of time 
awake were positively correlated with the DSM index ADHD score, thus indicating 
that as the disorder becomes more severe the quality and quantity of sleep is reduced. 
This finding is supported by the observation that sleep problems are commonly 
reported in adult ADHD (Sobanski et al., 2008) and furthermore that some of the key 
symptoms of ADHD; for example inattention and restlessness, are also common 
symptoms of sleep deprivation (Corkum et al., 1998). However, it is worth sounding 
a note of caution in the interpretation of any actigraphic data, in that it assesses the 
gross rhythm in motor output, and does not delineate between endogenous circadian 
processes and environmental factors, and the interaction between these, and thus 
provides limited mechanistic insight.
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3.4.2 Clock gene rhythms
BMAL1 expression exhibited a significant rhythm in the oral mucosa of the healthy 
control subjects with significant alterations in ADHD including a reduction in 
amplitude and hence a loss of significant rhythmicity. PER2 expression was also 
significantly rhythmic in the control group, whilst rhythmicity was also lost in 
ADHD. Although it was observed that the average amplitude of PER2 expression 
was reduced in ADHD, this between group difference was not statistically 
significant, and there were no significant between group differences of the area under 
the curve of both the BMAL1 and PER2 expression profiles. Furthermore, the DSM- 
IV ADHD score inversely correlated with the amplitude and percentage rhythm of 
BMAL1 and with the amplitude of the PER2, indicating a relationship between the 
strength of clock gene rhythmic expression and clinical ADHD ratings. Thus, a role 
for dysfunction in the entrainment of the circadian clock in ADHD may be 
tentatively postulated, although it is prudent to sound a number of notes of caution. 
Firstly, one particular peripheral circadian clock has been examined (as sampling of 
the master SCN clock is obviously not possible in human studies outside of 
retrospective post-mortem analysis). So an explanation for the loss of rhythmicity in 
both BMAL1 and PER2 observed in the ADHD sample is that rhythmic regulation of 
these factors is dependent on melatonin, and as melatonin rhythmicity is lost in 
ADHD, this drives the loss of BMAL1/PER2 rhythmicity. Secondly, alteration in 
circadian processes in peripheral pacemakers as noted here may not necessarily 
reflect changes in central processes (the key regulators of behaviour) or hence reflect 
the functioning of the master pacemaker. Having said this, it is worth noting that the 
characteristics of molecular rhythms in skin fibroblasts (Brown et al., 2008) and in 
hair follicles (Akashi et al, 2010) do correlate with behavioural measures from the 
subjects from whom the samples were derived, as they do in our present study 
(correlations between clock gene chronometrics and actigraphic period).
3.4.3 Melatonin
A robust significant rhythm of melatonin in the healthy control group was 
demonstrated as expected, and a loss of significant rhythmicity in adult ADHD was 
shown. This loss of rhythmicity was probably due to the reduced amplitude of the
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melatonin rhythm, although peak melatonin levels occurred at approximately the 
same time as the control group. Previous studies have reported an association of 
altered phasing of the melatonin rhythm with both childhood ADHD (Van der 
Heijden et al, 2005) and adult ADHD (Van Veen et al 2010). In these cases an 
abnormal rhythm of melatonin secretion was associated with the disorder, where it 
was comorbid with chronic sleep onset insomnia, and a delayed sleep phase and 
delayed dim light melatonin onset was observed (Van der Heijden et al., 2005). As 
the dim-light melatonin onset was not examined in the current study, a direct 
comparison between the present findings and those noted above cannot be made. A 
simple explanation for the dampened amplitude of melatonin secretion in ADHD is 
therefore that since melatonin secretion is inhibited by light, an altered sleep wake 
rhythm involving more nocturnal activity, and thus increased exposure to light, could 
suppress the secretion of melatonin. This hypothesis was supported by the actigraphy 
data, which demonstrate that the ADHD group were exposed to a significantly 
greater amount of nocturnal light during the hours of 12am to 6am, than the control 
group. However melatonin also plays a role in determining the sleep wake cycle, 
with a characteristic rise in melatonin levels 2 hours in advance of the habitual 
bedtime thought to act as a “gating” mechanism for sleep onset (Macchi and Bruce, 
2004, Wiechmann and Summers, 2008). It can therefore be postulated that 
disturbance in its rhythm may contribute to the disturbance in sleep exhibited in adult 
ADHD. Furthermore, as melatonin is thought to have a strong entraining influence 
upon the master circadian pacemaker through its ability to directly feed back to the 
SCN (Reppert and Weaver, 2001, Pierce et al., 2008), a dampening of the melatonin 
rhythm could have downstream effects upon the entrainment of the peripheral 
oscillators by the master circadian pacemaker.
3.4.4 Cortisol
The current data illustrated a significant rhythm of cortisol secretion in both the 
control group and in adult ADHD. Increased levels of cortisol in ADHD were 
indicated by the significantly greater area under the curve of the cortisol profile in 
the ADHD group in comparison to the controls. However, the rhythm of cortisol was 
phase delayed by approximately 2 hours in ADHD, as demonstrated by the 
significant difference in acrophase and amplitude/acrophase measures between the
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two groups. Studies have examined the awakening cortisol response in different 
chronotypes, and have shown higher awakening rises in morning types compared to 
evening types (Kudielka et al., 2006, Randier and Schaal, 2010), suggesting that 
eveningness might be associated with a phase-delay of the cortisol rhythm. 
Furthermore, an association of reduced robustness of the cortisol rhythm with ADHD 
was demonstrated by the inverse correlation between DSM-IV-ADHD score and the 
percentage rhythm of cortisol.
As the rhythm in cortisol is known to be centrally driven via the SCN master clock, 
(Keller et al., 2006), the phase-delay observed in our study may further reflect a 
deficit in the entrainment of the master circadian clock in adult ADHD to appropriate 
environmental and social stimuli. It is also possible that further downstream effects 
of a delayed phase of the cortisol rhythm may arise from its proposed role in the 
entrainment of the peripheral oscillators (Van Someren and Riemersma-Van Der 
Lek, 2007) and this may play a key role in the entrainment of the peripheral 
oscillators then a delayed phase in its rhythm could contribute to the altered clock 
gene rhythmicity in the oral mucosa that is demonstrated here. Seemingly normal 
diurnal rhythms of cortisol secretion have previously been demonstrated in adult 
ADHD (Lackschewitz et al., 2008, Hirvikoski et al., 2009) but as these studies did 
not undertake chronometric analysis, these findings may simply reflect the 
preservation of the rhythmic cortisol levels in adult ADHD (as reported here) but 
would not be able to detect the alterations in the phasing of the rhythm that we 
report. As the rhythm in cortisol is known to be centrally driven via the SCN master 
clock, the phase-delay observed in this study may further reflect a deficit in the 
entrainment of the master circadian clock in adult ADHD to appropriate 
environmental and social stimuli, and could potentially affect sleep timing and 
duration, which in turn could contribute to the pathogenesis of ADHD.
The rhythms of BMAL1 and PER2 expression and salivary melatonin and cortisol 
were all assessed using samples that were collected at 4-hourly time-points, to be 
representative of the 24-hour profile. This approach was implemented since sampling 
at more frequent time-points could impact too greatly upon the individual’s sleep- 
wake schedule, hence causing possible perturbations to the circadian system as a 
consequence. Furthermore, to impose a more frequent sampling schedule would be
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problematic for participant recruitment as this would impinge too much upon the 
individual’s social and sleep-wake schedules. However, the temporal resolution of 
the data must be considered when interpreting the findings, since a greater frequency 
of sampling would provide a more precise estimation of the chronometrics of the 
circadian rhythms. Nevertheless, the 4-hour sampling protocol was adequate enough 
to provide data that was capable of demonstrating between-group differences in 
circadian rhythmicity.
3.4.5 Relationship between the behavioural and molecular rhythms
Given the observed correlations between various actigraphic and chronometric 
parameters with the DSM-IV ADHD score, further examination of the relationships 
between clock gene expression, endocrine profiles and actigraphic measures of 
circadian rhythms and sleep were carried out.
The relationship between the actigraphic measures of sleep and the rest-activity 
rhythm and the chronometrics of the molecular rhythms were examined by 
correlation analysis. The amplitude of BMAL1 expression was inversely correlated 
with amount of activity in the 10 most active hours (M10) and the time of M10 onset 
(MlOo), which was suggestive of a link between the loss of BMAL1 rhythmicity with 
both hyperactivity and a later phase of behaviour. The acrophase of the BMAL1 
rhythm exhibited a positive correlation with the actigraphic period, and an inverse 
relationship with period deviation, which could be interpreted such that a later peak 
of BMAL1 expression is linked with increased period length of the actigraphic 
rhythm. BMAL1 acrophase was also positively correlated with relative amplitude, 
and inversely correlated with MlOo and L5, thus being suggestive of a later BMAL1 
acrophase being linked to a more robust actigraphic rhythm, with reduced 
hyperactivity. Since ADHD was associated with both eveningness and a reduced 
actigraphic period as demonstrated in the present study, and hyperactivity is a core 
symptom of the disorder, this would suggest that an earlier phase of the rhythm of 
BMAL1 could be associated with the disorder. Furthermore, a relationship between 
the acrophase of BMAL1 rhythmicity and sleep quantity is illustrated by a positive 
correlation between BMAL1 acrophase and both sleep bout duration and percentage 
sleep, and an inverse relationship of BMAL1 acrophase with percentage duration of
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time awake. This indicated that an earlier phase of rhythmic BMAL1 expression was 
associated with reduced sleep duration, which is a sleep measure that was shown to 
be significantly reduced in ADHD in the present study.
A link between the strength of the PER2 rhythm and sleep quantity was indicated by 
a positive correlation of sleep bout duration with PER2 amplitude and PER2 
percentage rhythm. This was of interest since reduced sleep quantity and loss of 
PER2 rhythmicity have both been shown to be associated with ADHD in this study. 
An association of robustness of the PER2 rhythm with an earlier phase of behaviour 
was provided by an inverse correlation of PER2 amplitude with get up time. 
Furthermore decreased PER2 rhythmicity also appeared to be linked with shortening 
of the period of behaviour, as demonstrated by significant positive correlations 
between the period of the actigraphic rhythm and amplitude and percentage rhythm 
of PER2, and inverse correlations between deviation of the actigraphic period from 
24 hours and the amplitude and percentage rhythm of PER2.
3.4.6 Relationship between the behavioural and endocrine rhythms
Significant relationships between the actigraphic measures of sleep and the rest- 
activity rhythm were also observed with the chronometrics of the endocrine rhythms.
A significant positive correlation of percentage rhythm of melatonin with both time 
spent in bed and assumed sleep, and of melatonin amplitude with both assumed and 
actual sleep duration were observed. It could therefore be suggested that when the 
rhythm of melatonin is reduced and even lost as is observed in ADHD, then this 
could be associated with reduced sleep quantity. An association of the phase of the 
melatonin rhythm and sleep duration was also indicated by the positive correlation of 
melatonin acrophase with actual sleep duration and actual percentage sleep, and in 
turn an earlier phase of the melatonin rhythm was associated with increased wake 
duration (an inverse relationship between melatonin acrophase and actual percentage 
wake duration was observed). A delayed dim light melatonin onset in adult ADHD 
has previously been documented, and in the same subjects increased sleep duration 
but with less efficiency and longer sleep latency was demonstrated when ADHD was 
not comorbid with sleep onset insomnia (Van Veen et al., 2010).
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An inverse relationship of cortisol acrophase with L5o and MlOo was also noted. 
This therefore suggested a link between a delayed phase of behaviour and a later 
phase of the cortisol rhythm, which was further supported by the positive correlation 
of cortisol acrophase with actigraphic rhythm acrophase observed. Cortisol 
acrophase was positively correlated with L5, M10 and actigraphic rhythm amplitude, 
thus indicating that hyperactivity, a key symptom of ADHD, may be linked with a 
later phase of cortisol rhythmicity. Assumed sleep duration, actual sleep duration and 
the time spent in bed were all inversely correlated with the acrophase of the cortisol 
rhythm, suggesting that reduced sleep quantity, which was reported in ADHD in the 
present study, was also linked with a delayed phase of cortisol rhythmicity. This was 
further supported by the inverse correlation between the area under the curve of 
cortisol and both actual sleep duration and sleep efficiency, which are sleep 
parameters that were shown to be significantly reduced in ADHD in the present 
study. Additionally, as earlier described, deviation of the period of the activity 
rhythm from 24 hours was associated with ADHD, and an inverse correlation 
between the percentage rhythm of cortisol and period deviation was also shown in 
the present data.
Another correlation that was demonstrated was the inverse relationship between the 
time of sleep start and the area under the cortisol curve, thus indicating that the 
robustness of the cortisol rhythm was associated with an earlier sleep start and hence 
an earlier phase of behaviour. This was further demonstrated by an inverse 
correlation between the percentage rhythm of cortisol and the acrophase of the 
activity rhythm. However, partly contradictory to these findings was the positive 
correlation between percentage rhythm of cortisol with bed time and the inverse 
relationship between cortisol percentage rhythm and time of sleep end observed in 
the present study. This would suggest that the rhythm of cortisol was more robust in 
individuals who woke earlier in the morning and went to bed later at night. One 
interpretation of these findings could be that increased robustness of cortisol 
rhythmicity was associated with individuals who had an enforced social schedule on 
their sleep-wake patterns, for example in individuals who were required to wake up 
early to go to work. This was of interest since a regular daily schedule and hence 
regular environmental light exposure directly after waking has been shown to
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increase the amplitude of the morning cortisol peak (Scheer and Buijs, 1999, Van
Someren and Riemersma-Van Der Lek, 2007).
Collectively the numerous correlations observed between the behavioural rhythm and 
the molecular and endocrine rhythms demonstrate potential interactions of peripheral 
circadian clock gene expression and endocrine secretion with the circadian rhythm of 
behaviour.
3.4.7 rs1801260 polymorphism in CLOCK
No association of the rs 1801260 polymorphism in the CLOCK gene with adult 
ADHD was observed in the present data, which is in contrast to previous studies, 
which showed that the T allele was associated with the disorder (Kissling et al., 
2008, Xu et al., 2010). Although, the low sample number and hence lack of statistical 
power could be a contributing factor to the lack of group-wise differences in 
genotype frequencies demonstrated here. However, genotype was found to have a 
main effect upon BMAL1 amplitude, cortisol amplitude and cortisol percentage 
rhythm. The rs 1801260 polymorphism is located within the 3’ UTR promoter region 
of CLOCK, and therefore it could be postulated that effects of the polymorphism 
could be upon mRNA translatability and stability (Robilliard et al., 2002). Since 
CLOCK is an integral component of the molecular clockwork, with its role as a 
transcriptional activator upon dimerization with BMAL1 (Reppert and Weaver, 2002, 
Hastings and Herzog, 2004, Hirota and Fukada, 2004), any alterations in its normal 
functioning could potentially affect the expression of other core clock genes and their 
protein products, consequently affecting circadian clock output, and hence associated 
behavioural and physiological functions.
3.4.8 Conclusions
Significant perturbations not only in the rhythmic secretion of endocrine factors that 
are key outputs and regulators of the master circadian clock but also in peripheral 
circadian clock gene expression and actigraphic measures of circadian organization 
of gross behaviour were observed in ADHD. Significant correlations were also found 
between the clinical scores and various parameters of the behavioural, endocrine and
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molecular circadian rhythms. It is therefore proposed that insufficiencies in the 
entrainment of the circadian clock to the light-dark cycle or other Zeitgebers could 
underlie the disturbance in the circadian system observed in adult ADHD. 
Collectively the data suggest a key role for circadian disturbance in the manifestation 
of sleep disturbance and the clinical symptoms of adult ADHD. Further work would 
aim to elucidate potential therapeutic roles for bright light therapy and melatonin 
administration in the treatment of ADHD symptoms. Further research into 
modulation of circadian deficits in ADHD may prove beneficial in understanding the 
underlying causes of the symptomology and may serve to aid in appropriate and 
efficacious treatment of the disorder.
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Chapter 4: The effects of ADHD medication upon circadian clock protein
expression in the rodent brain
4.1 Introduction
Pharmacological treatments for ADHD
Currently the two of the main forms of pharmacological treatment for ADHD are 
predominantly the psychostimulant methylphenidate, and to a lesser degree and more 
recently the anti-depressant atomoxetine (Biederman and Faraone, 2005). Both drugs 
exert their therapeutic action through manipulation of the catecholaminergic systems, 
with methylphenidate inducing increases in synaptic concentration of both dopamine 
and noradrenaline (Madras et al., 2005, Kim et al., 2010), whereas atomoxetine acts 
to increase mainly just synaptic noradrenaline levels (Kim et al., 2010). The precise 
mechanism by which dopamine and noradrenaline levels are increased by 
methylphenidate treatment are thought to be due to inhibition of their associated 
transporters proteins; the dopamine transporter (DAT) and the norepinephrine 
transporter (NET), which prevents re-uptake of both catecholamines thus facilitating 
their accumulation in the synapse (Madras et al., 2005, Sangal et al., 2006, Kim et 
al., 2010). Atomoxetine is also an inhibitor of NET, and upon binding to the 
transporter it prevents removal of noradrenaline from the synapse, but with minimal 
affinity for DAT (Kim et al., 2010).
Methylphenidate and atomoxetine effects upon sleep
Various effects of methylphenidate and atomoxetine upon sleep patterns of both 
childhood and adult ADHD patients have been documented (Sangal et al., 2006, 
Boonstra et al., 2007, Sobanski et al., 2008). Improvements to sleep in adult ADHD 
by methylphenidate treatment have been observed including a reduced number of 
actigraphically assessed nocturnal awakenings and an increase in nocturnal periods 
of uninterrupted sleep (Boonstra et al., 2007). A polysomnographic study also 
demonstrated a significant reduction in sleep onset latency and improved sleep 
efficiency in patients undergoing methylphenidate treatment (Sobanski et al., 2008). 
To the contrary an actigraphic study reports increased sleep onset latency in adult
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ADHD patients undergoing methylphenidate treatment (Boonstra et al., 2007), and 
insomnia has been documented in both methylphenidate medicated childhood and 
adult ADHD patients (Sangal et al., 2006) with the effect of the stimulant treatment 
wearing off being postulated as playing in role in sleep disturbance, causing greater 
difficulty in falling asleep and reduced sleep duration (Sangal et al., 2006). 
Atomoxetine treatment has been shown to improve both parental and self reported 
sleep in childhood ADHD, including a reduction in both time to fall asleep and 
difficulty to settle down, and an improvement in ease of getting up in the morning 
(Sangal et al., 2006). Furthermore, research directly comparing the effects of 
methylphenidate and atomoxetine upon sleep in childhood ADHD have indicated 
that atomoxetine has more beneficial effects upon sleep than that of methylphenidate, 
with increased reports of insomnia and increased sleep onset latency when being 
treated with methylphenidate as oppose to atomoxetine and when un-medicated 
(Sangal et al., 2006). Furthermore atomoxetine treatment improved childhood 
ADHD symptoms in the morning and evening compared to methylphenidate 
treatment (Sangal et al., 2006). However, a reduction in the number of sleep 
interruptions/awakenings were observed during the period of methylphenidate 
treatment in comparison to atomoxetine treatment and un-medicated periods (Sangal 
et al., 2006).
Moreover, the efficacy of methylphenidate treatment of ADHD has been shown to be 
dependant upon the time of administration, with morning administration in childhood 
ADHD patients being shown to improve attention during the daytime, but to cause 
behavioural and sleep problems in the evening (Boonstra et al., 2007). Whereas, late 
afternoon administration of methylphenidate appeared to reduce the problematic side 
effects upon sleep, whilst still exerting considerable therapeutic action (Kent et al., 
1995, Boonstra et al., 2007).
The observed interactions of methylphenidate and atomoxetine with the sleep/wake 
cycle are not entirely surprising since aspects of both the dopaminergic and 
noradrenergic systems are implicated in circadian clock functioning. Dopamine 
neurons have been shown to play a role in the regulation of light input to the retina 
(Witkovsky, 2004, McClung et al., 2005) and noradrenaline has been proposed as an 
entrainment signal originating from the SCN to entrain the peripheral oscillator of
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the pineal gland (Wongchitrat et al., 2009). Furthermore, the extracellular 
concentrations of dopamine and noradrenaline exhibit a circadian rhythm in various 
brain regions (Smith et al., 1992, Paulson and Robinson, 1994, Drijfhout et al., 1996, 
Paulson and Robinson, 1996, Castaneda et al., 2004).
Pharmacological effects upon the circadian system o f the rodent brain
The rodent brain is a model widely used in circadian studies, as direct assessment of 
in vivo effects upon the master circadian clock of the SCN and the slave oscillators in 
the periphery of the human brain is limited to post mortem tissue, which is 
susceptible to known perturbations of the circadian system in various disease states 
(Wu et al., 2006, Tseng et al., 2010) and with aging (Ando et al., 2010, Wyse and 
Coogan, 2010).
Earlier studies have demonstrated various interactions of pharmacological agents of 
the catecholaminergic systems with the rodent circadian system, including the 
opiates; morphine and heroine (Li et al., 2009a, Li et al., 2009b), the anti-depressant 
fluoxetine (Uz et al., 2005) the antipsychotic haloperidol (Coogan et al., 2011) and 
the psychostimulants; amphetamine (Paulson and Robinson, 1996, Gaytan et al., 
1999), methamphetamine (Honma et al., 1986, Honma et al., 1988, Moriya et al., 
1996, Masubuchi et al., 2001, Iijima et al., 2002, Yamamoto et al., 2005) and cocaine 
(Abarca et al., 2002, McClung et al., 2005, Uz et al., 2005). Furthermore it is well 
documented that under conditions of chronic methamphetamine administration the 
rodent circadian rhythms becomes de-synchronised from the LD cycle and exhibits 
rhythmicity that is entirely independent of the SCN (Honma et al., 1986, Tataroglu et 
al., 2006, Honma et al., 2008), and hence indicates the presence of an extra-SCN 
methamphetamine sensitive oscillator that employs alternative circadian clock 
machinery to that of the SCN (Mohawk et al., 2009).
As of yet there have been no documented investigations to examine the effects of 
atomoxetine upon the rodent circadian system, although the effects of chronic 
methylphenidate upon the rodent behavioural rhythm has been investigated. Chronic 
methylphenidate treatment was shown to produce a circadian activity rhythm in 
arrhythmic SCN-lesioned rats (Honma and Honma, 1992). Furthermore, chronic
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methylphenidate administration has been shown to alter the rodent diurnal locomotor 
rhythm in a dose-dependant manner (Algahim et al., 2009, Algahim et al., 2010, Lee 
et al., 2010). A phase shift in the activity rhythm of adult male rats was elicited by 
prolonged administration of a moderate dose that corresponds to peak plasma 
methylphenidate concentrations within the clinical dose range (Algahim et al., 2009). 
Whereas chronic methylphenidate treatment only altered the diurnal activity rhythm 
of young male rats when administered at a high dose (Algahim et al., 2010). Time-of 
day effects upon the action of methylphenidate have also been reported, with 
behavioural sensitization to methylphenidate being demonstrated to vary over the 24- 
hour cycle, with the greatest sensitization of rats to methylphenidate occurring during 
the light phase, and minimal sensitization during the dark phase (Gaytan et al., 2000).
Given the evidence of interactions of ADHD medication with the sleep wake cycle 
and the widely documented effects of psychoactive drugs upon the circadian system, 
it was therefore of interest to investigate how ADHD medications may modulate the 
molecular clockwork that form the basis of the circadian system. Therefore the main 
aims of this study were to examine and compare the effects of chronic 
methylphenidate and chronic atomoxetine upon the expression of circadian clock 
gene protein products in the mouse brain.
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4.2 Methods
Animals
C57B1/6J mice (n=75, 8 weeks of age, Charles River, UK) were housed in cages of 
three, with ad libitum access to food and water, and constant temperature and 
humidity, and were habituated to the housing conditions prior to beginning the 
experiments. The mice were subject to a 12:12 light/dark cycle, with lights on at 6 am 
(designated Zeitgeber Time ZTO), using standard fluorescent light bulbs (-100 lux at 
cage level). These experiments adhered to the guidelines outlined in the Animals 
(Scientific Procedures) Act, 1986, the European Communities Council Directive 
86/609 and by the Research Ethics Committee, School of Medicine, Swansea 
University. Every effort was made to minimise the animal numbers and suffering 
experienced.
The mice underwent chronic treatment of either 2.5mg/kg methylphenidate 
(Methylphenidate hydrochloride, Sigma-Aldrich, UK), 2.0mg/kg atomoxetine 
(Tomoxetine hydrochloride, Tocris Bioscience, UK) or a 0.9% saline control, and 24 
mice were assigned to each of these treatment groups. The doses chosen were 
according to previous literature, as they produce peak plasma levels within the 
clinical dose range in humans (Kuczenski and Segal, 2002, Algahim et al., 2009). 
The injections were equalized to a volume of lOOpl with 0.9% saline and 
administered intraperitoneally, once a day at ZT2 (8 am) for 7 days. The time of 
administration was chosen two hours into their light phase (sleep phase) to minimise 
disturbance to their sleep/wake cycle.
On day 7 the mice were killed, and 6  mice were killed from each treatment group at 
each of the 4 sampling time-points: ZT2, ZT8 , ZT14 and ZT20. This procedure was 
carried out in a light-proof room and under infra-red light for those mice sampled in 
the dark phase of the cycle. Mice were anaesthetised with chloral hydrate (pH 7.04), 
prior to transcardial perfusion with 4% paraformaldehyde (PFA). Once the brains 
were removed, they were post-fixed in 4% PFA at 4°C overnight, and then stored in 
0.1M phosphate buffer (PBS, pH7.4) at 4°C. The brains were then transferred into 
30% sucrose at 4°C until fully saturated, for cryoprotection.
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The brains were sliced into 30pm sections using a freezing-stage sliding microtome 
(Leica, Germany). The brain was mounted onto to the cutting platform of the 
microtome using embedding compound and maintained at -30°C whilst sectioning. 
Four serial sets of sections were collected from each brain and were stored in PBS 
containing 0.01% sodium azide (Sigma-Aldrich, USA) at 4°C, to prevent fungal 
growth.
Immunohistochem istry
Free-floating sections were processed for c-Fos, PER2, PERI and CLOCK 
immunohistochemistry. Primary and secondary polyclonal antibody staining with the 
binding of an avitin-biotin complex was used, as this method increases the antibody 
to signal ratio and so gives a high intensity of staining. The protocol consisted of a 
series of steps where the sections were incubated in solutions of 1ml volume. The 
solutions were changed using a hand pipette. This method reduced contact with the 
sections so that damage to the sections was minimized. During incubations the trays 
of sections were mixed on a see-saw rocker.
The sections were washed in PBS twice for 10 minutes each, to remove the sodium 
azide and any tissue debris. The sections were then incubated with 0.1M PBS and 
0.03% Triton-X-100 (PBX, Sigma-Aldrich, UK) for 10 minutes, to permeabilise the 
sections. This was followed by the incubation of the sections for 20 minutes in a PBS 
solution containing 1.5% hydrogen peroxide (Sigma-Aldrich, UK) to inhibit 
peroxidise activity. This was followed by two washes in PBS and a wash in PBX. 
The sections were then blocked in serum for 1 hour at room temperature to prevent 
non-specific binding of the primary antibody. The sections that were undergoing 
CLOCK and PERI detection were blocked in PBX containing 5% donkey serum 
(Sigma-Aldrich, UK). The sections undergoing c-Fos and PER2 detection were 
blocked in PBX containing 5% normal goat serum (NGS, Sigma-Aldrich, UK). The 
sections then underwent primary antibody incubation at 4°C using the following 
conditions:
c-Fos: PBX solution containing the rabbit polyclonal c-Fos primary antibody 
(dilution 1:8000; Santa Cruz Biotechnology, UK) and 2% NGS for 18 hours.
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PER2: PBX solution containing the rabbit polyclonal PER2 primary antibody 
(dilution 1:1000; Alpha Diagnostic International, USA) and 2% NGS for 42 hours. 
PERI: PBX solution containing the goat polyclonal PERI primary antibody (dilution 
1:500; Santa Cruz Biotechnology, UK) and 2% donkey serum for 42 hours.
CLOCK: PBX solution containing the goat polyclonal CLOCK primary antibody 
(dilution 1:500; Santa Cruz Biotechnology, UK) and 2% donkey serum for 42 hours.
The sections were washed twice with PBS and once with PBX, before incubation 
with biotinylated secondary antibodies, for 70 minutes, in light-proof conditions at 
room temperature:
PER2 & c-Fos: PBX solution containing goat anti-rabbit secondary antibody (1:400; 
Vector Laboratories, UK) and 2% NGS.
PERI & CLOCK: PBX solution containing rabbit anti-goat secondary antibody 
(1:400; Jackson Laboratories, USA) and 2% donkey serum.
The sections were then washed twice in PBS and once in PBX, before being 
incubated with a premixed PBX solution containing the avitin-biotin complex (0.4%; 
Vector Laboratories, UK) for 90 minutes in light-proof conditions at room 
temperature. The sections were then washed twice in PBS, followed by a wash for 10 
minutes in 0.1 M sodium acetate (Sigma-Aldrich, USA) to lower the pH of the 
sections to pH6 . The sections were then incubated with nickel-enhanced 
Diaminobenzidine (nickel DAB) and glucose oxidase (Sigma-Aldrich, USA). The 
staining for c-Fos was developed in 5 minutes, PER2 in 2 minutes, PERI in 4.5 
minutes and CLOCK in 4.5 minutes. The sections were then moved to a solution of 
0.1M sodium acetate (pH6 ) to stop the staining reaction. All sections underwent 
these same standard conditions, in order to minimise inter-assay variability.
Specificity of the staining of the target proteins was confirmed by processing 
separate sections using the same standard immunohistochemistry protocols described 
above, but with the primary antibody incubated prior to the procedure with its 
immunizing peptide, to block its activity (Figure 4.1).
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Figure 4.1. Photomicrographs o f immunostaining in the SCN (dotted line) o f saline 
control mice, using primary antibodies that have been blocked with the 
corresponding immunizing peptide. (A) c-Fos, (B) CLOCK, (C) PERI, (D) PER2. 
Scale bars = 100pm. Minimal immunoreactive cells were detected in each case, 
indicating specificity o f the primary antibody.
The sections were then washed twice in PBS and mounted in dilute PBS onto 
polycycline-coated microscope slides (Fisher-Scientific, UK). The sections were then 
left to dry out overnight. Once dried the m ounted sections underwent dehydration 
and delipifying steps using Ethanol (Fisher-Scientific, UK) and Histoclear (National 
Diagnostics, UK): 3 minutes in 70% ethanol, 3 minutes in 95% ethanol, 2 steps o f 3 
minutes in 100% ethanol, and finally 2 steps o f 3 minutes in histoclear. The sections 
were then coverslipped using mounting media (Entellan; Merck, UK).
Image analysis
The Zeiss Axioskop light microscope (Zeiss, Jena, Germany) equipped with an 
Axiocam digital camera was used to examine the brain sections. Three to six images 
were quantitated per time-point, region and mouse. Two measures o f 
immunoreactivity, the optical density and the cell/count per area, were calculated 
using image analysis software (ImageJ 1.43u, National Institutes o f Health, USA). 
For the counting o f immunoreactive cells, the images were adjusted for background, 
and a threshold value was set that was optimal for the visualisation o f each antigen. 
For the measurement o f optical density, both the optical densities o f the region of 
interest and an unstained control region were measured. The optical density o f the 
control region was subtracted from the optical density o f the region o f interest to 
allow for calculation o f the optical density adjusted for non-specific staining. 
Anatomical regions were identified according to the stereotaxic co-ordinates defined
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in the mouse brain atlas (Paxinos and Franklin, 2004). Immunoreactivity was 
examined in the suprachiasmatic nuclei (SCN) at the mid-rostral level, the 
paraventricular nucleus of the hypothalamus (PVN), the dorsal medial nucleus of the 
hypothalamus (DMH), the basolateral (BLA) and central (CeA) amygdala, the 
hippocampus (CA1, CA3, dendate gyrus (DG)), the caudate putamen (CPu), the 
ventral tegmental area (VTA), the nucleus accumbens including the core (ACBC) 
and shell (ACBSH) regions, and the cerebral cortex including the prefrontal 
infralimbic cortex (ILC), the prefrontal prelimbic cortex (PLC) and the cingulate 
cortex (CC).
Statistical analysis
Average immunoreactivity was calculated per mouse, time-point, treatment group 
and brain region. The statistical software SPSS (IBM Corporation, USA) was used 
on a PC to test for significant main effects of time and treatment by 2-way ANOVA, 
with Tukey post-hoc testing to describe specific effects within main effects.
Cosinor analysis was performed on a PC using statistical software (CircWave vl.4, 
Department of Chronobiology, University of Groningen, Netherlands), to test 
whether the data exhibited a significant circadian rhythm. This program determines if 
a statistically significant (p<0.05) sinusoidal wave can be fitted to the data, by 
automatically adding harmonics to the wave fit to best describe the data. The 
following function describes the wave-form:
p i sin i2n — + q{ cos i2n — 
r r _
Where a is the average; i is either 1, 2, 3, when 1 it indicates the fundamental wave, 
when 2 it describes the first harmonic, when 3 it describes the second harmonic, pi is 
the sine coefficient of the (i-l)* harmonic, qi is the coefficient of the (i-l)* harmonic; 
t is the time-point value (modulo x); f(t) is the calculated function value at time point 
t, a and b are linear estimates for the sine and cosine contribution to a flat line (when 
i=0), the fundamental wave (i=l), first harmonic (i=2), second harmonic (i=3).
f ( t )  = a + ^
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4.3 Results
CLOCK, PERI, PER2 and c-Fos immunoreactivity were assessed both 
densitometrically and by quantification of immunoreactive cells in the SCN, PVN, 
CC, CPu and in the VTA, whilst immunoreactivity in all other brain regions 
analysed, were assessed by immunoreactive cell quantification alone. The 
measurement of a significant co-sinor fit and acrophase were equivalent between the 
two methods in all cases (appendix 1), and therefore immunoreactive cell count data 
alone is presented in the main text. The staining of the CLOCK, PERI, PER2 and c- 
Fos gene expression protein products in all of the brain regions examined was 
predominantly nuclear (figures 4.3, 4.5, 4.7, 4.9, 4.11, 4.13, 4.15, 4.17, 4.19, 4.21, 
4.23, 4.25, 4.27, 4.29, 4.31, 4.33, 4.35, 4.37, 4.39, 4.41). Significant main effects of 
time and treatment upon protein expression were assessed by 2 -way analysis of 
variance (ANOVA) with tukey post-hoc testing to determine the specific effects 
within the main effects demonstrated. Co-sinor analysis was used to determine if 
there was a significant rhythmic pattern of protein expression.
4.3.1 Circadian clock protein expression in the hypothalamus
CLOCK expression in the hypothalamus
CLOCK was expressed in the all three regions of the hypothalamus examined; SCN, 
PVN and the DMH (figures 4.2-4.3). Its expression was not rhythmic in the SCN of 
the saline control mice (figure 4.2A, table 4.1). However, there was a significant 
rhythm of CLOCK gene protein product expression in the DMH and PVN of these 
mice, with acrophases at ZT8 (figures 4.2D and 4.2G, table 4.1). CLOCK expression 
in the SCN of the methylphenidate and atomoxetine treated mice however, was not 
rhythmic (figures 4.2B-C, table 4.1). Rhythmic expression of CLOCK in the DMH 
of the methylphenidate and atomoxetine treated mice with an acrophase at ZT2, 6  
hours in advance of the acrophase observed in the saline control mice was detected 
(figures 4.2E-F, table 4.1). The expression of CLOCK in the PVN was rhythmic with 
an acrophase in the early subjective day exhibited by both the methylphenidate and 
atomoxetine treated mice (figures 4.2H-J, table 4.1). No significant main effect of 
time, treatment, or interaction of time and treatment were detected upon CLOCK
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expression in the SCN and DMH. However, a significant effect of time upon PVN 
CLOCK expression was shown (df=3, F=2.986, P<0.05), and a main effect of 
treatment was nearing significance (df=2, F=3.018, P=0.057), whilst there was no 
interaction of time and treatment detected.
B r a in  r eg io n A c r o p h a se  o f  Im m u n o r e a c t iv ity  (h )
T r e a tm e n t C L O C K P E R I P E R 2 c-F o s
S C N S A L n.s. -Z T 1 4 -Z T 1 4 ~ Z T 6
M P D n.s. -Z T 1 4 ~Z T 2 ~Z T 6
A T O n.s. -Z T 1 4 n.s. ~Z T 6
D M H S A L ~Z T 8 ~Z T 8 n.s. -Z T 1 4
M P D ~Z T 2 ~Z T 2 n.s. ~Z T 2
A T O ~Z T 2 ~Z T 2 n.s. ~Z T 2
P V N S A L ~Z T 8 -Z T 1 4 -Z T 1 4 -Z T 2 0
M P D ~Z T 5 n.s. -Z T 1 4 -Z T 2 0
A T O ~Z T 5 ~Z T 2 -Z T 2 0 ~Z T 8
Table 4.1. Acrophases of rhythmic immunoreactivity of CLOCK, PERI, PER2 and 
c-Fos in the hypothalamus of each treatment group; saline (SAL), methylphenidate 
(MPD) and atomoxetine (ATO), assessed by co-sinor analysis, n.s = not significantly 
rhythmic.
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Figure 4.2. CLOCK immunoreactivity measured as immunoreactive cell counts in 
the SCN, DMH and PVN of mice chronically treated with either saline control, MPD 
or ATO. A fitted curve indicates rhythmic expression assessed by co-sinor analysis. 
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Figure 4.3. Photomicrographs o f CLOCK immunostaining in the SCN and DMH 
during the mid subjective day (ZT8) and mid subjective night (ZT20) and in the PVN 
during the early subjective day (ZT2) and early subjective night (ZT14) o f mice that 
underwent chronic treatment o f MPD, ATO or a saline control. Scale bars = 100pm.
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PERI expression in the hypothalamus
PERI expression was observed in all three hypothalamic regions examined (figure 
4.5, table 4.1). The saline control mice exhibited rhythmic expression of PERI in the 
SCN, DMH and PVN, peaking at ZT14, ZT8  and ZT14 respectively (figures 4.4A, 
4.4D, 4.4G, table 4.1). There was a significant effect of time upon PERI expression 
in the SCN (df=3, F=42.603, PO.OOl). There was no significant main effect of 
treatment upon SCN PERI expression and PERI expression in the SCN of chronic 
methylphenidate and chronic atomoxetine treated mice was rhythmic, with 
acrophases unaltered from that of the saline control, peaking at ZT14 (figures 4.4A- 
C, table 4.1). A significant effect of time upon PERI expression was observed in the 
DMH (df=3, F=4.463, PO.Ol). Although no main effect of treatment or interaction 
of time and treatment were observed, there was a shift in acrophase of PERI 
expression in the DMH of animals who underwent chronic methylphenidate and 
atomoxetine treatment to ZT2 in comparison to an acrophase at ZT8  in the saline 
control (figures 4.4D-F, table 4.1). A loss of rhythmicity of PERI expression in the 
PVN of chronic methylphenidate treated mice and a shift in the acrophase of 
rhythmic PERI expression in the PVN of atomoxetine mice to ZT2 was shown 
(figures 4.4H-J, table 4.1). Furthermore there was a significant main effect of 
treatment upon PERI expression in the PVN (df=2, F=24.358, PO.OOl). Post-hoc 
testing showed PERI expression was increased in the PVN of chronic 
methylphenidate treated mice in comparison to chronic atomoxetine treated mice and 
the saline control mice (PO.OOl), and PERI expression in the PVN of mice that had 
been chronically treated with atomoxetine was dampened in comparison to the 
methylphenidate treated mice and the saline control mice (PO.OOl).
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Figure 4.4. PERI immunoreactivity measured as immunoreactive cell counts in the 
SCN, DMH and PVN of mice chronically treated with saline control (SAL), MPD or 
ATO. A fitted curve indicates a significant rhythm assessed by co-sinor analysis.
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Figure 4.5. Photomicrographs o f PERI immunostaining in the SCN and PVN (early 
subjective day (ZT2) and early subjective night (ZT14) and in the DMH (mid 
subjective day (ZT8) and mid subjective night (ZT20), o f mice chronically treated 
with either MPD, ATO or saline control. Scale bars = 100pm.
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PER2 expression in the hypothalamus
In the SCN and PVN of the saline control mice PER2 expression was rhythmic, with 
an acrophase of ZT14 (figures 4.6A and 4.6G, table 4.1), whilst arrhythmic lower 
levels of PER2 expression were observed in the DMH of these mice (figure 4.6D, 
table 4.1). There was a shift in the acrophase of the rhythmic expression of PER2 to 
ZT2 in the SCN of mice that were subject to chronic methylphenidate treatment and 
a loss of significant rhythmic expression of PER2 in the SCN of chronic atomoxetine 
treated mice (figures 4.6B and 4.6C respectively, table 4.1). A significant main effect 
of treatment upon PER2 expression in the SCN (df=2, F=34.953, PO.OOl) was 
shown and a significant interaction of time and treatment was observed (PO.OOl), 
although there was no significant main effect of time. PER2 expression was reduced 
in the SCN of methylphenidate treated mice (PO.Ol) and atomoxetine treated mice 
(PO.OOl) in comparison to the saline control. The atomoxetine treated mice also 
exhibited reduced PER2 expression in the SCN in comparison to the 
methylphenidate treated mice (PO.OOl). PER2 expression in the DMH of 
methylphenidate and atomoxetine treated mice did not exhibit rhythmicity, similarly 
to the saline control (figures 4.6E-F, table 4.1), and there was also no effect of time, 
treatment, or interaction of time and treatment upon PER2 expression in the DMH. 
PER2 expression was rhythmic in the PVN of methylphenidate and atomoxetine 
treated mice, with an acrophase at ZT14 and ZT20 respectively (figures 4.6H-J, table
4.1). Although there was no significant main effect of time, or interaction of time and 
treatment, there was a significant main effect of treatment upon PER2 expression in 
the PVN (df=2, F=161.437, PO.OOl) and post-hoc testing revealed that in 
comparison to the saline control, PER2 expression was significantly reduced in the 
PVN of methylphenidate treated mice (PO.OOl) and atomoxetine treated mice 
(PO.OOl), with PER2 expression being further reduced in the atomoxetine treated 
mice in comparison to the methylphenidate treated mice (PO.Ol).
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Figure 4.6. PER2 immunoreactivity measured as immunoreactive cell counts in the 
SCN, DMH and PVN o f mice chronically treated with either saline control, MPD or 
ATO. A fitted curve indicates a significant rhythm assessed by co-sinor analysis. 
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Figure 4.7. Photomicrographs o f PER2 immunostaining in the SCN and PVN (early 
subjective day (ZT2) and early subjective night (ZT14) and in the DMH (mid 
subjective day (ZT8) and mid subjective night (ZT20) o f mice chronically treated 
with either MPD, ATO or saline control (SAL) Scale bars = 100pm.
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cFos expression in the hypothalamus
/
cFos was rhythmically expressed in the SCN, DMH and PVN of the saline control 
mice, with acrophases of ZT8 , ZT14 and ZT20 respectively (figures 4.8A, 4.8D, 
4.8G, table 4.1). The expression of c-Fos was rhythmic in the SCN of both the 
methylphenidate and atomoxetine treated mice, and was unaltered from that of the 
saline control, with an acrophase at ZT8 (figures 4.8B-C, table 4.1). There was a 
significant effect of time upon c-Fos expression in the SCN (df=3, F=21.796, 
P<0.001), but no effect of treatment or interaction of time and treatment. The 
acrophase of rhythmic c-Fos expression in the DMH exhibited a 12-hour shift to 
peak at ZT2 in the methylphenidate and atomoxetine treated mice compared to the 
saline control (figures 4.8E-F, table 4.1). A significant main effect of treatment upon 
c-Fos expression in the DMH was observed (df=2, F=6.264, PO.Ol), with an 
increase in c-Fos expression in the DMH of animals chronically treated with 
methylphenidate in comparison to atomoxetine (PO.05) and saline (PO.Ol), whilst 
there was no significant effect of time or interaction of time and treatment. The 
acrophase of rhythmic c-Fos expression in the PVN of atomoxetine treated mice 
shifted to ZT8 , in comparison to an acrophase of ZT20 observed in the 
methylphenidate treated mice and the saline control (figures 4.8G-J, table 4.1). In the 
PVN there was no significant main effect of treatment or time upon c-Fos 
expression, although there was a significant interaction of time and treatment (df=6 , 
F=4.108, PO.Ol).
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Figure 4.8. c-Fos immunoreactivity measured as immunoreactive cell counts in the 
SCN, DMH and PVN o f mice chronically treated with saline control (SAL), MPD or 
ATO. A fitted curve indicates a significant rhythm assessed by co-sinor analysis.
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Figure 4.9. Photomicrographs o f c-Fos immunostaining in the SCN and PVN during 
the mid subjective day (ZT8) and mid subjective night (ZT20) and in the DMH 
during the early subjective day (ZT2) and the early subjective night (ZT14), o f mice 
that underwent chronic treatment o f MPD, ATO or saline control (SAL). Scale bars = 
100pm.
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4.3.2 Circadian clock protein expression in the limbic forebrain
CLOCK expression in the limbic forebrain
CLOCK was expressed in all regions of the limbic forebrain examined; CA1, CA3 
and DG of the hippocampus, and the BLA and the CEA of the amygdala. The 
expression of CLOCK was not significantly rhythmic in any of the regions of the 
limbic forebrain examined in the saline control mice or the methylphenidate treated 
mice (figures 4.10A-B, 4.10D-E, 4.10G-H, 4.10K-L, 4.10N-P, table 4.2). However 
there was a significant rhythm of CLOCK expression in the BLA of the atomoxetine 
treated mice, with an acrophase at ZT2 (figure 4.10M, table 4.2), whilst CLOCK 
expression was not significantly rhythmic in the CA1, CA3, DG and CEA of the 
atomoxetine treated mice (figures 4 .IOC, 4.10F, 4.10J, 4.10Q, table 4.2). No 
significant main effects of treatment, time, or interaction of time and treatment upon 
CLOCK expression in the any of the regions of the limbic forebrain examined was 
observed.
Brain region Acrophase of Immunoreactivity (h)
Treatment CLOCK PERI PER2 c-Fos
CA1 SAL n.s. ~ZT2 n.s. as.
MPD n.s. n.s. n.s. ~ZT2
ATO n.s. ~ZT2 ~ZT2 n.s.
CA3 SAL n.s. ~ZT2 n.s. as.
MPD n.s. n.s. n.s. n.s.
ATO n.s. ~ZT2 n.s. n.s.
DG SAL n.s. n.s. n.s. as.
MPD n.s. n.s. n.s. as.
ATO n.s. n.s. as. ~ZT2
BLA SAL n.s. n.s. n.s. n.s.
MPD n.s. n.s. as. as.
ATO ~ZT2 n.s. as. as.
CEA SAL n.s. n.s. as. as.
MPD n.s. n.s. as. as.
ATO n.s. n.s. -ZT20 as.
Table 4.2. Co-sinor analysis of immunoreactivity of CLOCK, PERI, PER2 and c- 
Fos in the limbic forebrain of each treatment group; saline (SAL), methylphenidate 
(MPD) and atomoxetine (ATO). n.s = not significantly rhythmic.
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Figure 4.10. CLOCK 
the CA1, CA3, DG,
immunoreactivity measured by immunoreactive cell counts in 
BLA and CEA o f mice that underwent chronic treatment of
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either a saline control (SAL), methylphenidate (MPD) or atomoxetine (ATO).
Presence o f a fitted curve indicates a significant rhythm as assessed by co-sinor
analysis.
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Figure 4.11. Photomicrographs o f CLOCK immunostaining in the hippocampus 
(dashed box = CA1, solid ellipse = CA3, dotted box = DG, scale bars = 200pm) and 
in the CEA during the mid subjective day (ZT8) and mid subjective night (ZT20) and 
in the BLA during the early subjective day (ZT2) and early subjective night (ZT14) 
o f mice that underwent chronic treatment o f either methylphenidate (MPD), 
atomoxetine (ATO) or a saline control (SAL). (Scale bars = 100pm for BLA and 
CEA).
PER I expression in the limbic forebrain
PERI expression was rhythmic in the CA1 and CA3 regions o f the saline control 
mice, with acrophases at ZT2 in both cases (figures 4.12A and 4.12D, table 4.2), 
although PERI expression in the DG, BLA and CEA was not significantly rhythmic 
in these mice (figures 4.12G, 4.12K, 4.12N, table 4.2). PERI expression in the DG, 
BLA and CEA regions o f both the methylphenidate and atomoxetine treated mice did 
not exhibit rhythmicity, which is unaltered from the non-rhythmic PERI expression 
in these regions in the saline control (figures 4.12H-J, 4.12L-M, 4.12P-Q, table 4.2). 
PERI expression in the CA1 and CA3 regions o f atomoxetine treated mice, was 
significantly rhythmic with an acrophase at ZT2 in each case, and was thus unaltered 
from the saline control (figures 4.12C, 4.12F, table 4.2). However, the 
methylphenidate treated mice exhibited a loss o f rhythmic PERI expression in both 
o f these regions (figures 4.12B, 4.12E, table 4.2). There was a significant main effect 
o f time upon PERI expression in the CA1, CA3 and BLA regions (df=3, 7^= 10.445,
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PO.OOl; df=3, F=8.253, P<0.001; df=3, F=3.745, P<0.05 respectively), but not 
upon PERI expression in the DG and CEA regions. However, no significant main 
effects of treatment or interactions of time and treatment were observed upon PERI 
expression in any of the regions of the limbic forebrain examined.
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Figure 4.12. PERI immunoreactivity measured by immunoreactive cell counts in the
CA1, CA3, DG, BLA and CEA o f mice that underwent chronic treatment o f either a
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saline control (SAL), methylphenidate (MPD) or atomoxetine (ATO). Presence o f a
fitted curve indicates a significant rhythm as assessed by co-sinor analysis.
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Figure 4.13. Photomicrographs o f PERI immunostaining in the hippocampus 
(dashed box = CA1, solid ellipse = CA3, dotted box = DG, scale bars = 200pm) and 
in the BLA and CEA during the early subjective day (ZT2) and early subjective night 
(ZT14) o f mice that underwent chronic treatment o f either methylphenidate (MPD), 
atomoxetine (ATO) or a saline control (SAL). (Scale bars = 100pm for BLA and 
CEA).
PER2 expression in the limbic forebrain
PER2 expression was not rhythmic in any o f the limbic forebrain regions examined 
o f the saline control mice and the methylphenidate treated mice (figures 4.14A-B, 
4.14D-E, 4.14G-H, 4.14K-L, 4.14N-P, table 4.2). However, PER2 expression was 
significantly rhythmic in the C A 1 and CEA regions o f the atomoxetine treated mice, 
with acrophases o f ZT2 and ZT20 respectively (figures 4.14C, 4.14Q, table 4.2), 
whilst PER2 expression did not exhibit a significant rhythm in CA3, DG and BLA 
regions o f the atomoxetine treated mice (figures 4.14F, 4.14J, 4.14M, table 4.2). 
There was no significant main effect o f treatment or interaction o f time and treatment 
upon PER2 expression in any o f the regions o f the limbic forebrain examined. There 
was a significant main effect o f time upon PER2 expression in the CA1 and CEA 
regions (df=3, F=4.587, P<0.01, and df=3, F=3.829, P<0.05 respectively), but not in 
the CA3, DG and BLA regions.
170
(A) CA1 SAL m C A l  MPD (C \CA1  ATQ
6 OE-4
5 OE-4 -_ i
® e4  OE-4 SC4 0E-4!
c t
I a 3 06 -4
EZ HIMEZ
■ £ 2 oe3n if 2 OE-4
1 OE-4
8  14
Z e itg e b e r  t im e  (h)
1 1
8  14
Z e itg e b e r  tim e  (h)
6 OE-4 
>  5  OE-4’BS-
l g  4 OE-4
20
S  2 OE-4 
1 OE-4 
OOEO d
8  1 4  2 0
Z e i t g e b e r  t i m e  ( h )
(D) CAS SAL (E)CAS MPD (Ft CA3 ATQ
5 - 4  OE-45 - 4  OE-4' 5 - 4  OE-4
o =3 OE-4 
E C 5 ?30E-4
£5
EZ20E-4 E Z 2  0E-42 0E-4
10E-4 1 OE-4
OOEO"
2  8  14
Z e itg e b e r  tim e  (h)
14 
tim e  (h)Z e itg e b e rZ e itg e b e i tim e  (h)
(H) DG MPD (J )DG  ATQ(G) DG SAL
1 2E-41 2E-4- 1 2E-4
Sl90E'5s cu j j  9  OE-5
c 2“I | 6  0E-5 
EZ
c 2“
|  j  6  OE-514E .0
S6 j F -
3 OE-5*  3 OE-5 3 OE-5
0 OEuDOEOi 8  14
Z e itg e b e i tim e  (h)
14 
tim e (h)Z e itg e b e i tim e  (h)
(IVl) BLA ATQ(K ) BLA SAL (L) BLA MPD
3 OE-4 ? o r .  -:3 OE-4
£ §2 OE-4- £ C20E-4£ §2 OE-4-
ooEcr
Z e itg e b e r  t im e  (h)
8 14
Z e itg e b e r  tim e  (h)
(N) CEA SAL (P) CEA MPD
14
Z e itg e b e r  tim e  (h)
(O) CEA ATO
5 OE-4
5 - 4  OE-4 5 - 4  OE-4
o =3 OE-4 0 - 3  OE-4
E£
E 1 2 OE-4 E Z 2 OE-4
S1 10E-4 B* 1 OE-4
OOEO- OOEO1
5 OE-4
i f —4 OE-4-
o = 3 0 E -4
E Z  2 OE-4
!" 1 OE-4
8 14
Z e itg e b e r  tim e  (h)
2 8 14 20
Z eitg eb e r tim e  (h)Z e itg e b e r  tim e  (h)
Figure 4.14. PER2 immunoreactivity measured by immunoreactive cell counts in the 
CA1, CA3, DG, BLA and CEA o f mice that underwent chronic treatment o f either a
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saline control (SAL), methylphenidate (MPD) or atomoxetine (ATO). Presence o f a
fitted curve indicates a significant rhythm as assessed by co-sinor analysis.
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Figure 4.15. Photomicrographs o f PER2 immunostaining in the hippocampus 
(dashed box = CA1, solid ellipse = CA3, dotted box = DG, scale bars = 200pm) and 
in the BLA during the early subjective day (ZT2) and early subjective night (ZT14) 
and in the CEA during the mid subjective day (ZT8) and mid subjective night (ZT20) 
o f mice that underwent chronic treatment o f either methylphenidate (MPD), 
atomoxetine (ATO) or a saline control (SAL). (Scale bars = 100pm for BLA and 
CEA).
c-Fos expression in the limbic forebrain
c-Fos expression was not rhythmic in any o f the regions o f the limbic forebrain 
examined in the saline control mice (figures 4.16A, 4.16D, 4.16G, 4.16K, 4.16N, 
table 4.2). c-Fos expression was also not significantly rhythmic in the CA3, BLA and 
CEA regions o f both the atomoxetine and methylphenidate treated mice (figures 
4.16E-F, 4.16L-M, 4.16P-Q, table 4.2). However, there was a significant main effect 
of treatment upon c-Fos expression in the BLA (df=2, F= 12.987, PO.OOl), the CEA 
(df=2, F=8.213, P O .O l) and in the CA3 (df=2, F=34.325, PO.OOl), with Post-hoc 
testing revealing a significant increase in c-Fos expression in the BLA and CA3 
regions o f the methylphenidate treated mice in comparison to that o f the atomoxetine 
treated mice and the saline control (all PO.OOl), c-Fos expression was also increased 
in the CEA o f the methylphenidate treated mice in comparison to that o f the saline 
control (PO .O l). There was a significant main effect o f time upon c-Fos expression 
in the CA3 region (df=3, F=5.734, P O .O l), but not the CEA and BLA regions, and
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there was no significant interaction of time and treatment upon c-Fos expression in 
the CA3, BLA and CEA regions.
The methylphenidate treated mice exhibited rhythmic c-Fos expression in the CA1 
region, with an acrophase at ZT2, which is in contrast to the non-rhythmic expression 
exhibited by the saline control and atomoxetine treated mice (figures 4.16A-C, table
4.2). A significant main effect of both time and treatment upon c-Fos expression in 
the CA1 region was demonstrated (df=3, F=15.482, PO.OOl and df=2, F=35.465, 
PO.OOl respectively), in addition to a significant interaction of time and treatment 
(df=6 , F=10.475, PO.OOl). Post-hoc analysis revealed c-Fos expression in the CA1 
region of mice who had undergone methylphenidate treatment was significantly 
greater than that of both the atomoxetine treated mice and the saline control (both 
PO.OOl). c-Fos was expressed with a significant rhythm in the DG region of the 
atomoxetine treated mice, with an acrophase of ZT2, whereas its expression was not 
rhythmic in the same region of the methylphenidate treated mice or the saline control 
(figures 4.16G-J, table 4.2). There was a significant main effect of both time and 
treatment upon c-Fos expression in the DG (df=3, F=8.957, PO.OOl and df=2, 
F=23.823, PO.OOl respectively), with post-hoc testing revealing an increase in c- 
Fos expression in the DG of both methylphenidate and atomoxetine treated mice in 
comparison to the saline control (PO.OOl, PO.05 respectively). Furthermore, c-Fos 
expression in the DG was increased in the methylphenidate treated mice in 
comparison to the mice that had undergone atomoxetine treatment (PO.Ol). There 
was however no significant interaction of time and treatment upon c-Fos expression 
in the DG.
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Figure 4.16. c-Fos immunoreactivity measured by immunoreactive cell counts in the 
CA1, CA3, DG, BLA and CEA o f mice that underwent chronic treatment o f either a
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saline control (SAL), methylphenidate (MPD) or atomoxetine (ATO). Presence o f a
fitted curve indicates a significant rhythm as assessed by co-sinor analysis.
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Figure 4.17. Photomicrographs o f c-Fos immunostaining in the hippocampus 
(dashed box = CA1, solid ellipse = CA3, dotted box = DG, scale bars = 200pm) and 
in the BLA and CEA during the early subjective day (ZT2) and early subjective night 
(ZT14) o f mice that underwent chronic treatment o f either methylphenidate (MPD), 
atomoxetine (ATO) or a saline control (SAL). (Scale bars = 100pm for BLA and 
CEA).
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4.3.3 Circadian clock protein expression in the cerebral cortex
Clock expression in the cerebral cortex
CLOCK was expressed without significant rhythmicity in the CC, PLC and ILC of 
the saline control mice and the methylphenidate treatment group (figures 4.18A-B, 
4.18D-E, 4.18G-H, 4.19, table 4.3). Whilst CLOCK was expressed without 
significant rhythmicity in the PLC and ILC of the atomoxetine treatment group 
(figures 4.18F, 4.18J, 4.19, table 4.3), there was a significant rhythm of CLOCK 
expression with an acrophase at ZT2 in the CC of the atomoxetine treatment group 
(figures 4.18C, 4.19, table 4.3). There was however no significant effects of time, 
treatment, or interaction of time and treatment upon CLOCK expression in the PLC 
or ILC, and in the CC.
Brain region Acrophase o f Immunoreactivity (h)
Treatment CLOCK PERI PER2 c-Fos
CC SAL n.s. n.s. n.s. n.s.
MPD n.s. n.s. n.s. n.s.
ATO ~ZT2 n.s. n.s. n.s.
PLC SAL n.s. n.s. n.s. n.s.
MPD n.s. n.s. n.s. n.s.
ATO n.s. n.s. n.s. n.s.
ILC SAL n.s. n.s. n.s. n.s.
MPD n.s. n.s. n.s. n.s.
ATO n.s. n.s. n.s. -ZT18
Table 4.3. Acrophases of rhythmic immunoreactivity of CLOCK, PERI, PER2 and 
c-Fos in the cerebral cortex of each treatment group; saline (SAL), methylphenidate 
(MPD) and atomoxetine (ATO), assessed by co-sinor analysis, n.s = not significantly 
rhythmic.
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Figure 4.18. CLOCK immunoreactivity measured by immunoreactive cell counts in 
the CC, PLC and ILC o f mice chronically treated with either saline control (SAL), 
methylphenidate (MPD) or atomoxetine (ATO). A fitted curve indicates a significant 
rhythm assessed by co-sinor analysis.
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Figure 4.19. Photomicrographs o f CLOCK immunostaining in the CC, PLC and ILC 
o f mice that underwent chronic treatment o f either methylphenidate (MPD), 
atomoxetine (ATO) or a saline control (SAL) during the early subjective day (ZT2) 
and early subjective night (ZT14). Scale bars = 100pm.
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Perl expression in the cerebral cortex
PERI was expressed in the CC, PLC and ILC o f the saline control mice and in the 
methylphenidate and atomoxetine treatment groups (figure 4.21), without significant 
rhythmicity in each case (figures 4.20A-J, table 4.3). There was also no significant 
main effect o f treatment or interaction o f time and treatment upon PERI expression 
in either o f these regions. There was however a significant main effect o f time upon 
PERI expression in the CC (df=3, ^=3.364, P<0.05), whilst there was no significant 
effect o f time upon PERI expression in the PLC and ILC.
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Figure 4.20. PERI immunoreactivity measured by immunoreactive cell counts in the 
CC, PLC and ILC o f mice chronically treated with either saline control (SAL), 
methylphenidate (MPD) or atomoxetine (ATO). A fitted curve indicates a significant 
rhythm as assessed by co-sinor analysis.
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Figure 4.21. Photomicrographs o f PERI immunostaining in the CC during the mid
subjective day (ZT8) and mid subjective night (ZT20) and in the PLC and ILC 
during the early subjective day (ZT2) and early subjective night (ZT14).of mice that 
underwent chronic treatment o f either methylphenidate (MPD), atomoxetine (ATO) 
or a saline control (SAL). Scale bars = 100pm.
Per 2 expression in the cerebral cortex
Whilst PER2 was expressed in all regions o f the cerebral cortex examined in all three 
treatment groups (figure 4.23), it was not significantly rhythmic in any o f these cases 
(figures 4.22A-J, table 4.3). There was also no significant main effect o f treatment or 
interaction o f time and treatment upon PER2 expression in any o f these brain 
regions. A significant main effect o f time upon PER2 expression in the CC was 
observed (df=3, F=3.721, P<0.05), whilst there was no effect o f time upon PER2 
expression in the PLC and ILC.
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Figure 4.22. PER2 immunoreactivity measured by immunoreactive cell counts in the 
CC, PLC and ILC o f mice chronically treated with either saline control (SAL), 
methylphenidate (MPD) or atomoxetine (ATO). A fitted curve indicates a significant 
rhythm as assessed by co-sinor analysis.
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Figure 4.23. Photomicrographs o f PER2 immunostaining in the CC, PLC and ILC of 
mice that underwent chronic treatment o f either methylphenidate (MPD), 
atomoxetine (ATO) or a saline control (SAL) during the early subjective day (ZT2) 
and early subjective night (ZT14). Scale bars = 100pm.
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c-Fos expression in the cerebral cortex
c-Fos was expressed in all three regions examined of the cerebral cortex in all three 
treatment groups (figure 4.25) and this was without rhythmicity in these regions of 
the methylphenidate treatment group and the saline control (figures 4.24A-B, 4.24D- 
E, 4.24G-H, table 4.3). c-Fos was not rhythmically expressed in the CC and PLC of 
the atomoxetine treatment group (figures 4.24C, 4.24F, table 4.3), however there was 
a significant rhythm of c-Fos expression in the ILC of these mice with an acrophase 
at -ZT18 (figure 4.24J, table 4.3). A significant main effect of treatment upon c-Fos 
expression in the PLC and ILC (df=2, F=18.925, P>0.001; df=2, F=19.029, PO.OOl 
respectively) and in the CC was shown (df=2, F= 17.643, PO.OOl). Post-hoc analysis 
revealed significantly greater c-Fos expression in the CC, PLC and ILC of the 
methylphenidate treatment group in comparison to both the atomoxetine treatment 
group and the saline control (all PO.OOl). A significant effect of time upon c-Fos 
expression was also observed in the CC (df=3, F=12.456, PO.OOl), PLC (df=3, 
F=5.675, PO.Ol) and ILC (df=3, F=8.027, PO.OOl). There was no significant 
interaction of time and treatment in any of the regions examined.
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Figure 4.24. c-Fos immunoreactivity measured by immunoreactive cell counts in the 
CC, PLC and ILC o f mice chronically treated with either saline control (SAL), 
methylphenidate (MPD) or atomoxetine (ATO). A fitted curve indicates a significant 
rhythm as assessed by co-sinor analysis.
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Figure 4.25. Photomicrographs o f c-Fos immunostaining in the CC and PLC (early 
subjective day (ZT2) and early subjective night (ZT14) and in the ILC (mid 
subjective day (ZT8) and mid subjective night (ZT20) o f mice chronically treated 
with MPD, ATO or a saline control (SAL). Scale bars = 100pm.
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4.3.4 Circadian clock protein expression in the striatum
CLOCK expression in the striatum
CLOCK was expressed in all three regions of the striatum examined; CPu, nucleus 
accumbens core (AcbC) and nucleus accumbens shell (AcbSh), in the saline control 
mice and in both the atomoxetine and methylphenidate treated mice (figure 4.27). 
The expression of CLOCK in the saline control mice was significantly rhythmic in 
the CPu with an acrophase at ZT20 (figure 4.26A, table 4.4), but did not exhibit 
rhythmicity in either AcbC or AcbSh (figures 4.26D, 4.26G, table 4.4). CLOCK 
expression was also rhythmic in the CPu of the methylphenidate and atomoxetine 
treated mice, but with an acrophase at ZT2 and ~ ZT5 respectively (figures 4.26B-C, 
table 4.4). CLOCK did not exhibit rhythmic expression in either the AcbC or AcbSh 
regions of the methylphenidate and atomoxetine treated mice, similarly to the saline 
control (figures 4.26E-F, 4.26H-J, table 4.4). No significant main effect of treatment 
upon CLOCK expression in the CPu, AcbC or AcbSh were detected, and there was 
no significant effect of time upon CLOCK expression in the AcbC and AcbSh, whilst 
there was a significant effect of time upon CLOCK expression in the CPu (df=3, 
F=6.759, PO.Ol). A significant interaction of time and treatment upon CLOCK 
expression was also detected in the CPu (df=6 , F=2.816, PO.05), but not in the 
AcbC and AcbSh.
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Brain Acrophase of Immunoreactivity (h)
region Treatment CLOCK PERI PER2 c-Fos
CPu SAL -ZT20 ~ZT2 ~ZT2 n.s.
MPD ~ZT2 ~ZT2 -ZT14 n.s.
ATO ~ZT5 ~ZT2 ~ZT2 n.s.
AcbC SAL n.s. n.s. n.s. n.s.
MPD n.s. n.s. n.s. n.s.
ATO n.s. n.s. n.s. n.s.
AcbSh SAL n.s. n.s. n.s. n.s.
MPD n.s. n.s. -ZT20 n.s.
ATO n.s. n.s. n.s. n.s.
Table 4.4. Acrophases of rhythmic immunoreactivity of CLOCK, PERI, PER2 and 
c-Fos in the striatum of each treatment group; saline (SAL), methylphenidate (MPD) 
and atomoxetine (ATO), assessed by co-sinor analysis. n.s=not significantly 
rhythmic.
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Figure 4.26. CLOCK immunoreactivity measured by immunoreactive cell counts in 
the CPu, AcbC and AcbSh of mice chronically treated with saline control (SAL), 
MPD or ATO. A fitted curve = significant rhythm as assessed by co-sinor analysis. 
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Figure 4.27. Photomicrographs o f CLOCK immunostaining measured by 
immunoreactive cell counts in the CPu (mid subjective day (ZT8) and mid subjective 
night (ZT20) and in the AcbC and AcbSh (early subjective day (ZT2) and early 
subjective night (ZT14) o f mice that underwent chronic treatment o f MPD, ATO or a 
saline control (SAL) Scale bars = 100pm.
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PERI expression in the striatum
PERI expression was rhythmic in the CPu of all treatment groups, with an acrophase 
at ZT2 in each case (figures 4.28A-C, table 4.4). No significant effect of treatment 
upon PERI expression in the CPu was detected, although there was a significant 
effect of time upon PERI expression in the CPu (df=3, F=4.399, PO.Ol), and a 
significant interaction of time and treatment (df=6 , F=2.813, PO.05).
PERI expression was not rhythmic in the either the AcbC or AcbSh regions of all 
three treatment groups (figures 4.28D-J, table 4.4), although a significant main effect 
of treatment upon PERI expression in the AcbC and AcbSh was detected (df=2, 
F=3.915, PO.05 and df=2, F=3.651, PO.05 respectively). Post-hoc analysis 
revealed a significant increase in PERI expression in the AcbC of the 
methylphenidate treatment group compared to the atomoxetine treatment group 
(PO.05) and significantly greater PERI expression in the AcbSh of the 
methylphenidate treatment group compared to the saline control (P<0.05). There was 
however no significant main effects of time or interaction of time and treatment upon 
PERI expression in the AcbC and AcbSh.
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Figure 4.28. PERI immunoreactivity measured by immunoreactive cell counts in the 
CPu, AcbC and AcbSh o f mice chronically treated with either saline control (SAL), 
methylphenidate (MPD) or atomoxetine (ATO). A fitted curve indicates a significant 
rhythm assessed by co-sinor analysis.
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Figure 4.29. Photomicrographs o f PERI immunostaining measured by 
immunoreactive cell counts in the CPu, AcbC and AcbSh of mice that underwent 
chronic treatment o f MPD, ATO or a saline control (SAL) during the early subjective 
day (ZT2) and early subjective night (ZT14). Scale bars = 100pm.
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PER2 expression in the striatum
PER2 expression was not rhythmic in the AcbC and AcbSh regions in the saline 
control mice (figures 4.30D, 4.30G, table 4.4), whereas PER2 expression was 
rhythmic in the CPu of these mice, with an acrophase at ZT2 (figure 4.30A table 
4.4). PER2 expression was also not rhythmic in the AcbC regions of the 
methylphenidate and atomoxetine treated mice and in the AcbSh region of the 
atomoxetine treated mice (figures 4.30E-F, 4.30J, table 4.4), although rhythmic 
expression of PER2 was demonstrated in the AcbSh of methylphenidate treated 
mice, with an acrophase at ZT20 (figure 4.30H, table 4.4). The phase of PER2 
expression in the CPu of atomoxetine treated mice was unaltered from the saline 
control, with peak expression at ZT2 (figure 4.30C, table 4.4), whereas PER2 
expression in the CPu of the methylphenidate treated mice was phase reversed with 
an acrophase at ZT14 (figure 4.30B, table 4.4).
A significant main effect of treatment upon PER2 expression in the CPu was shown 
(df=2, F=31.512, P<0.001) and post-hoc analysis demonstrated that PER2 expression 
in the CPu of mice that had undergone both methylphenidate and atomoxetine 
treatments was elevated in comparison to that of the saline control (PO.OOl). 
Furthermore, PER2 expression was increased in the CPu of methylphenidate treated 
mice in comparison to the atomoxetine treated mice (PO.Ol). There was also a 
significant effect of time (df=3, F=2.874, PO.05) and a significant interaction of 
time and treatment (df=6 , F=5.944, PO.OOl) upon PER2 expression in the CPu.
Significant main effects of both time and treatment upon PER2 expression were also 
demonstrated in the AcbC (df=3, F=6.784, PO.Ol and df=2, F=6.618, PO.Ol 
respectively), with a significant increase in PER2 expression in the atomoxetine 
treatment group compared to the saline control (PO.Ol). There was no significant 
main effect of treatment or time upon PER2 expression in the AcbSh, and no 
significant interaction of time or treatment upon PER2 expression in the AcbC and 
AcbSh.
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Figure 4.30. PER2 immunoreactivity measured by immunoreactive cell counts in the 
CPu, AcbC & AcbSh o f mice chronically treated with saline control (SAL), MPD or 
ATO. A fitted curve indicates a significant rhythm assessed by co-sinor analysis.
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Figure 4.31. Photomicrographs o f PER2 immunostaining in the CPu and AcbC
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during the early subjective day (ZT2) and early subjective night (ZT14) and in the 
AcbSh during the mid subjective day (ZT8) and mid subjective night (ZT20) o f mice 
that underwent chronic treatment o f MPD, ATO or a saline control (SAL). Scale bars 
-  100pm.
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c-Fos expression in the striatum
c-Fos expression was not rhythmic in the AcbC, AcbSh and CPu regions of the saline 
control, methylphenidate and atomoxetine treated mice (figures 4.32A-J, table 4.4). 
However, ANOVA revealed significant main effects of both treatment and time upon 
c-Fos expression in the CPu (df=2, F=47.708, PO.OOl and df=3, F=8.804, PO.OOl 
respectively), and a significant interaction of time and treatment (df=6 , F=2.401, 
PO.05). Post-hoc testing showed an elevation of c-Fos expression in the CPu of 
both the methylphenidate and atomoxetine treated mice (PO.OOl and PO.Ol 
respectively) in comparison to the saline control. c-Fos expression was also greater in 
the CPu of the methylphenidate treated mice than the atomoxetine treatment group 
(PO.OOl). There was also a significant main effect of treatment upon c-Fos 
expression in AcbC and AcbSh (df=2, F=7.077, PO.Ol and df=2, .F=l 1.223, 
PO.OOl), with post-hoc testing revealing a significant increase in c-Fos expression 
in the AcbC of the methylphenidate treatment group compared to the atomoxetine 
treatment group (PO.Ol) and significantly increased expression of c-Fos in the 
AcbSh of the methylphenidate treated mice in comparison to the atomoxetine treated 
mice and the saline control (PO.OOl and PO.Ol respectively). There was also a 
significant main effect of time upon the expression of c-Fos in the AcbSh (df=3, 
F=4.587, PO.Ol), but not in the AcbC, whilst there was no significant interaction of 
time and treatment in either region.
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Figure 4.32. c-Fos immunoreactivity measured by immunoreactive cell counts in the 
CPu, AcbC and AcbSh o f mice chronically treated with saline control (SAL), MPD 
or ATO. A fitted curve = significant rhythm, as assessed by co-sinor analysis.
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Figure 4.33. Photomicrographs o f c-Fos immunostaining in the CPu, AcbC and
- •
  - I .  .
AcbSh of mice that underwent chronic treatment o f either methylphenidate (MPD), 
atomoxetine (ATO) or a saline control (SAL) during the early subjective day (ZT2) 
and early subjective night (ZT14). Scale bars = 100pm.
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4.3.5 Circadian clock protein expression in the ventral tegmental area
CLOCK expression in the VTA
CLOCK was expressed in the VTA of all treatment groups without significant 
rhythmicity as assessed by co-sinor (figures. 4.34-4.35, table 4.5), and no significant 
main effects of time, treatment or interactions of time and treatment upon VTA 
CLOCK expression were detected.
Brain
region Treatment
Acrophase of Immunoreactivity (h)
CLOCK PERI PER2 c-Fos
VTA SAL n.s. n.s. -ZT14 -ZT20
MPD n.s. n.s. n.s. -ZT20
ATO n.s. n.s. n.s. n.s.
Table 4.5. Acrophases of rhythmic immunoreactivity of CLOCK, PERI, PER2 and 
c-Fos in the VTA of each treatment group; saline (SAL), methylphenidate (MPD) 
and atomoxetine (ATO), assessed by co-sinor analysis. n.s = not significantly 
rhythmic.
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Figure 4.34. CLOCK immunoreactivity measured by immunoreactive cell counts in 
the VTA of mice that underwent chronic treatment o f saline control (SAL), MPD or 
ATO. A fitted curve = significant rhythm, as assessed by co-sinor analysis.
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Figure 4.35. Photomicrographs o f CLOCK immunostaining in the VTA o f mice that 
underwent chronic treatment o f either methylphenidate (MPD), atomoxetine (ATO) 
or a saline control (SAL) during the early subjective day (ZT2) and early subjective 
night (ZT14). Scale bars = 100pm.
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PERI expression in the VTA
PERI was expressed in the VTA o f all treatment groups (figure 4.37), however its 
expression was not significantly rhythmic in each case (figure 4.36, table 4.5). There 
was however a significant main effect o f treatment upon PERI expression in the 
VTA (df=2, 7^ = 18.181, P<0.001). Post-hoc testing revealed a significant increase in 
PERI expression in the VTA o f the atomoxetine treatment group in comparison to 
both the methylphenidate treatment group and the saline control (P<0.01 and 
PO.OOl respectively). Furthermore, PERI expression was also greater in the VTA o f 
the methylphenidate treatment group than in that o f the saline control (P<0.05). No 
significant main effects o f time or interaction o f time and treatment upon PERI 
expression were detected.
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Figure 4.36. PERI immunoreactivity measured by immunoreactive cell counts in the 
VTA o f mice that underwent chronic treatment o f either a saline control (SAL), 
methylphenidate (MPD) or atomoxetine (ATO). Presence o f a fitted curve indicates a 
significant rhythm as assessed by co-sinor analysis.
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Figure 4.37. Photomicrographs o f PERI immunostaining in the VTA o f mice that 
underwent chronic treatment o f either methylphenidate (MPD), atomoxetine (ATO) 
or a saline control (SAL) during the early subjective day (ZT2) and early subjective 
night (ZT14). Scale bars = 100pm.
PER2 expression in the VTA
PER2 expression was significantly rhythmic, with an acrophase at ZT14 in the VTA 
of the saline control group (figure 4.38A, table 4.5), whilst its expression was not 
significantly rhythmic in the VTA of the methylphenidate and atomoxetine treatment 
groups (figures. 4.38B-C, table 4.5). There was also a significant main effect o f time 
upon PER2 expression in the VTA (df=3, F=4.000, P<0.05), although there was no 
significant effect o f treatment or interaction o f time and treatment.
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Figure 4.38. PER2 immunoreactivity measured by immunoreactive cell counts in the 
VTA o f mice that underwent chronic treatment o f either a saline control (SAL), 
methylphenidate (MPD) or atomoxetine (ATO). Presence o f a fitted curve indicates a 
significant rhythm as assessed by co-sinor analysis.
ATO
Figure 4.39. Photomicrographs o f PER2 immunostaining in the VTA o f mice that 
underwent chronic treatment o f either methylphenidate (MPD), atomoxetine (ATO) 
or a saline control (SAL) during the early subjective day (ZT2) and early subjective 
night (ZT14). Scale bars = 100pm.
195
c-Fos expression in the VTA
c-Fos was expressed with a significant rhythm in the VTA o f the saline control and 
the methylphenidate treatment groups, with an acrophase at ZT20 in both cases 
(figures. 4.40A-B, table 4.5), whereas c-Fos expression in the VTA o f the 
atomoxetine treatment group did not exhibit significant rhythmicity (figure 4.40C, 
table 4.5). A significant main effect o f treatment upon c-Fos expression was 
observed in the VTA (df=2, F=25.803, PO.OOl), and post-hoc  testing revealed a 
significant increase in c-Fos expression in the VTA of the methylphenidate treatment 
group compared to both the atomoxetine treatment group and the saline control 
(PO.OOl in both cases). There was also a significant main effect o f time upon VTA 
c-Fos expression (df=3, F = 1 1.271, PO.OOl), and a significant interaction o f time 
and treatment (df=6, F=2.848, PO .05).
(A) VTA SAL (B) VTA MPD tC) VTA ATO
4 OE-514 OE-54 OE-5
OE-5 I I 3 OE-5
c 2"
2 OE-5
-€»»
£  1 0E-5
2 5 2 OE-5-| | 2 OE-5 IOE-5 i C - -J-'C '2 8
Zeitgeber tim e (h)
2 8 14 20
Zeitgeber time (h) Zeitgeber time (h)
Figure 4.40. c-Fos immunoreactivity measured by immunoreactive cell counts in the 
VTA of mice that underwent chronic treatment o f saline control (SAL), MPD or 
ATO. Fitted curve = significant rhythm as assessed by co-sinor analysis.
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Figure 4.41. Photomicrographs o f c-Fos immunostaining in the VTA o f mice that 
underwent chronic treatment o f either methylphenidate (MPD), atomoxetine (ATO) 
or a saline control (SAL) during the mid subjective day (ZT8) and mid subjective 
night (ZT20). Scale bars = 100pm
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4.4 Discussion
Chronic administration of both methylphenidate and atomoxetine was shown to exert 
a number of effects upon the expression of clock proteins and the c-Fos protein, a 
marker of neuronal activation.
4.4.1 Circadian clock protein expression in the hypothalamus 
SCN
Constitutive expression of CLOCK and robust rhythms of PERI and PER2 
expression peaking during the early subjective night were demonstrated in the master 
pacemaker of the SCN of the saline treated mice, which is in agreement with well 
documented findings in the literature (Gekakis et al., 1998, Field et al., 2000). c-Fos 
was rhythmically expressed in the SCN of the saline treated mice, with peak 
expression in the mid subjective day. Neither methylphenidate nor atomoxetine 
altered the circadian profiles of PERI, CLOCK or c-Fos. However, c-Fos expression 
was increased in the SCN by atomoxetine treatment compared to that of the 
methylphenidate treated mice, thus suggesting that atomoxetine may activate the 
SCN to a greater extent than methylphenidate.
Methylphenidate reduced PER2 expression in the SCN, and atomoxetine reduced 
SCN PER2 expression further still. Furthermore, the expression of PER2 was 
completely phase reversed in the SCN of methylphenidate treated mice, exhibiting an 
acrophase in the early subjective day to coincide with the time of injection. This is of 
particular interest since the development of a rat anticipatory locomotor rhythm in 
response to chronic methylphenidate treatment of an equivalent dose as used in the 
present study has been reported (Algahim et al., 2009). These findings would also 
suggest that both methylphenidate and atomoxetine may modulate the master 
circadian clock via the alteration of PER2 expression, with the greatest effect being 
exerted by methylphenidate.
The ability of chronic methylphenidate administration to alter the phase of PER2 
expression in the SCN is in contrast to the effects of chronic administration of the
197
psychostimulant methamphetamine, which has been shown to not affect SCN clock 
gene expression including PER2 (Masubuchi et al., 2000, Iijima et al., 2002). 
However it is worth noting that these studies have assessed circadian clock gene 
expression, and whilst SCN PER2 protein expression is altered in the present study, 
this may not necessarily mean that the rhythm of PER2 mRNA is altered in the same 
manner, as a functional disconnection between clock genes and their protein products 
has been documented (Reddy et al., 2006). Hence the unaltered circadian clock gene 
mRNA observed in the SCN after chronic methamphetamine treatment may not 
necessarily translate to unaltered profiles of circadian clock gene protein product 
expression.
Dopamine and its associated neurons have been implicated in SCN functioning, 
including in the entrainment of the master pacemaker and in the regulation of light 
input to the retina (Witkovsky, 2004, McClung et al., 2005). The rhythm of 
noradrenaline in the SCN is driven by the master pacemaker, independently of light 
input (Cagampang et al., 1994) and it has been proposed as an entrainment signal 
from the SCN to the peripheral oscillator of the pineal gland, hence exerting 
regulation of melatonin production (Wongchitrat et al., 2009). It is therefore possible 
that since methylphenidate is an inhibitor of dopamine and noradrenaline re-uptake 
by DAT and NET (Madras et al., 2005, Kim et al., 2010), and atomoxetine 
selectively inhibits NET mediated noradrenaline removal (Kim et al., 2010), the 
subsequent increases in synaptic dopamine and noradrenaline could impact upon 
these aspects of the circadian system. Moreover, since the SCN is the site of the 
master circadian pacemaker, and PER2 is a core clock protein in the molecular 
mechanism that drives circadian rhythms (Gekakis et al., 1998, van der Horst et al., 
1999, Reppert and Weaver, 2001, Guilding and Piggins, 2007), any alteration in its 
rhythm could have knock on effects upon not only the other core clock genes and 
their protein products but also the expression of clock controlled genes and therefore 
could ultimately affect the physiological and behavioural processes that are regulated 
by them.
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DMH
In the present study PER2 was not rhythmically expressed in the DMH of the saline 
treated mice, and this was in agreement with previous findings (Feillet et al., 2008), 
and furthermore PER2 expression was unaltered by methylphenidate and 
atomoxetine. CLOCK, PERI and c-Fos were rhythmically expressed in the DMH of 
the saline treated mice, with CLOCK and PERI expression peaking around the mid 
subjective day as previously documented (Feillet et al., 2008, Wyse and Coogan, 
2010), whilst c-Fos peak expression occurred in the early subjective night. The 
effects of chronic methylphenidate and chronic atomoxetine treatment upon CLOCK, 
PERI and c-Fos expression in the DMH were very similar, with a phase shift in 
expression of the three proteins, peaking in the early lights-on phase at the time of 
treatment administration in each case. This would suggest that in the DMH, the 
mechanism by which these drugs elicit phase shifts share similar properties. 
However, only methylphenidate induced neuronal activation of the DMH, as 
demonstrated by an increase in c-Fos expression.
The DMH receives efferents from the SCN, and is thought to be a major output 
nucleus of the master pacemaker (Saper et al., 2005), with roles in the circadian 
regulation of various behaviours, including the autonomic stress response, feeding, 
rhythmic corticosteroid production and the regulation of sleep (Bellinger et al., 1976, 
Kalsbeek et al., 1996, Bemardis and Bellinger, 1998, DiMicco et al., 2002, Chou et 
al., 2003). This is of particular interest since methylphenidate and atomoxetine 
mediated sleep alterations have been documented in ADHD (Sangal et al., 2006, 
Boonstra et al., 2007, Sobanski et al., 2008). It could therefore be postulated that 
these effects upon sleep may occur in part through modulation of circadian 
functioning in the DMH.
Furthermore, numerous studies have documented an association of altered HPA-axis 
activity with various aspects of ADHD (Virkkunen, 1985, Moss et al., 1995, Hanna 
et al., 1996, Gaub and Carlson, 1997, Gershon, 2002, Hong et al., 2003, Blomqvist et 
al., 2007, Sondeijker et al., 2007, Lackschewitz et al., 2008, Hastings et al., 2009, 
van West et al., 2009), and alterations in HPA axis activity by both atomoxetine 
(Chamberlain et al., 2007a, Sofuoglu et al., 2009) and methylphenidate (Joyce et al.,
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1986) have been reported, although a lack of effect of methylphenidate upon plasma 
cortisol in ADHD has also been shown (Lee et al., 2008). Due to the role the DMH 
plays in the stress response and the circadian rhythm of corticosteroid production 
(Bellinger et al., 1976, Kalsbeek et al., 1996, Bemardis and Bellinger, 1998, 
DiMicco et al., 2002, Chou et al., 2003), it is plausible that the observed effects of 
ADHD medication upon circadian clock protein expression in the DMH could 
impact upon these processes also.
In addition to time-keeping signals originating from the SCN, the DMH also receives 
input from other regions of the hypothalamus, cortex, hippocampus and brainstem 
(Thompson and Swanson, 1998), and thus may be involved in the incorporation of 
the two, enabling optimal functioning to suit the behavioural state (Chou et al., 
2003). Therefore any alteration in circadian functioning in the DMH could 
consequently affect the circadian functioning of these brain regions, and vice versa.
PVN
PERI and PER2 were rhythmically expressed in the PVN of the saline treated mice, 
with peak expression in the early subjective night. An earlier study documented a 
similar rhythm of PER2 expression although PERI expression was shown to be 
arrhythmic (Feillet et al., 2008). In the present study CLOCK expression was 
rhythmic in the PVN peaking in the mid subjective day of these mice in accordance 
with previous reports (Wyse and Coogan, 2010). c-Fos was also rhythmically 
expressed in the saline treated mice with peak expression during the mid subjective 
day.
Both atomoxetine and methylphenidate affected circadian clock protein expression in 
the PVN. Atomoxetine treatment caused phase shifts in CLOCK and PER2 with peak 
expression earlier in the subjective day and in the mid subjective night respectively, 
whilst the rhythmic expression of PERI and c-Fos were completely phase reversed to 
peak in the early subjective day and mid subjective day respectively. In comparison 
only the rhythmic expression of CLOCK and PERI were altered in the PVN of the 
methylphenidate treated mice, with peak CLOCK expression occurring earlier in the 
subjective day, as seen in the atomoxetine treatment group, and there was a loss of
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rhythmic PERI expression. Methylphenidate and atomoxetine had opposing effects 
upon the level of PERI expression, with methylphenidate being shown to increase 
PERI expression, whereas atomoxetine treatment reduced the expression of PERI in 
the PVN. PER2 expression in the PVN was dampened by both methylphenidate 
treatment, and to a greater degree atomoxetine treatment. CLOCK expression was 
also reduced in the PVN by both methylphenidate and atomoxetine treatment. This 
therefore indicated that atomoxetine not only had a greater influence than 
methylphenidate upon circadian clock protein expression in the PVN, but 
atomoxetine also altered the rhythm of neuronal activation in this brain region, as 
indicated by the phase shift of c-Fos expression.
Direct projections from the DMH to the PVN indicate a functional link between the 
two hypothalamic regions (ter Horst and Luiten, 1986, Thompson et al., 1996, 
Elmquist et al., 1998, Chou et al., 2003), and hence it is not surprising that circadian 
alterations by methylphenidate and atomoxetine are observed in both of these 
regions. The PVN has also been implicated in the regulation of SCN driven 
melatonin rhythms (Klein et al., 1983, Vrang et al., 1995, Chou et al., 2003). 
Similarly to the DMH, the PVN has also been implicated in the regulation of 
corticosteroid release (Tokunaga et al., 1986, Chou et al., 2003) and the HPA-axis 
mediated stress response (Thome et al., 2000), and therefore any modulation of 
circadian clock protein levels and its rhythmicity in the PVN by these drugs, could 
consequently influence these functions also.
4.4.2 Circadian clock protein expression in the limbic forebrain
In the present study PER2, CLOCK and c-Fos were not rhythmically expressed in 
the hippocampus and amygdala regions examined of the saline treated mice. PER2 
expression has been previously shown to be rhythmic in the mouse BLA, CEA, CA1, 
CA3 and DG regions (Lamont et al., 2005, Feillet et al., 2008, Wang et al., 2009). 
Whilst CLOCK expression has been shown to oscillate in the DG, BLA and CEA, 
and to be arrhythmic in the CA1 and CA3 regions of young adult mice (Wyse and 
Coogan, 2010).
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PERI was expressed rhythmically in the CA1 and CA3 regions of the saline treated 
mice with peak expression in the early subjective day, whilst PERI expression was 
not rhythmic in the DG, BLA and CEA regions in the saline treated mice. A previous 
study has also demonstrated arrhythmic PERI expression in the BLA, and rhythmic 
PERI expression in the CA1 with an acrophase in the late subjective night, although 
unlike the present study PERI expression was also rhythmic in the CEA and DG 
regions with acrophases in the mid and late subjective night respectively (Feillet et 
al., 2008). PERI gene expression has also been shown to be rhythmic in the rat 
hippocampus and amygdala (Li et al., 2009a).
However when drawing comparisons between the current data and other studies a 
number of factors, which could impact upon the patterns of clock gene and protein 
expression should be noted. Firstly, in the present study circadian rhythms of clock 
protein expression were assessed by immunohistochemical analysis at four six- 
hourly time-points across the cycle, and therefore there may not be the temporal 
resolution to detect significant rhythmicity as documented in other studies that have 
examined circadian rhythms at more frequent time-points. Secondly, as previously 
mentioned a functional disconnection between clock genes and their protein products 
has been documented (Reddy et al., 2006), and hence rhythmic gene expression may 
not necessarily translate to a similar protein expression profile. Thirdly, not only may 
there be differences in the pharmacokinetics of rats and mice (Koda et al., 2010), but 
also mouse strain differences in the circadian system, including the endogenous 
period and phase shifting light responses have been reported (Schwartz and 
Zimmerman, 1990, Hofstetter et al., 1995, Feillet et al., 2008), and lastly age has also 
been shown to impact upon circadian clock gene and protein expression (eg Ando et 
al. 2010, Wyse and Coogan, 2010).
Methylphenidate treatment resulted in the loss of rhythmic PERI expression in the 
CA1 and CA3 regions, an effect also observed upon PERI gene expression in the 
hippocampus of rats undergoing withdrawal after chronic morphine treatment (Li et 
al., 2009a). PERI expression in the CA1 and CA3 regions was unaltered by 
atomoxetine treatment. However, atomoxetine did induce rhythmic expression of 
clock proteins that were otherwise arrhythmic in the saline control mice. These 
included PER2 expression in the CA1 and CEA regions with acrophases in the early
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subjective day and mid subjective night respectively, and a rhythm o f CLOCK 
expression in the BLA peaking in the early subjective day. The increase in c-Fos 
expression indicated that methylphenidate caused an increase in neuronal activation 
throughout the limbic forebrain, whereas atomoxetine only exerted an effect upon 
neuronal activation in the DG, and this was to a lesser degree than that o f 
methylphenidate. Furthermore, methylphenidate treatment induced a rhythm o f c-Fos 
expression in the CA1 region, and atomoxetine treatment induced a rhythm o f c-Fos 
expression in the DG, indicating that neuronal activation in response to these drugs is 
subject to regulation by a circadian oscillator in these regions.
The main functions o f the amygdala are thought to be involved with the reward 
system, and in forming associations between negative emotional stimuli and 
environmental cues (LeDoux, 2000, Davis and Whalen, 2001, Koob and Le Moal, 
2001, Everitt et al., 2003, Nestler and Carlezon, 2006). Whereas the hippocampus is 
implicated in the functions o f declarative memory and spatial learning (Nestler and 
Carlezon, 2006), and it has been postulated that these processes may be altered by 
disruptions in sleep and circadian rhythms (D ijk et al., 1992, Peigneux et al., 2004, 
Ellenbogen et al., 2006, Wright et al., 2006, Ruby et al., 2008, Wang et al., 2009). 
This is demonstrated by P E R 2  knockout mice that exhibit attenuated hippocampal 
long-term potentiation (Wang et al., 2009) and P E R I  knockout mice which 
demonstrate impaired performance on memory tasks (Jilg et al., 2010). Hence the 
alterations o f circadian protein expression in the limbic forebrain elicited by 
methylphenidate and atomoxetine could impact upon these processes also.
4 . 4 . 3  C i r c a d i a n  c l o c k  p r o t e i n  e x p r e s s i o n  i n  t h e  c e r e b r a l  c o r t e x
PERI, PER2, CLOCK and c-Fos were all arrhythmically expressed in the CC, PLC, 
and ILC o f the saline control mice. Atomoxetine was shown to have a greater effect 
upon the circadian clock proteins than methylphenidate, and this was in the CC 
where rhythmic expression o f CLOCK with an acrophase in the early subjective day 
and an increase in PER2 expression were observed. Atomoxetine also caused the 
expression o f c-Fos to be rhythmic in the ELC, with peak expression during the mid 
subjective night, indicating that atomoxetine induced circadian regulation o f 
neuronal activation in the ILC. Methylphenidate treatment however produced an
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increase in c-Fos expression in all three regions o f the cerebral cortex examined, thus 
demonstrating that whilst methylphenidate does not effect circadian functioning o f 
the cerebral cortex it does cause a widespread increase in neuronal activation 
throughout the region.
A  contributory factor to the greater effects o f atomoxetine upon cerebral cortex 
circadian clock protein expression observed could be an increased abundance o f NET 
compared to DAT, since this has been observed in the preffontal cortex (Gehlert et 
al., 1993, Soucy et al., 1997, Sesack et al., 1998, Koda et al., 2010). Furthermore, 
atomoxetine has been shown to increase dopamine levels in the preffontal cortex, due 
to the non-selective uptake o f dopamine by NET, which is blocked by atomoxetine 
(Bymaster et al., 2002, Koda et al., 2010).
The frontal cortex is known to be involved in working memory, attention, impulse 
control and other executive functions (Nestler and Carlezon, 2006), and as previously 
mentioned input to the DMH is received from the frontal cortex along with other 
brain regions to allow for the incorporation o f behavioural and time-keeping cues 
(Thompson and Swanson, 1998), and could therefore promote circadian regulation o f 
these behaviours associated with the frontal cortex, and for perturbations in circadian 
clock protein expression in the cerebral cortex to impact upon these behaviours.
4 . 4 . 4  C i r c a d i a n  c l o c k  p r o t e i n  e x p r e s s i o n  i n  t h e  s t r i a t u m
The expression o f PERI, PER2, CLOCK and c-Fos was not rhythmic in the AcbC 
and AcbSh o f the saline control. There have been mixed reports regarding the 
oscillation o f clock gene expression in the striatum. In accordance with the current 
findings, arrhythmic C L O C K  gene expression has been demonstrated in the nucleus 
accumbens o f the rat (L i et al., 2009a), whereas P E R  gene expression in the nucleus 
accumbens o f rats has been shown to be both rhythmic (L i et al., 2009a) and 
arrhythmic (Masubuchi et al., 2000). PERI, PER2 and CLOCK expression was 
rhythmic however in the CPu o f the saline control mice in the present study, with 
PERI and PER2 exhibiting acrophases in the early subjective day, and a CLOCK 
acrophase just after the mid subjective night. Again these protein profiles differ from 
the corresponding gene expression profiles reported in an earlier study, where P E R I
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and P E R 2  expression was shown to be rhythmic, whilst C L O C K  expression was 
arrhythmic in the CPu o f rats (Masubuchi et al., 2000).
Chronic methylphenidate treatment exerted a more widespread effect upon striatal 
protein expression than chronic atomoxetine treatment. The effects o f atomoxetine 
upon protein expression were mainly limited to the CPu, including an increase in 
PER2 and PERI expression, and a phase shift o f CLOCK expression to peak in the 
mid subjective day. Although an increase in PER2 expression in the AcbC by 
atomoxetine treatment was also observed, and this is in contrast with the effects o f 
the antidepressant fluoxetine, o f which chronic administration decreased striatal 
P E R 2  gene expression in the mouse striatum (Uz et al., 2005). However, whilst both 
atomoxetine and fluoxetine belong to the same class o f tri-cyclic antidepressants, 
they do differ in the their actions upon the catecholaminergic systems, with 
atomoxetine being primarily an inhibitor o f noradrenaline reuptake (Kim et al., 
2010), whereas fluoxetine is a 5-HT selective reuptake inhibitor (Thome et al., 
2000).
On the other hand, methylphenidate treatment exerted effects upon protein 
expression in all three regions o f the striatum examined, and showed similarities to 
the effects o f other psychostimulants upon the circadian system in the striatum. 
Methylphenidate phase reversed the rhythm o f PER2 expression in the CPu, with 
peak expression in the early subjective night, which is very similar to the effect upon 
P E R 2  expression in the CPu o f chronic methamphetamine treatment, which has been 
shown to phase reverse P E R 2  gene expression in this brain region (Masubuchi et al., 
2000). Similarly to the documented increase in striatal P E R I  expression by chronic 
cocaine treatment (Uz et al., 2005), PERI expression was increased by 
methylphenidate in all three striatal regions examined, but to a lesser degree in the 
CPu than exhibited by the atomoxetine treated mice. PER2 expression was also 
increased in the CPu by methylphenidate and this was to a greater degree than that o f 
the atomoxetine treated mice, but in contrast to the effect o f chronic cocaine 
treatment, which has been shown to decrease P E R 2  expression (Uz et al., 2005).
Similar to the effect o f atomoxetine, methylphenidate also phase shifted CLOCK 
expression in the CPu, but this was to an acrophase in the early subjective day, which
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was the time o f methylphenidate administration. Unlike atomoxetine, 
methylphenidate induced a rhythm o f PER2 expression in the AcbSh, and also 
modulated c-Fos expression, and this was in all three region o f the striatum, where its 
expression was increased in the CPu and AcbSh in comparison to both the saline and 
atomoxetine treated mice, and increased in the AcbC in comparison to the 
atomoxetine treated mice. This therefore indicated that methylphenidate increased 
neuronal activation throughout the striatum, and this is in agreement with findings 
that methylphenidate increased c - F o s  gene expression in the striatum (Yano and 
Steiner, 2005a, Yano and Steiner, 2005b, Steiner et al., 2010).
Furthermore the findings o f the present study that in comparison to the anti­
depressant atomoxetine, the psychostimulant methylphenidate exerted greater effect 
upon striatal clock gene expression, is in accordance with an earlier report that the 
psychostimulant cocaine exerted greater influence upon clock gene expression in the 
striatum than did the antidepressant fluoxetine (Uz et al., 2005). It is known that 
atomoxetine does not increase extracellular noradrenaline levels in the striatum 
(Koda et al., 2010), due to a lack o f NET as demonstrated by minimal 
immunoreactivity fibres (Schroeter et al., 2000), and this could therefore underlie the 
minimal effect o f atomoxetine upon striatal circadian clock protein expression in 
comparison to methylphenidate.
Whilst the effects o f methylphenidate upon the circadian system o f the striatum 
shared some similarities with the effects o f methamphetamine and cocaine, the effect 
upon all the proteins was not identical. The psychostimulants methylphenidate, 
methamphetamine and cocaine all share the pharmacological property to block 
reuptake o f dopamine and noradrenaline, thus enhancing their actions at postsynaptic 
receptors (Yano and Steiner, 2007, Steiner et al., 2010), and the systemic 
administration o f methylphenidate has been shown to have a potency that is 
equivalent to that o f cocaine and amphetamine (Parran and Jasinski, 1991, Massello 
and Carpenter, 1999, Algahim et al., 2009). However, cocaine and methamphetamine 
differ from methylphenidate as they both have the capacity to affect serotonin levels 
also (Russell, 2003, Yano and Steiner, 2007, Steiner et al., 2010), and it is therefore 
possible that it is these contrasting pharmacological properties that may be 
responsible for the differential molecular effects o f these drugs.
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Along with the VTA, the nucleus accumbens is heavily implicated in the brains 
reward system, with dopaminergic input to the nucleus accumbens from the VTA 
being central to drug reward (Wise, 1998, Koob and Le Moal, 2001, Nestler and 
Carlezon, 2006, Imbesi et al., 2009). Furthermore, the nucleus accumbens and CPu 
are thought to be involved in the rhythm o f locomotor activity and hyperactive 
behaviour (Masubuchi et al., 2000). It is therefore o f particular interest that 
methylphenidate exerts an effect upon circadian clock protein expression in the 
nucleus accumbens, since hyperactivity is a core symptom o f ADHD (Rosier et al., 
2004) and deficits in the circadian system have been shown to produce hyperactive 
behaviour as demonstrated by the CLOCK mutant mouse (McClung et al., 2005).
4 . 4 . 5  C i r c a d i a n  c l o c k  p r o t e i n  e x p r e s s i o n  i n  t h e  v e n t r a l  t e g m e n t a l  a r e a
PER2 and c-Fos were rhythmically expressed in the VTA o f the saline control mice 
with acrophases during the early and mid subjective night, whilst PERI and CLOCK 
were not. Previous research has documented rhythmic expression o f the P E R 2 , P E R I  
and C L O C K  genes in the rat VTA (L i et al., 2009a).
Both treatments influenced protein expression in the VTA. The rhythmicity o f PER2 
and c-Fos expression in the VTA were lost by both methylphenidate and atomoxetine 
treatment, although methylphenidate did cause an increases in c-Fos and PERI 
expression. Atomoxetine treatment caused a greater still increase in PERI expression 
than that o f methylphenidate, and also increased the expression o f CLOCK. This 
therefore indicated that not only did both treatments perturb circadian clock protein 
expression but also abolished the circadian rhythm o f neuronal activation, whilst 
methylphenidate also increased the degree o f neuronal activation in the VTA.
The VTA is involved in the regulation o f attention, memory, reward and motivation 
(Chudasama and Robbins, 2004, Wise, 2004, Nicola et al., 2005). Furthermore the 
VTA neurons are the main source o f dopamine projections to the limbic forebrain 
(Chudasama and Robbins, 2004, Wise, 2004, Nicola et al., 2005) and the VTA has 
been shown to part o f a synaptically linked circuit with the medial preoptic nucleus 
and the SCN (Luo and Aston-Jones, 2009). Moreover, CLOCK has been implicated 
in the regulation o f dopaminergic neurotransmission in the VTA, as part o f the
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reward circuit (McClung et al., 2005). It is therefore possible that an alteration in 
VTA functioning could have downstream effects upon the circadian regulation o f the 
behavioural processes regulated by these brain regions also, including the sleep- 
wake cycle (Luo and Aston-Jones, 2009).
4 . 4 . 6  M e c h a n i s m s  b y  w h i c h  t h e  A D H D  m e d i c a t i o n s  i n t e r a c t  w i t h  t h e  c i r c a d i a n  
s y s t e m
A possible mechanism by which methylphenidate and atomoxetine could produce the 
alterations to the circadian system o f the mouse brain observed could be via 
modulation o f aspects o f the cAMP system (Uz et al., 2005). The phosphorylation o f 
mitogen activated protein kinase (MAPK) and cAMP response element binding 
protein (CREB) is stimulated by dopamine (Yan et al., 1999) and noradrenaline 
(Tamotsu et al., 1995, Thonberg et al., 2002). An induction o f P E R I  expression by 
activation o f MAPK and CREB has been demonstrated i n  v i t r o  (Akashi and Nishida, 
2000, Yagita and Okamura, 2000), and in addition to P E R I , a number o f other 
circadian clock genes contain are known to possess CRE binding sequences 
including C L O C K , B M A L 1 ,  and P E R 2  (Takahata et al., 2000, Travnickova-Bendova 
et al., 2002).
The presence o f a methamphetamine sensitive oscillator that functions independently 
o f the SCN has been widely documented (Mohawk et al., 2009). Under conditions o f 
chronic methamphetamine treatment the rodent locomotor rhythm has been shown to 
become uncoupled from the LD cycle, and perturbed physiological rhythms in 
association with this has been observed (Honma et al., 1986, Honma et al., 1988, 
Tataroglu et al., 2006). There are a number o f indications that the formation o f the 
methamphetamine-induced oscillation may involve the dopaminergic system, 
including the ability o f methamphetamine to influence dopaminergic neuronal 
functioning (Masubuchi et al., 2000), and the effect o f the dopamine receptor 
antagonist, haloperidol, to cause phase-dependant phase shifts in the 
methamphetamine induced locomotor rhythm (Honma and Honma, 1995). On the 
basis that the dopaminergic system is involved in the methamphetamine sensitive 
oscillator, then activation o f this clock may not be limited to just methamphetamine, 
but could be extended to other pharmacological agents that interact with the
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catecholaminergic systems, including methylphenidate. This hypothesis is further 
supported by the rat anticipatory locomotor rhythm produced in response to chronic 
methylphenidate treatment (Algahim et al., 2009), and the perturbation o f circadian 
clock protein profiles throughout the mouse brain by chronic methylphenidate 
administration observed in the present study. Furthermore atomoxetine has been 
shown to interact with the dopaminergic system in brain regions such as the 
preffontal cortex, where it increases levels o f noradrenaline and dopamine (Bymaster 
et al., 2002, Koda et al., 2010), and so could interact with this SCN-independent 
oscillator also. However in order to determine this not only w ill the corresponding 
effects upon locomotor activity need to be studied, but circadian profiles o f clock 
protein expression and the behavioural rhythm w ill need to be examined under free- 
running conditions to determine i f  they persist in the absence o f light as the dominant 
Zeitgeber.
4 . 4 . 7  C o n c l u s i o n s
The current data demonstrates numerous effects o f both methylphenidate and 
atomoxetine upon the circadian system in a neuroanatomically differentiated manner. 
This could therefore have implications for the functioning o f various behaviours that 
are governed by these brain regions, and explain the wide variety o f therapeutic and 
adverse side effects o f these drugs, including upon the sleep/wake cycle that are 
observed.
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Chapter 5: Conclusions
5.1 Overall discussion
The main aims o f this work were firstly to establish a non-invasive method o f 
sampling the human circadian clock, secondly to apply this technique for the 
assaying o f human circadian clock functioning in adult ADHD, and thirdly to 
investigate the effects o f ADHD medication upon the circadian system.
The oral mucosa o f healthy participants was the tissue chosen, since sampling could 
be carried out by the study participants themselves, without the need to attend a sleep 
clinic, therefore minimising the risk o f circadian disturbance caused by the sampling 
protocol. The successful quantification o f robustly rhythmic circadian clock gene 
expression and the interactions o f the molecular circadian rhythms with behaviour, 
indicating the molecular circadian rhythm parameters as markers o f circadian clock 
functioning, demonstrated the usefulness o f the technique. However although 
adequate for RT-PCR gene expression analysis in the present study, the RNA 
integrity was relatively low, and therefore for future studies it may be useful to utilise 
a circadian oscillator present in other peripheral tissues such as hair cells, as this has 
been documented to be a tissue that is easily accessible and from which highly intact 
RNA can be extracted (Akashi et al., 2010). Furthermore with larger quantities o f 
RNA, a greater number o f clock genes could be assayed and microarray techniques 
could be implemented for a more standardised screening o f a larger cohort o f 
subjects for multiple clock genes and their associated clock controlled genes.
Once this method had been validated, the next step was to apply this technique to a 
larger clinical cohort o f ADHD patients and healthy controls, and this revealed 
significant perturbations in the molecular circadian clock in ADHD, in addition to 
the disturbance o f endocrine and behavioural rhythms in these patients, therefore 
further validating the protocol as an accurate method o f assaying human circadian 
clock function in both healthy subjects and patient populations.
The findings o f the present study provide much scope for further investigations into 
the circadian deficit in ADHD. Analysis o f a wider number o f core circadian clock 
genes would provide vital information on what effect the disturbed rhythmicity o f 
clock gene expression observed has upon the other molecular clock components, or
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indeed whether the perturbations observed could be the result o f a wider deficit in the 
core molecular clock mechanism. Furthermore, analysis o f the expression o f core 
clock controlled genes could help elucidate the potential effects o f perturbed 
peripheral clock gene expression upon downstream behavioural and physiological 
processes. Moreover, comorbidity o f ADHD with other disorders has been 
documented, for example with personality disorders (Modestin et al., 2001, 
Biederman and Faraone, 2005), and ADHD itse lf is differentiated as 3 separate 
subtypes; predominantly hyperactive-impulsive, predominantly inattentive and 
combined (McGough and Barkley, 2004, Biederman and Faraone, 2005). Therefore, 
further research to ascertain i f  deficits in the circadian system are associated with 
specific ADHD subtypes and symptomology would be valuable. Since, chronic sleep 
onset insomnia has been associated with ADHD (Boonstra et al., 2007, Van Veen et 
al., 2010), it would also be o f interest to investigate i f  the circadian rhythm 
disturbance associated with ADHD in the present study, is replicated in ADHD 
cohorts that are comorbid with insomnia and those that do not suffer from a sleep 
disorder, to establish i f  the circadian deficit is associated with ADHD or rather with 
an underlying sleep disorder that is comorbid with ADHD.
The significant disturbance o f the circadian system observed in ADHD, raised the 
question o f what impact ADHD medication may have upon the circadian clock, and 
i f  perhaps some o f the therapeutic and adverse side-effects o f these medications may 
exert their action in part through modulation o f the circadian clock. To examine this 
hypothesis further we assessed the effects o f chronic administration o f the 
psychostimulant methylphenidate and the anti-depressant atomoxetine upon 
circadian clock gene protein product expression throughout various regions o f the 
rodent brain, that are implicated in the circadian clock and in the catecholaminergic 
systems that are targets o f these drugs. Both drugs were shown to influence circadian 
clock protein expression in numerous brain regions in alternate manners. Both the 
mRNA and the proteins o f the core clock components play a role in various aspects 
o f the molecular clockwork, and so the sampling o f clock protein levels in the current 
study provide vital information regarding the functioning o f the molecular circadian 
system, although further analysis o f mRNA levels by in situ hybridization would be 
required to validate whether the disturbance seen at the protein level is also
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replicated in mRNA expression. Furthermore, the sampling o f a greater number o f 
time-points would further describe the molecular rhythms.
Due to the indications o f a potential dysfunction in the entrainment o f the circadian 
clock in ADHD in the present study and the ability o f methylphenidate and 
atomoxetine to alter molecular circadian rhythms in the rodent brain, including in the 
master pacemaker, it may be postulated that chronic administration o f these 
medications could act as a compensatory mechanism for the deficits in the 
entrainment o f the circadian system to environmental time-keeping cues in ADHD. 
Future work to assess how the impact o f methylphenidate and atomoxetine upon the 
molecular clockwork correlates with the rodent behavioural rhythm under conditions 
without light as the dominant Zeitgeber, would help elucidate the effects o f these 
medications upon intrinsic rhythmicity o f the circadian clock and to further 
understand what implications the modulation o f the molecular circadian system has 
upon behaviour. Moreover assessment o f how these medications affect molecular 
and behavioural rhythms in rodent models o f ADHD would provide valuable insight 
into how these medications interact with the master circadian pacemaker and the 
slave oscillators o f peripheral brain regions in ADHD. This study could also be 
extended further to assess the affects o f ADHD medication upon the human circadian 
system also, by utilising peripheral clock gene expression as a marker o f the 
molecular circadian clock, and by assessing endocrine and behavioural rhythms in 
pre and post medicated ADHD patients. Furthermore it would be o f interest to 
examine the circadian rhythms o f expression o f a wider set o f clock genes and clock 
controlled genes in this manner, as this would contribute to further understanding o f 
both the positive and negative effects o f pharmacological treatments for ADHD upon 
the circadian system.
5 . 1 . 1  C o n c l u s i o n s
To summarise, the establishment o f deficits in the circadian system on the 
behavioural, molecular and endocrine levels in ADHD, and furthermore the 
associations observed between circadian rhythm parameters and clinical ADHD 
scores indicate a key role for circadian clock disturbance in the manifestation o f 
sleep disturbance and clinical symptoms. Moreover, the interactions o f the
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pharmacological ADHD treatments with the molecular circadian clock indicate a 
potential mechanism by which these treatments may interact with the circadian 
system. Therefore, further elucidation o f the effects o f ADHD treatments upon the 
circadian system o f ADHD patients could ultimately prove beneficial in 
understanding the symptomology o f the disorder and the most appropriate and 
efficacious treatments for the disorder.
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Appendix 1; A comparison o f the statistical analysis o f the immunoreactivity 
data assessed bv immunoreactive cell counts and optical density.
Brain
Region
Treatment Method of 
measuring 
immunoreactivity
Acrophase of immunoreactivity (Zeitgeber time)
CLOCK PERI PER2 c-Fos
SCN SAL Cell Counts n.s. ~ZT14 -ZT14 ~ZT6
Optical density n.s. ~ZT14 ~ZT14 ~ZT10
MPD Cell Counts n.s. ~ZT14 ~ZT2 ~ZT6
Optical density n.s. ~ZT14 ~ZT2 ~ZT6
ATO Cell Counts n.s. ~ZT14 n.s. ~ZT6
Optical density n.s. -ZT14 n.s. ~ZT10
PVN SAL Cell Counts ~ZT8 -ZT14 ~ZT14 -ZT20
Optical density ~ZT6 -ZT16 ~ZT11 ~ZT20
MPD Cell Counts ~ZT5 n.s. ~ZT14 -ZT20
Optical density -ZT24 n.s. -ZT15 ~ZT20
ATO Cell Counts ~ZT5 ~ZT2 -ZT20 ~ZT8
Optical density ~ZT4 ~ZT2 ~ZT21 ~ZT8
CPu SAL Cell Counts -ZT20 ~ZT2 ~ZT2 n.s.
Optical density ~ZT22 ~ZT1 ~ZT4 n.s.
MPD Cell Counts ~ZT2 ~ZT2 -ZT14 n.s.
Optical density ~ZT2 ~ZT2 -ZT15 n.s.
ATO Cell Counts ~ZT5 ~ZT2 ~ZT2 n.s.
Optical density ~ZT2 ~ZT1 ~ZT2 n.s.
CC SAL Cell Counts n.s. n.s. n.s. n.s.
Optical density n.s. n.s. n.s. n.s.
MPD Cell Counts n.s. n.s. n.s. n.s.
Optical density n.s. n.s. n.s. n.s.
ATO Cell Counts ~ZT2 n.s. n.s. n.s.
Optical density n.s. n.s. n.s. n.s.
VTA SAL Cell Counts n.s. n.s. -ZT14 -ZT20
Optical density n.s. n.s. ~ZT15 ~ZT19
MPD Cell Counts n.s. n.s. n.s. -ZT20
Optical density n.s. n.s. n.s. ~ZT20
ATO Cell Counts n.s. n.s. n.s. n.s.
Optical density n.s. n.s. n.s. n.s.
A l. l Summary table comparing the co-sinor analysis o f CLOCK, PERI, PER2 and 
c-Fos immunoreactivity assessed by measurement o f immunoreactive cell counts and 
optical density, n.s. = not significantly rhythmic.
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Protein Brain Region Method of 
measuring 
immunoreactivity
Main effect 
of time
Main effect 
of treatment
Interaction 
of time x 
treatment
CLOCK SCN Cell Counts n.s. n.s. n.s.
Optical density n.s. n.s. n.s.
PVN Cell Counts P<0.05 n.s. n.s.
Optical density P O .O l PO .O O l n.s.
CPu Cell Counts P O .O l n.s. P O .0 5
Optical density PO .O O l n.s. n.s.
CC Cell Counts n.s. n.s. n.s.
Optical density n.s. n.s. n.s.
VTA Cell Counts n.s. n.s. n.s.
Optical density PO .O O l PO .O O l P O .O l
PERI SCN Cell Counts PO .O O l n.s. n.s.
Optical density P O .O l n.s. n.s.
PVN Cell Counts n.s. PO .O O l n.s.
Optical density P O .O l PO .O O l PO .O Ol
CPu Cell Counts n.s. P O .O l P O .0 5
Optical density PO .O O l PO .O O l n.s.
CC Cell Counts P O .0 5 n.s. n.s.
Optical density n.s. n.s. n.s.
VTA Cell Counts n.s. PO .O O l n.s.
Optical density n.s. PO .O O l n.s.
PER2 SCN Cell Counts n.s. PO .O O l PO .O Ol
Optical density n.s. PO .O O l n.s.
PVN Cell Counts n.s. PO .O O l n.s.
Optical density P O .O l PO .O O l P O .0 5
CPu Cell Counts P O .0 5 PO .O O l PO .O Ol
Optical density n.s. PO .O O l PO .O O l
CC Cell Counts P O .0 5 n.s. n.s.
Optical density n.s. P O .O l n.s.
VTA Cell Counts n.s. P O .0 5 n.s.
Optical density n.s. P O .0 5 n.s.
c-Fos SCN Cell Counts PO .O O l n.s. n.s.
Optical density PO .O O l P O .0 5 n.s.
PVN Cell Counts n.s. n.s. P O .O l
Optical density n.s. n.s. PO .O O l
CPu Cell Counts PO .O O l PO .O O l P O .0 5
Optical density n.s. PO .O O l P O .0 5
CC Cell Counts PO .O O l PO .O O l n.s.
Optical density P O .0 5 n.s. n.s.
VTA Cell Counts PO .O O l n.s. P O .0 5
Optical density PO .O O l n.s. P O .0 5
A1.2 Summary table comparing the ANOVA statistics o f the CLOCK, PERI, PER2 
and c-Fos immunoreactivity data assessed by measurement o f immunoreactive cell
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counts and optical density, n.s. = not significantly rhythmic. A  2-way ANOVA 
testing for main effects o f time and treatment, w ith T u k e y  p o s t - h o c  analysis was 
carried out.
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